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Schistosomiasis is a chronic debilitating disease caused by schistosomes. Schistosomes
are multicellular organisms, which present a wide variety of antigens in the host. Among
these, it is generally accepted that the glycoconjugates expressed by the schistosomes play
a very important role in the immunology of schistosomiasis. Central to this thesis is the
interaction of antibodies with one of the abundantly expressed carbohydrate antigens,
Lewis X, studied from a structural point of view.
This chapter will begin with a general introduction to schistosomiasis, the disease
and the parasite life cycle, followed by a short overview of the different carbohydrate
structures expressed by the schistosomes. This leads to a section about the function of
Lewis X in the immunology of schistosomiasis and other diseases (Helicobacter pylori
infection and cancer). As one of the main objectives of this thesis was the elucidation of
the structure of an anti-Lewis X Fab fragment in complex with its Lewis X antigen, an
introduction to protein-carbohydrate interactions in general and techniques used to
measure the thermodynamics of these interactions are given. Two crystallographic studies
involving Lewis X have been reported so far and are also discussed. Finally, all available
data on three-dimensional structures of antibodies and Fab fragments, will be reviewed, in
particular previously solved Fab fragments in complex with an oligosaccharide.
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1. Schistosomiasis
This introduction will start with a short overview on schistosomiasis, the schistosomal life
cycle and the glycoconjugates expressed by different life stages of the parasite.
1.1. Life cycle and disease
Schistosomes are digenetic blood-dwelling trematodes causing a chronic, debilitating,
sometimes fatal disease called schistosomiasis. The three main species infecting humans
are Schistosoma mansoni, S. haematobium and S. japonicum. Schistosomiasis is endemic
in 74 tropical developing countries. S. mansoni  is found in parts of Africa, South America
and the Caribbean and the Middle East; S. haematobium in Africa and the Middle East;
and S. japonicum in the Far East. Schistosomiasis is the major parasitic worm infection in
the world, with some 200 million people infected [3,4] and another 600 million at risk of
becoming infected.
Figure 1.1Schistosome life cycle.
(adapted from: http://www.dpd.cdc.gov/DPDx/HTML/Schistosomiasis.htm)
The parasites have a complex life cycle, involving an intermediate host and a definitive
host (Figure 1.1). The eggs of the schistosomes in the urine or stool of an infected person
hatch on contact with fresh water and release miracidia. To survive, this motile form must
find a fresh water snail within 8-12 hours and infect it. In the snail massive asexual
replication occurs, 2 successive generations of sporocysts develop and subsequently
cercariae are produced.  Upon release from the snail, the infective cercariae swim and try
to find and penetrate the skin of their definitive host. After infection, the cercariae shed
their forked tail and become schistosomula. These schistosomula enter the capillaries,
migrate to the lungs and then travel to their final location. After about three weeks, the
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larvae have developed into either male or female adult worms and start pairing. Adult
worms in humans reside in the mesenteric venules in various locations depending on the
species. For instance, S. japonicum is more frequently found in the superior mesenteric
veins draining the small intestine, whereas S. mansoni occurs more often in the superior
mesenteric veins draining the large intestine. These two Schistosoma species cause
intenstinal schistosomiasis. S. haematobium most often occurs in the venous plexus of the
bladder, causing urinary schistosomiasis. After four to six weeks the adult female worms
start to lay from 200 to 2000 eggs per day, this can last over an average period of 5 years
or longer, depending on the species. About 50 % of the eggs produced by the female are
excreted with the faeces (intestinal schistosomiasis), or with the urine (urinary
schistosomiasis). The rest remains in the body, where they get trapped in the intestinal or
bladder wall. Some of these eggs will be transported via the blood circulation to the liver
or other organs. The trapped eggs get encapsulated in large granulomas, which are
responsible for the main pathology of schistosomiasis [5]. The granulomas may cause
liver fibrosis and portal hypertension in the case of intestinal schistosomiasis and bladder
cancer or renal failure in the case of urinary schistosomiasis.
People become infected by contact with water used in normal daily activities
such as personal or domestic hygiene and swimming, or by professional activities such as
fishing, rice cultivation and irrigation. Due to lack of information or insufficient attention
to hygiene, infected individuals may contaminate their water supply with faeces or urine.
To date the only cure for the disease is by treatment with the safe and effective drug
praziquantel, which however does not prevent reinfection [6]. The most feasible long-term
solution to fight schistosomiasis would be to raise the standard of living for people in
endemic areas by provision of a safe and adequate water supply, sanitation and health
education. Furthermore, studies are underway for the development of a vaccine. One
antigen, glutathione S-transferase has been tested as a possible vaccine and it has
successfully passed phase I clinical trials and is now in phase II trials [7]. However, it
should be noted that this vaccine only had limited efficacy in animal trials. Currently, the
schistosomal genome is being elucidated and this will undoubtedly have an enormous
impact on faster identification of new targets for diagnostics, drugs and vaccines [8].
1.2. Glycoconjugates of schistosomes
Schistosomes have an average life span of 3-5 years (and may survive up to 30 years) in
the hostile environment of their definitive host. Thus, this parasite must have developed
remarkable mechanisms to escape the immune response of its host. It is thought that the
glycoconjugates, which are abundantly expressed throughout all life stages of the parasite
play an important role in many of these escape mechanisms. Parasite glycans were found
to induce immunomodulatory effects, for instance by down-regulating the host-protective
TH-1 type immune response or the induction of anti-inflammatory responses [9]. In order
to gain better insight into the immunology of the disease and possibly find new diagnostic
or intervention tools, it is of great interest to study the structure and function of these
carbohydrates synthesized by the parasite. With the use of mass spectrometry and NMR
spectroscopy, many carbohydrate structures from all different life stages of the parasite
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have been identified (for reviews see [10,11] and references cites therein). Below a short
overview will be given on the schistosomal glycoproteins and glycolipids identified so far.
Schistosomal glycans are conjugated to proteins, both N- and O-linked, and lipids.
Interestingly, the parasite expresses both host-specific and parasite-specific
oligosaccharides. For example, the N-glycans of schistosomes can have a typical Man5-
9GlcNAc-Asn (high mannose-type) structure [12] resembling those found in mammals.
But also complex-type di-, tri- and tetraantennary structures were found, which sometimes
had unusual core fucosylation and/or xylosylation in the egg and cercarial stages (Figure
1.2) [13-15]. The β1-2 core xylose and α1-3 core fucose were also found on N-glycans of
some other helminths, insect and plants but not in mammalians [16].
Figure 1.2 Di-, tri- and tetra-antennary structures found on the schistosomal N-glycans. The N-
glycans of S mansoni eggs and cercariae and S japonicum eggs were found to contain the unusual
β1-2 core xylose and α1-3 and/or α1-6 core fucose.
A frequently occurring motif found on the N-linked diantennary structures is a
terminal LacdiNAc (LDN, GalNAcβ1-4GlcNAcβ), with or without a fucose in an α1-3
linkage to the GlcNAc (LDNF) [15,17]. Later these structures were also discovered on
several glycoproteins of both invertebrate and vertebrate species [18] . Another host-
related carbohydrate determinant that is widely expressed by the parasite is Lewis X (Lex,
Galβ1-4[Fucα1-3]GlcNAcβ). N-linked tri- and tetraantennary structures of S mansoni
adults were shown to carry Lex, within fucosylated poly-N-acetyllactosamine chains [19].
Furthermore, Lex is also carried by cercarial O-glycans [20] and S. mansoni cercarial
glycolipids are dominated by terminal Lex and pseudo-Ley structures (Fucα1-3Galβ1-
4[Fucα1-3]GlcNAc) [21]. Lex has also been found in glycolipid extracts from adult
worms, but could hardly be detected on egg glycolipids [22,23].
In contrast to the relatively simple and common glycans, the schistosomes also
express highly unusual and complex terminal sequences containing schistosome specific
Fucα1-2Fuc units. These sequences, which were identified on the cercarial glycocalyx O-
glycans, contain (Fucα1-2)0/1Fucα1-2Fuc moieties carried on repeating GalNAcβ1-
4GlcNAcβ1-3Galα1-3 units. These fucosyl units are α1-3 linked to an internal GlcNAc
and/or the terminal GalNAc (Figure 1.3a) [24]. The O-glycans from S. mansoni eggs also
carry multifucosylated HexNAc sequences similar as the cercarial O-glycans.
Furthermore, glycosphingolipids of S. mansoni schistosomal eggs also appear to carry
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4[(Fucα1-2)1/2Fucα1-3]GlcNAc (Figure 1.3b) [25]. The carbohydrate is attached to the
ceramide (cer) via a so-called schisto-core (GalNAcβ1-4Glcβ1-cer) [21,26].
Figure 1.3 a) S. mansoni cercarial O-glycans carrying the unique Fucα1-2Fuc moieties. b) Egg
glycosphingolipids from S. mansoni.
Furthermore, it has been shown that two major antigens, which are regularly
being released from the gut of adult worms in relatively high amounts, namely the
circulating cathodic and anodic antigen (CCA and CAA respectively), contain large
unusual O-glycans. The major fraction of the O-linked glycans of CCA consists of a poly-
Lex backbone of approximately 25 repeating units (Figure 1.4a), having a GalNAc as the
reducing terminal moiety [27]. CAA is negatively charged, its O-glycan contains the
branched disaccharide repeating unit -6[GlcAβ1-3]GalNAcβ1- (Figure 1.4b), furthermore
a small portion of poly-Lex carbohydrate chains were found to be present on CAA [28].
Both CCA and CAA are excreted in such significant amounts that sensitive assays to
diagnose schistosomiasis are based on the detection of these antigens in an ELISA using
anti-carbohydrate monoclonal antibodies (Mabs).
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2. Lewis X
Lex is expressed in all life stages of the schistosome, which are present in the definitive
host. To date many studies have shown that Lex is important in the immunology and
diagnosis of schistosomiasis. Other infectious species, such as Helicobacter pylori and
certain types of cancer cells also express Lex. Below an overview is given on the current
knowledge of the presence and possible role of Lex in physiological and pathological
processes.
2.1. Lewis X and schistosomiasis
Although Lex is expressed as well on N- and on O- glycans as on glycolipids in the
different life stages of the parasite, its expression seems to be regulated. With the use of
an anti-Lex Mab, Lex expression throughout the different developmental life stages was
probed in immunofluorescence assays [29,30]. It was found that on the cercariae Lex was
only present on the oral sucker, whereas in schistosomula, Lex appeared in patches on the
entire surface. In the adult worm, strong fluorescence was found in the gut and in addition
on the tegument. Furthermore the egg-shells were stained, while Kupffer cells that
surround worms and eggs in infected hamster livers were stained, indicating that Lex
containing glycoconjugates are secreted by the worms and the eggs [30].
Over the years many studies have been conducted to investigate the role of Lex
and Lex binding proteins in the immunology of schistosomiasis. It has indeed been found
that upon a schistosomal infection infected individuals mount an anti-Lex humoral
immune response [31-35]. It was found that the induced anti-Lex antibodies are cytolytic
towards the host's granulocytes and myeloid cells [31,32,36]. It remains however to be
established whether this autoimmune effect plays a significant role in the
immunopathology of schistosomiasis in vivo.
Lex itself has been implicated to have an immunomodulatory effect, recently
reviewed in [9]. A striking TH-1 to TH-2 switch has been observed in schistosomiasis at
the onset of egg laying and many studies have suggested that Lex is involved in this TH-2
skewing. It has been reported that Lex containing glycoconjugates can induce splenic
B220+ B-cells from infected mice to proliferate and secrete IL-10 and prostaglandin E2,
two molecules known to down-regulate TH-1 T-cells [37]. In another study it was shown
that mice immunized with lacto-N-fucopentaose III (LNFPIII), a pentasaccharide
containing Lex at its non-reducing end, conjugated to human serum albumin (HSA)
mounted a strong TH-2 response and HSA-specific antibodies. These strong effects were
not observed in mice immunized with HSA alone, suggesting that Lex is a potent inducer
of TH-2 responses and can act as an adjuvant by inducing antibody production against
protein antigens [38]. In addition, also in infected humans Lex containing glycoconjugates
were found to induce IL-10 production by peripheral blood mononuclear cells (PBMCs)
[39]. This production of IL-10 leads to a down-regulation of the protective immune
response. Furthermore, it was demonstrated recently that LNFPIII can drive the
differentiation of naive dendritic cells to a DC2 phenotype via a mechanism dependent on
Toll-like receptor 4 (TLR4) [40]. It is not exactly clear how LNFPIII can promote the DCs
towards TH-2 type DC2 cells via TLR4 because LPS interactions with TLR4 were found
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to induce TH-1 type immunity. It has been suggested that accessory molecules associated
with the extracellular domain of TLR4 may be responsible for differential binding to the
stimulants, which will lead to different signaling events important for driving the immune
response. In addition, it was recently described that Lex binds the dendritic cell receptor
DC-SIGN [41], suggesting that this receptor molecule might aid in the induction of a TH-2
type immune response [40].
Lex and anti-Lex Mabs are also important immunodiagnostic tools for the
diagnosis of schistosomiasis. With the use of selected anti-schistosome Mabs [42],
sensitive antigen-detection based assays could be developed for the diagnosis of
schistosomiasis [43,44]. The detection of schistosome specific antigens in serum and
excreta of infected individuals was found to correlate rather well with the active infection
[45]. These antigen-detection assays are mostly focused on the detection of CCA and
CAA, two antigens that are excreted from the gut of the adult worms in relatively high
amounts into the circulation of the host [46]. As mentioned CCA contains polymeric Lex
on its immunoreactive part, it is therefore not unreasonable to assume that the Mabs used
in the CCA assay recognize some part of the polymeric Lex chain. From an
immunodiagnostic viewpoint, it would be of importance to study the exact Lex
determinant recognized by these Mabs.
2.2. Lewis X and Helicobacter pylori
Another infectious species that synthesizes Lex is Helicobacter pylori. H. pylori is a gram
negative bacterium, infecting about 50 % of the global population. The presence of this
bacterium in the gastric mucosa is associated with active gastritis and can also lead to
severe gastric diseases including gastric and duodenal ulcers and adenocarcinoma (for a
review see [47]). The O-antigen of lipopolysaccharide (LPS) expressed in most H. pylori
strains is comprised of Lewis blood group antigens, including long chains of Lex [48].
Over the years several functions have been ascribed to the role of the expression of Lex by
the bacteria [49]. It has been suggested that, through molecular mimicry, Lex may play a
role in protecting H. pylori by immune evasion from the host immune response [50].
However, strong evidence supporting this role has never really been found [49].
Furthermore, it was anticipated that antibodies against the O-antigen might bind to Lex
structures in the gastric epithelia and cause autoimmune-mediated inflammation [51].
However from later studies it became clear that the Lex antigen did not induce gastric
auto-antibodies in humans [52] or promoted immune evasion through molecular mimicry.
Another role for Lex could be mediating the adhesion of the bacterium to the gastric
epithelium, it was suggested that Lex-Lex homotypic interactions may be important for this
adhesion [53]. However, in a later study no Lex-Lex mediated adhesion of H. pylori was
observed to a certain cell type (parietal cell canaliculi) which is known to express Lex
[53,54]. Furthermore, the expression of Lex by H. pylori is thought to be very important
for colonization of mice. It was suggested that the colonization occurs via Lex adhesion
and that Lex-binding lectins are involved, but a mechanism has not been discovered yet.
Although later it was demonstrated that H. pylori knockout mutants, which do not express
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Lex, also colonized mice [55]. Therefore, it remains to be elucidated to what extent Lex is
actually involved in colonization of humans and adhesion to gastric receptors [56].
2.3. Histo-blood group antigen Lewis X
Lex is not a pathogen-specific carbohydrate, it is one of the histo-blood group antigens. It
is based on fucosylated Type 2 chains (Galβ1-4GlcNAcβ, N-acetyl-lactosamine, LacNAc)
and expressed by most higher organisms (for a review on the blood group antigens see
[57,58]). Lex was described for the first time as stage-specific embryonic antigen (SSEA-
1) in mouse [59]. With the use of anti-SSEA-1 Mabs the distribution of Lex was studied
first in mouse and later also in human tissue. Initially Lex was found to be highly
expressed on the embryo cell surface at the morula stage (8-16 cell) [60]. As the
appearance of Lex correlated with the onset of compaction during embryonic development
it was assumed to play a role in cell-cell adhesion although a Lex binding partner (e.g. a
lectin) could not be identified. Later it was proposed that Lex-Lex interactions mediated by
Ca2+, Mg2+ or Mn2+ were responsible for the cell-cell interaction and that no protein
binding partners were involved [61]. Indeed, the interaction could be inhibited either by
EDTA, anti-Lex antibodies or Lex itself and these results were confirmed in several other
studies [62-65]. Furthermore, during further embryonic development Lex is found at the
egg cylinder stage in the embryonic ectoderm and after subsequent development it is
present on brain and primordial germ cells. In adult mice, Lex was localized on sperm
cells and in brain and kidney tissue [60,66,67]. In humans it was found on germ cells in
human fetal (but not adult) testis and in adult human tissues in the brain, kidney, stomach,
although localized in the epithelial components and not widespread throughout the whole
organs [68]. Furthermore, from extracts of human granulocytes glycopeptides were
isolated that contained N-linked fucosylated polylactosaminoglycans, i.e. oligomeric Lex
on tetraantennary cores [69].  Earlier in 1969 the Lex determinant had already been
described to be present at the non-reducing end of a pentasaccharide found in human milk:
Lacto-N-fucopentaose III (LNFPIII) [70]. In humans the Lex determinant is often α2-3
sialylated at the non-reducing end. Sialyl Lewis X (sLex) has been described as a ligand
for cell adhesion molecules called selectins, which are present on activated endothelium
(E- and P-selectin), leukocytes (L-selectin) and platelets (P-selectin). Upon an
inflammatory stimulus these lectins are over-expressed and mediate the initial attachment
of leukocytes and neutrophils to the endothelium by rolling across the inflamed cell wall
via sLex [71,72]. Furthermore, sLex and E-, P- and L-selectin have been implicated to play
a role in tumor metastasis [73].
2.4. Lewis X and cancer
Originally the Mab defining the SSEA-1 antigen was obtained by immunization of a
mouse with the murine teracarcinoma cell line F9, indicating that Lex is also expressed by
tumor cells. Lex was found both on glycoproteins and glycolipids in many different types
of carcinomas (for reviews see [74-76]), for instance on myeloid leukemia, colorectal
carcinomas, choriocarcinomas, differentiated hepatomas and on most adenocarcinomas.
Interestingly, some Lex expressing tumors do not originate from tissue that expresses Lex
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such as breast and ovary, hence Lex might be used as a tumor marker in specific cases
[68]. Not only monomeric Lex but also oligomeric Lex has been reported to be expressed
on certain tumor glycolipids. Hakomori et al. [77] have studied glycolipids extracted from
human colonic and liver adenocarcinoma and found that these glycolipids contain the Lex
determinant. However, they differed from those of erythrocytes (known to contain
monomeric Lex). By using methylation analysis, mass spectrometry, enzymatic
degradation and proton NMR spectroscopy they found that the glycolipids contained di-
and trimeric Lex determinants, which were not expressed on glycolipids from normal
colonic mucosa and liver tissue. In a follow-up study [78] they immunized mice with the
tumor glycolipids obtaining a Mab that interacted with di- and trimeric Lex but not with
monomeric Lex. As some tumors express oligomeric Lex, whereas the normal tissue only
expresses monomeric Lex it was proposed that these Mabs could be used to differentiate
tumor cells from normal cells. To date it is still not entirely clear why tumor cells express
mono- and oligomeric Lex. As Lex plays an important role in compaction of cells during
embryonic development it is likely to be involved in cell to cell interactions either via
carbohydrate-protein or carbohydrate-carbohydrate interactions. It has been suggested that
the elongated fucosylated structures may facilitate invasion of tumor cells and metastasis
[77]. Alternatively, the decoration with Lex may serve to shield the tumor from clearance
by the immune system.
3. Protein-carbohydrate interactions
The following section contains an overview of what is already known about the basic
features of protein-carbohydrate interactions. This is followed by the description of two
methods to determine the thermodynamics of complex formation and a paragraph on two
previously solved structures involving Lex.
3.1. Basic features
Over the past years high-resolution X-ray structures in combination with surface plasmon
resonance analysis and NMR spectroscopy [79] along with other techniques used to
examine the thermodynamics and kinetics of protein-carbohydrate interactions, have
revealed the basic features of protein-carbohydrate interactions. Protein-carbohydrate
interactions are mainly stabilized by hydrogen bonds, which are the major determinants of
both affinity and specificity in the complex (for reviews see [80-82]). Two types of
hydrogen bonds can be formed: a) cooperative hydrogen bonds and b) bidentate hydrogen
bonds. The cooperative hydrogen bonds are the result of the simultaneous participation of
a sugar hydroxyl group as a hydrogen bond donor and acceptor. Normally, the amino
function of an amino acid side chain donates an hydrogen bond to the hydroxyl group,
which in turn donates an hydrogen bond to a side or main chain oxygen atom of a
carbonyl group (Figure 1.5). Bidentate hydrogen bonds are formed when two adjacent
hydroxyl groups, which should be both equatorial or one equatorial and one axial, interact
with different atoms on the same planar polar side chain (Figure 1.5). Furthermore, a
sugar ring oxygen atom in combination with an axial C4 or a C6 hydroxyl group can also
participate in a bidentate hydrogen bond. The ideal distance between the pair of oxygen
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atoms was found to be ca. 2.8 Å for bidentate hydrogen formation with the planar side
chains.
Figure 1.5 Schematic diagram of
the hydrogen-bonding interactions
between β-D-glucose and D-
galactose binding protein (adapted
from [81]). An intricate hydrogen
bond network is present. All sugar
hydroxyl groups are involved in
cooperative hydrogen bonds. The
C1 and C2, C2 and C3, C3 and C4
hydroxyl groups and the sugar ring
oxygen and C6 hydroxyl group are
involved in bidentate hydrogen
bonds. Water 313 bridges between
the protein and the sugar.
Since the distance between two adjacent axial hydroxyl groups is approximately 3.6 Å and
the oxygen atoms point in opposite directions, these are less likely to be engaged in
bidentate hydrogen bonds. The formation of both cooperative and bidentate hydrogen
bonds leads to the creation of intricate networks of hydrogen bonds between sugar and
protein residues resulting in highly stable protein-sugar complexes.
Many of the residues in carbohydrate-binding pockets have polar planar side chains (Asn,
Asp, Glu, Gln, Arg and His) which are capable of forming these extensive hydrogen bond
networks. In addition, apart from the numerous hydrogen bonds, many more atoms are
located within Van der Waals distance to the sugar substrate, further contributing to the
stability of the complex. Some Van der Waals contacts are made via stacking of aromatic
residues on one or two sides of the glycoside rings. The aromatic residues align with the
hydrophobic patch of the pyranoside, which is dependent on the orientation of the
hydroxyl groups on the sugar ring. Aromatic residues are thought to play a role in
conferring specificity because of their ability to distinguish between different sugar
epimers. For instance, D-glucose has a hydrophobic patch on the β-face composed of C3,
C5 and C6, whereas on the α-face a minor hydrophobic patch is composed of C2 and C4.
Water molecules have also been found to aid in stabilization of protein-
carbohydrate complexes by establishing extra hydrogen bonds via bridging between the
carbohydrate ligand and protein residues. In addition, they can also contour the base of the
binding site to improve the Van der Waals contacts. It should be noted that the role of
water molecules in protein-carbohydrate complexes is still not completely understood and
a subject of ongoing investigations in several laboratories.
Most carbohydrate ligands only bind weakly to protein receptors. In order to compensate
for this, many carbohydrate-binding proteins can aggregate and form multivalent clusters,
which bind carbohydrates with high affinity. At the same time carbohydrate ligands are
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often presented in a multivalent manner, for example heavily glycosylated proteins or
highly dense glycolipids on the cell surface. In multivalent interactions increased affinity
is observed compared to the sum of the corresponding monovalent binding of the ligand to
the protein, this is called the glycoside cluster effect (for a review see [83]). One
explanation for this phenomenon is that multivalent ligands can cross-link and aggregate
the protein, although further study is necessary for a full understanding.
3.2. Measuring the thermodynamics of protein-carbohydrate interactions
At constant temperature, the free energy of complex formation is determined by the
enthalpy and entropy of the process. Protein-carbohydrate complex formation is usually
accompanied by a favorable enthalpy contribution with the energy stemming from
hydrogen bond formation and Van der Waals contacts. The entropy term, which is usually
described in four types of motion: translational, rotational, vibrational and conformational
is often negatively contributing to the binding because of greater motional restriction. To
overcome this unfavorable entropy contribution is has been suggested that besides the
enthalpy gain, the solvent also plays an important role. Both protein and carbohydrate are
hydrated, carrying a shell of ordered water molecules in their close vicinity. Upon
interaction, water molecules shielding the binding sites must be removed to yield
favorable interactions between the protein and carbohydrate ligand. The release of ordered
water molecules to the bulk solvent will be accompanied by a significant gain in entropy
and hence increase the free energy of complex formation [84].
3.2.1. Isothermal titration calorimetry
A powerful technique to study the thermodynamics of protein-carbohydrate interactions is
isothermal titration calorimetry (ITC) [85]. The heat evolved during the addition of the
carbohydrate ligand to its protein-binding partner is measured as a function of the ligand
concentration. From a single titration, providing sufficient data points are measured, the
enthalpy of binding (∆H), the association constant (K) and the binding stoichiometry (n)
can be obtained. The binding constant is related to the Gibbs free energy of binding (∆G)
and the entropy of binding (∆S) can be calculated from the known thermodynamic
relationship (1):
∆G = ∆H- T∆S = -RT lnK (1)
It should be noted that care should be taken in the interpretation of multivalent
interactions, which are often observed in protein-carbohydrate assemblies. Multivalency
effects might increase the overall affinity compared to the sum of the affinities of the
single binding sites, this could complicate the fitting of the titration curve.
One disadvantage of the technique is the relatively large amount of material required for
each experiment, despite the development of very sensitive micro-calorimeters (e.g.
MicroCal, from Northampton, MA, USA). A typical experiment should be performed at a
value of c between 10 and 100, where c is a unitless product of the concentration of
binding sites and the binding constant. Thus in the range of protein-carbohydrate
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interactions, which is usually millimolar to micromolar affinity, at least micromolar
concentrations of binding sites is required in the cell, which has a volume of 1.4 mL.
ITC has been successfully used to map the binding modes of anti-carbohydrate Mabs. By
comparing the affinity constants of carbohydrate ligands with their deoxy and/or
deoxyfluoro derivatives, patterns of binding could be revealed. For instance the loss of an
hydrogen bond might be reflected in loss of free energy of the system [86,87]. In another
study the effect of oligomerization of a carbohydrate ligand for binding was investigated.
The relative contribution of the enthalpy and the entropy term to the free energy of
binding was measured. Interestingly, the free energy of binding of all the different
oligomers was constant. The unfavorable entropy contribution of the longer oligomers
was compensated for by an increased enthalpy term because of more favorable
interactions [88].
3.2.2. Surface plasmon resonance
Another well established method to measure the protein-carbohydrate interaction is by
surface plasmon resonance (SPR) analysis using BIAcore technology [89]. This technique
allows a rapid and efficient way of studying interactions in real time (without the use of
labels). One of the reactants is immobilized on the surface of a biosensor chip (ligand),
and the interaction of a second reactant (analyte) in solution with the immobilized ligand
is measured. As the analyte binds to the ligand, the accumulation of protein on the surface
results in an increase in the refractive index. The change in refractive index is measured
and the result plotted as response or resonance units (RUs) versus time (a sensorgram).
Thus, the association and dissociation behavior of the interaction can be monitored in real
time (see the BIAcore technology handbook for a detailed explanation of the detection by
surface plasmon resonance). At the same time, a background response will also be
generated if there is non-specific binding to the carrier molecule or a difference in the
refractive indices of the running and sample buffers. This background response must be
subtracted from the sensorgram to obtain the actual binding response. The background
response is recorded by injecting the analyte through a control or reference flow cell,
which has the unliganded carrier molecule or an irrelevant ligand immobilized to the
sensor surface. One major advantage of the method is that the reactant that is available in
limited amounts can be immobilized on the chip and re-used after each experiment,
provided that the surface can be properly regenerated without destruction of the ligand. As
the method is very sensitive, only low amounts of material are required for each
experiment, 5-10 µg of ligand, e.g. neoglycoconjugate, is needed for immobilization onto
the sensorchip. For the analyte, experiments are usually performed with injections of less
than 20 µl per sample, with 1 ng protein/mm2 bound to the surface already corresponding
to a signal of 1000 RU. Another advantage is the fact that the sensor chips have four
channels on which different ligands can be immobilized and the interaction of an analyte
with these ligands can be measured simultaneously.
Both qualitative and quantitative analyses of interactions can be done with a
BIAcore [90]. For instance a panel of Mabs can rapidly be screened for qualitative binding
or non-binding to the immobilized ligand [30]. In the case of quantitative analysis, both
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thermodynamics and kinetics of binding can be determined [91]. With SPR, the affinity
constant can be calculated from equilibrium binding analysis, which involves injecting a
series of analyte concentrations and measuring the level of binding at equilibrium. The
relationship between the binding level and analyte concentration enables the affinity
constant to be calculated [92]. In principal it is also possible to indirectly determine ∆H by
Van 't Hoff analysis by measuring KD over a range of temperatures. In practice this is
technically difficult and likely to be inaccurate, therefore ITC is the preferred method of
determining these thermodynamic parameters. Furthermore, the binding rates (kon and koff)
of interactions can be measured by injecting a series of analyte concentrations. A detailed
explanation about measuring accurate thermodynamic and kinetic parameters of
interactions and interpretation of the data is beyond the scope of this introduction, for an
overview see the BIAcore application handbook and [93].
One major drawback of the thermodynamic and kinetic analysis on a BIAcore is
that a 1:1 interaction between ligand and analyte is required for proper determination of
the parameters. In the case of antibody-ligand interactions (2 binding sites in case of IgG
and 10 binding sites in case of IgM) this would therefore not be the method of choice.
Nevertheless a study has been published in which the binding kinetics of an antibody-
carbohydrate interaction were studied by SPR [94]. The binding kinetics of intact IgG, a
Fab fragment and a monomeric and dimeric scFv fragment were compared. The results
showed that a much faster off-rate for the monovalent protein forms were responsible for
the lower affinity of the monovalent interactions. The on-rate of the intact IgG was the
same as that obtained for the Fab and the scFv fragments, whereas the on-rate for the
dimeric scFv fragment was approximately 5-fold higher. An explanation for equal on-
rates for the Fab fragment and the intact antibody may be a more unfavorable interaction
energy for the intact IgG because of less flexibility or more unfavorable steric interactions
compared to the dimeric scFv fragment. The off-rates of both the intact IgG and the
dimeric scFv fragment were approximately 20-fold slower.
3.3. Structural studies involving Lex
As was mentioned earlier, X-ray crystallography has provided much insight into protein-
carbohydrate interactions. To date the structures of many protein-carbohydrate complexes
have been published, including complexes with antibodies, animal and plant lectins (for a
full overview see http://www.cermav.cnrs.fr/lectines) and polysaccharide metabolizing
enzymes, such as glycoside hydrolases and glycosyltransferases [95].
Two X-ray structures involving Lex are available. The structure of Lex alone has
been solved [96,97] and recently the structure of a C-type lectin (DC-SIGN) in complex
with Lex was reported [1]. In 1996 two structures of the trisaccharide Lex were published
[96] and [97]. These were the first structures of a histo-blood group antigen. The reported
structures were very similar and the structure reported by Perez et al. [96] is discussed
here. In the asymmetric unit two independent Lex molecules were present. The
conformation of these two molecules was very similar except for the glycosidic torsion
angle at the Galβ1-4GlcNAc linkage, which differed by 10°. From NMR and molecular
modeling studies a similar conformation of Lex was observed, this is not very surprising as
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Figure 1.6 Packing of Lex within the crystal in long
parallel rows. The head-to head contact between the
Gal en Fuc residues might mimic the biological Lex-
Lex homotypic interaction.
it had already been established that the conformation of this trisaccharide is rather rigid
[98,99]. Interestingly, Lex is packed in the crystal in such a way that long rows of identical
molecules are formed (Figure 1.6). The two rows display a head-to-head arrangement.
This allows interaction between fucose and galactose residues from neighboring
molecules, which was indeed proposed for the Ca2+ mediated homotypic Lex-Lex
interaction [100]. Thus the crystal structure provided more evidence for the Lex-Lex
interactions involved in cell adhesion processes.
Recently, the structure of the dendritic cell receptor DC-SIGN in complex with
Lex was reported [1]. DC-SIGN, which can bind human immunodeficiency virus and
enhance infection, was originally found to bind to high mannose glycans N-linked
oligosaccharides [101,102]. In a later study it was also found that DC-SIGN can bind to
soluble egg antigen and that this interaction could be inhibited by an anti-Lex and an anti-
LDNF Mab. In addition, DC-SIGN strongly interacted with a neoglycoprotein carrying
Lex. These results suggest that Lex and possibly LDNF are also ligands for DC-SIGN [41].
In the same study, from site-directed mutagenesis experiments it was hypothesized that
the binding site for Lex and HIV gp120
(containing high mannose type N-glycans) are
located in different (perhaps overlapping)
regions on the carbohydrate recognition domain
(CRD) of the lectin.
Figure 1.7 A comparison of the binding of the
branched mannsose structure and Lex (black) to DC-
SIGN. The binding of the mannose structure (grey) is
extended into the secondary binding site (picture was
adapted from [1]).
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Figure 1.8 Overall architecture of
IgG, consisting of a dimer of a
light and heavy chain, which are
linked via disulfide bridges.
This hypothesis turned out not to be entirely correct. Indeed the crystal structures of DC-
SIGN in complex with Man4 and Lex (PDB codes 1SL4 and 1SL5 respectively) revealed
that the lectin has a primary and a secondary binding site [1], but both sugars bind to the
primary binding site of the lectin. Although, the binding of the branched mannose
structure involves more extended interaction with the secondary binding site (Figure 1.7).
In the primary binding site the 3- and 4-OH groups of both the fucose (from Lex) and the
mannose interact with the protein via coordination with the Ca2+. Because the 4-OH in the
fucose is axial and in the mannose equatorial, these residues have a different orientation in
the binding site. As a result the fucose is located close to Val351 making a Van der Waals
interaction, which is an important factor for the stability of the complex. In the case of the
mannose ligand, Val351 is 3.9 Ǻ away and does not contribute a Van der Waals
interaction. This explains why from the site-directed mutagenesis experiments the Val351
to Gly mutation had an effect on Lex binding but not on the binding of branched mannose
structures. Furthermore, it was suggested that the key to make a distinction between self
and non-self antigens by DC-SIGN was that on the surface of pathogens highly dense
clusters of oligosaccharides are present, which are uncommon to endogenous cell
surfaces. The closely spaced glycans could allow for high affinity binding of the multiple
CRDs in the DC-SIGN tetramer. Perhaps more carbohydrate-binding proteins, which were
found to interact with carbohydrate structures other than Lex could display dual specificity
as found for DC-SIGN. Binding studies, in combination with X-ray crystallography and
site-directed mutagenesis might reveal new binding partners for Lex, this could lead to
new insights in the innate or cellular immune response towards Lex.
4. Antibody-carbohydrate interactions
As this thesis deals with Lex-antibody interactions, this section focuses on previously
determined Fab-carbohydrate structures. First a general introduction of the overall
architecture of antibodies and the structure of
Fab fragments will be given.
4.1. Antibody architecture
Antibodies, also known as immunoglobulins
(Ig) consist of a dimer of a light and a heavy
chain, which are linked via disulfide bridges
(Figure 1.8) [103]. The light chain can be one of
two classes or isotypes, namely κ or λ, whereas
the heavy chain may belong to any of five
different isotypes γ, µ, δ, α or ε, which also
determine the class to which the antibody
belongs (IgG, IgM, IgD, IgA or IgE). All these
different classes of antibodies have different
effector properties in the elimination of antigens
[104]. IgG, IgD and IgE exist as monomers
whereas IgM and IgA exist as pentamers and dimers respectively. A large number of IgG
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molecules have been sequenced and it was found that the main sequence variability was
located in the amino-terminal part of the molecule, hence its name variable domain. The
C-terminal domain showed hardly any variability in the sequence and is named the
constant domain. In the light chain there is one variable and one constant domain (VL and
CL respectively), the heavy chain consists of one variable and three constant domains (VH
and CH1,2 or 3 respectively). In both the heavy and the light chain variable domains, several
invariant glycine residues are found at positions 99 and 101 in VL and at positions 104 and
106 in VH. These glycines were implicated in providing flexibility, permitting adjustment
of VL and VH to enable maximum contacts with the antigenic determinants [105].
Interestingly, after comparing many sequences of variable domains it was noticed that
three regions within the variable domain were highly variable, whereas the rest of the
chain was rather homologous. These three regions are called the hypervariable regions or
complementary determining regions (CDRs) and vary in size and sequence between
different antibodies, thereby determining the specificity. The three CDRs of both the
heavy and the light chain together form the antigen-binding site at the tip of the molecule,
with the rest of the residues of the variable domain constituting the framework. CH1 and
CH2 are connected via a hinge region. This hinge region makes the molecule rather
flexible allowing optimal alignment with the antigen, but making crystallization of intact
antibodies a difficult task. Therefore before crystallization, most antibodies are cleaved at
the hinge region with papain, to obtain the so-called fragment antigen binding (Fab). A
Fab fragment still binds the antigen and is easier to crystallize.
Both constant and variable domains of the heavy and the light chain show close
structural similarity despite the difference in sequence (Figure 1.9).
Figure 1.9 Immunoglobulin fold of A)
constant domain and B) variable domain.
(picture was adapted from [106])
All domains have the immunoglobulin fold, which can be described as two anti-parallel β-
sheets that are tightly packed against each other and joined together via a disulfide bridge.
This topology can be regarded as a form of the Greek key barrel. The constant domains
have seven β-strands connected via short loops. The variable domain has nine β-strands,
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with the two extra β-strands compared to the constant domain being inserted into the loop
region that connects β-strands C and D. These two β-strands form the framework that
positions CDR2 close to the two other CDRs. The hypervariable regions are located in
three loops that connect the β-strands. The variable domains of the heavy and the light
chain are tightly associated via the five-stranded β-sheet, each sheet forms half a barrel.
As a result of the association a complete barrel structure is formed by eight anti-parallel β-
strands, with the six CDR loops located at one end of the barrel (Figure 1.10).
Figure 1.10 Schematic diagram of a) the
barrel formed by the packing of the light
and the heavy variable domains. b) The
six CDRs are located at the top of the
barrel. (Picture was adapted from [106]).
Although the hypervariable regions vary in size and sequence between different
antibodies, it has been found that five of the six hypervariable regions usually have one of
a small number of main chain conformations, called canonical structures [107]. The
conformation of a particular canonical structure is determined by the length of the loop
and residues present at key sites [108]. For the three CDRs of Vκ, six CDR-L1, one CDR-
L2 and six CDR-L3 canonical structures were identified. In the case of Vλ, four CDR-L1
and two CDR-L3 canonical structures have been described, a similar structure was
observed for CDR-L2 in Vκ and Vλ chains. In the heavy chain only for CDR-H1 and
CDR-H2 canonical structures can be described, three and four respectively.a As the third
CDR of the heavy chain is far more variable than the others in length, sequence and
structure it was not possible to ascribe a particular set of canonical structures to this loop.
However, several groups have extensively studied a large number of CDR-H3 loops and
from this they were able to formulate some rules to predict the conformation of CDR-H3
[109-111]. They distinguished two types of conformations of the H3 region, the kinked or
extended region (also called bulged or non-bulged respectively). Scanning the residues
from the C-terminal end of CDR-H3, the first major choice is at residue 101, which can
either form a β-bulge or continue the regular pattern of β-sheet hydrogen bonding, this
distinguishes between kinked or extended, although some exceptions to this rule have
been found as well. Furthermore, the length of the CDR-H3 loop is of importance to
                                                          
a The canonical classification of the CDRs, the CDR-H3 terminal conformation and H3-
rules and modeling of the antigen binding site on basis of the sequence is available from:
http://acrmwww.biochem.ucl.ac.uk/abs/index.html.
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predict its conformation, loops with 12 up to 22 residues were observed and some
similarities between loops with the same number of residues were
found. As the side chain of certain residues within the CDR-H3 region as well as other
CDR loops neighboring CDR-H3 are also of influence to the conformation of the loop, it
may not always be possible to accurately predict its conformation. However, the growing
number of high-resolution structures of antibodies aids to a more precise prediction of the
CDR-H3 conformation. Already for a long time antigen binding-sites have been modeled
[112], and the models will become more accurate with increasing knowledge about the
CDR regions and newly found correlations between length and sequence of the CDRs and
the nature of the antigen [113].
The CDRs determine the overall shape of the binding-site and this is correlated
with the type of antigen. Deep pockets are characteristic for antibodies that bind small
haptens whereas antibodies that bind proteins have a relatively flat surface [114]. In 1975,
the binding properties of binding sites in Mabs specific for both terminal and non-terminal
antigenic determinants in dextran (polyGluα1-6) were studied [115]. One Mab interacted
with a terminal glucose and did not precipitate with a synthetic linear dextran of about 200
α(1-6)-linked glucoses, whereas another Mab did precipitate linear dextran. It was
hypothesized that Mabs binding a terminal sugar represent a cavity-type antibody whereas
a Mab binding an internal chain of oligosaccharides represents a groove-type antibody.
Later in a cloning and sequencing study by Borden and Kabat [116] it was indeed shown
that the Mab specific for the terminal glucose had a small cavity into which the glucose
would fit with the rest of the site being a groove. At present the structures of fourteen Fab
and one Fv fragments in complex with an oligosaccharide have been solved (Table 1.1).
Most Mabs were complexed with a branched oligosaccharide and displayed a cavity-type
binding site. One strictly linear polysaccharide was co-crystallized and this Mab showed a
groove-type binding site. Thus the proposed cavity/groove-type binding sites for terminal
or internal sugars fits well with the observed structures. Interesting differences between
the modes of binding of the Fabs to the carbohydrate antigens will be discussed below.
4.2. Fab-carbohydrate structures
The first Fab fragment that was solved in complex with an oligosaccharide was anti-
Salmonella Mab Se155-4 in complex with a bacterial dodecasaccharide [117]. It was
found that this Mab binds epitopes distributed along the polysaccharide O-antigen that is
anchored to the outer membrane of the pathogenic Salmonella of serogroup B. This O-
antigen is built up from repeating units of four sugars (Table 1.1).
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1F4X S-20-4 Fab cavity Ogawa monosaccharidea 2.3 [120]
1F4Y S-20-4 Fab cavity Ogawa disaccharideb 2.8 [120]
1M7D SYA/J6 Fab groove Rhaα1-3(2-deoxy-
Rha)α1-3GlcNAcβ-OMe
2.3 [87]




1Q9Q S25-2 Fab cavity Kdoα2-8Kdoα2-4Kdo
 α2-O-allyl
1.49 [121]
1Q9R S25-2 Fab cavity Kdo 1.73 [121]
1Q9T S25-2 Fab cavity Kdoα2-8Kdoα2-O-allyl 1.45 [121]
1Q9V S25-2 Fab cavity Kdoα2-4Kdoα2-O-allyl 1.74 [121]













1OP3 2G12 Fab cavity Manα1-2Manα 1.75 [2]






cA novel binding site was created by domain swapping of the two VH domains.
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Although the Fab was co-crystallized with a dodecasaccharide, the electron
density map only showed density for three sugar residues (Gal, Man and Abe). It became
clear that the branched Abe was snuggled up in a small pocket, with the rest of the
carbohydrate chain bound along the surface of the antibody. It should be noted that the
residues are bound perpendicular to the VH and VL interface rather than parallel. This
interface could be classified as a groove-like with a cavity antigen-binding site (Figure
1.11a). Aromatic residues dominated the binding site and played a major role in defining
the specificity and lining the binding site, two tryptophanes were found to stack with the
sugar residues. Furthermore, a water molecule was found at the bottom of the binding site,
bridging the Fab with the Abe. Another Mab displaying a real cavity-type binding site is
anti-tumor Mab BR96 which binds Lewis Y [122]. Its binding site is completely different
compared to the binding site of Se155-4, a large deep binding site is formed that fits the
complete tetrasaccharide (Figure 1.11b). This pocket is also predominantly formed by
aromatic residues, but interestingly no stacking interactions between aromatic side chains
and pyranose rings were observed and no water molecules were observed bridging the
carbohydrate ligand and the protein.
Figure 1.11 Surface representations of Fab-carbohydrate complexes. A) Mab Se155-4, a groove is
formed perpendicular to the VH-VL interface, with the Abe snuggled up in a pocket. B) Mab BR-96
has a large pocket, which completely fits the Ley tetrasaccharide. C) Mab S20-4, the terminal ogawa
monosaccharide is embedded in a small cavity is present at the VH-VL interface D) Mab SYA/J6
displays a large groove along the VH-VL interface which can bind the internal repeat of the sugar
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Recently, the structure of another Fab fragment (hu3S193) in complex with Ley was
published [123]. Remarkably, both Mabs bound the Lex portion of Ley in very similar
ways utilizing, except for two ligand contact residues, the same interactions. The most
obvious differences between these two Mabs were in the mode of binding to the Ley-
specific fucose residue. In BR-96 no obvious specificity-determining interactions were
observed between the Ley-specific fucose residue and the protein, whereas in hu3S193 this
fucose residue was held in place by two solvent molecules, that bridged between the
fucose and Tyr H33. Furthermore, in hu3S193 the side-chain of Asn L28 makes two
hydrogen bonds with this fucose. In BR-96 the CDR-L1 main chain conformations are
different and the Asn L28 side chain is pointing away from the binding cavity.
In contrast with the previous three Mabs discussed, which interact with at least
three sugar residues, anti-cholera Mab S20-4 is specific for a monosaccharide [120]. From
a surface representation it can immediately be seen that an extended binding pocket is
formed by two adjacent pockets at the interface of VH and VL (Figure 1.11c) that is
specific for the terminal antigenic Ogawa monosaccharide (Table 1.1). From a
fluorescence titration experiment it was concluded that this terminal residue accounts for
90 % of the binding energy and it was shown that polymerization of the ligand (2 to 6
residues) did not have a
significant effect on the affinity
for the carbohydrate ligand. The
interaction between the Fab and
the sugar residue is stabilized by
six direct hydrogen bonds. No
water molecules were trapped in
the complex and no aromatic
stacking interactions were
present. Interestingly, for this
complex the hydrophobic
character of the central binding
pocket plays a critical role in
carbohydrate recognition. The 2-
O-methyl group of the
monosaccharide is buried in this
pocket formed by aromatic and
aliphatic side chains, no
interaction was found with a
non-methylated derivative.
So far only one
structure has been reported of a
Mab recognizing a linear
bacterial polysaccharide [87];
Mab SYA/J6 which is specific
for Shigella flexneri Y
Figure 1.12 Model of glycan recognition of GP120
by 2G12. Glycans bind simultaneously to two
binding sites at the VL-VH and the VH-VH' interface.
Adapted from [2]).
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lipopolysaccharide. Parallel at the interface of VH and VL a groove-type binding site was
observed, which is about 25 Å long, 10 Å deep at the center and 12 Å wide. As clearly
seen from Figure 1.11d this binding pocket is much larger than the binding sites of the
Mabs displaying the cavity-type binding site. All residues of the co-crystallized
pentasaccharide were visible in the electron density map and made contacts with the
protein both via hydrogen bonds and Van der Waals interactions, no aromatic stacking
interactions were observed. Furthermore, two water molecules bridge between the ligand
and the protein. From the crystallographic data it was concluded that this Mab is indeed
specific for internal repeating oligosaccharides because the non-reducing terminal sugar of
the pentasaccharide was partially exposed to the solvent and a model of the O-
polysaccharides fitted the binding site without steric clashes. This also correlates with the
proposed groove-like binding site for Mabs that are specific for linear internal
polysaccharides.
Recently, a structure was solved of a Fab in complex with a branched
carbohydrate structure, which is present on gp120 envelope glycoprotein [2]. A very
unusual mode of binding was observed as not only a regular carbohydrate binding site was
formed at the interface of VH and VL, but also second one by domain swapping of the VH
domains (Figure 1.12). Biophysical experiments such as gel-filtration, ultra-centrifugation
and negative stain electron-microscopy supported that the domain swapped Fab dimer is
the functionally relevant form of the antibody. This oligomeric structure of 2G12 could
then account for the unusually high affinity recognition of a carbohydrate antigen by
providing a surface for multivalent interaction of carbohydrate clusters present on the
surface of gp120.
Although many basic features of protein-carbohydrate interactions have been
found in the above described complexes, each Mab contained its own specific antigen-
binding site having specific interactions with the antigen, which could not always have
been predicted as is nicely illustrated by the unusual binding mode of Mab 2G12. In
general protein-carbohydrate interactions play a key role in many biological processes
such as cell signaling and fertilization. But also infection with bacteria, viruses and
parasites involves carbohydrate-mediated recognition and in some cases tumor metastatic
processes are mediated by protein-carbohydrate interactions. A better understanding of
these interactions at the molecular level will enable the development of novel, effective
and highly selective therapeutics in a wide range of applications.
5. Scope of this thesis
The trisaccharide Lex both in monomeric and oligomeric form is involved in many
physiological but also pathological biological processes. This thesis focuses on the
structural aspects of Lex-antibody interactions in relation to a schistosomal infection, In
particular, antibodies to the different oligomeric forms of Lex were studied both in vitro
and in vivo. So far, only the humoral immune response towards monomeric Lex in a
schistosomal infection has been studied. Likewise in functional immunological studies
only the effect of monomeric Lex in the stimulation of the cellular immune response was
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investigated so far. As the schistosomes express both monomeric and oligomeric Lex, we
believe that the humoral immune system can discriminate between different oligomeric
states of Lex. To address this, we have first chemically synthesized mono- di- and trimeric
Lex, which is discussed in chapter 2. Next, in chapter 3, the conjugation of the synthesized
Lex-derivatives to bovine serum albumin is described followed by the screening of a large
panel of anti-schistosomal Mabs for their interaction with these and commercially
available Lex neoglycoconjugates using surface plasmon resonance. The Mabs that did
interact with the Lex neoglycoconjugates could be divided into three groups according to
their interaction behavior with one or more of the Lex neoglycoconjugates. From each
group one Mab was selected for X-ray structural studies. chapter 4 deals with the
digestion of the selected Mabs to obtain Fab fragments, their purification and finally
crystallization of the obtained Fab fragments. Subsequently in chapter 5, after successful
crystallization and X-ray analysis of anti-monomeric Lex Fab fragment 291-2G3-A, the
structure of this Fab with and without Lex is discussed. After the promising result found in
chapter 3 indicating that the humoral immune response upon a schistosomal infection can
indeed discriminate between mono- and oligomeric Lex, it was also decided to study the
anti-Lex response in vivo in a time course study in mice infected with S. mansoni. The
results of this study are discussed in chapter 6. Apart from Lex, many more interesting
carbohydrate structures are expressed by the schistosomes. For example the structures
present on the O-glycans of the cercariae and the glycolipids of eggs contain the
schistosome specific Fucα1-2Fuc unit. A set of spacer-linked GlcNAc derivatives
containing one, two or three fucoses (Fucα1-20-2Fucα1-3GlcNAcβ-spacer) was
synthesized and screened for interaction with a panel of anti-schistosomal Mabs. In
analogy with the results obtained from the interaction study with the Lex oligosaccharides
(chapter 3), the Mabs could be grouped according to their interaction with one or more of
the fucosylated sugars. These Mabs were subsequently used in immunofluorescence
assays to probe the different fucosylated structures on frozen sections of adult worms. The
results and discussion of this study are presented in chapter 7.
In addition, in chapter 8 the structure of an empty capsid of turnip yellow mosaic
virus is presented. The structure of this empty capsid was compared to a previously
published structure of the intact virus. Certain differences were found between the
capsids, which might have implications for the encapsidation or decapsidation of viral
RNA in the capsid.
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2
The synthesis of monomeric,
dimeric and trimeric Lewis X
derivatives
Summary
Both monomeric and oligomeric Lewis X are expressed by schistosomes, tropical
parasitic worms that cause schistosomiasis. It is known that individuals infected with
these parasites raise an immune response against Lewis X. To be able to discriminate
between a possible anti-monomeric or anti-oligomeric Lewis X immune response,
monomeric, dimeric and trimeric Lewis X have been synthesized. The synthesis of these
oligosaccharides is described in this chapter. A key step in the synthesis was the selective
β-coupling of Lewis X building block 16 to various acceptors by performing the
glycosylation reaction at low temperature in acetonitrile (nitrile effect). The Lewis X
oligosaccharides were synthesized with an aminohexyl linker. This functional handle
allows for conjugation to a carrier molecule such as bovine serum albumin, for use in
immunological studies. In addition, β-O-methylated glycosides of mono-, and dimeric
Lewis X were synthesized for use in crystallographic studies.
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Introduction
Schistosoma species are trematode worms that cause a chronic, debilitating, sometimes
fatal disease called schistosomiasis in vertebrates, including humans in the tropics. These
parasites have a complex life cycle involving a fresh water snail intermediate host and a
vertebrate definitive host. Throughout the different life stages of the schistosome
numerous antigenic carbohydrate structures are expressed on its surface or are excreted
into the circulation of its host. It is thought that the major humoral immune response
against the parasites is directed against these glycan structures ([1] and references cited
therein). One carbohydrate structure that is abundantly expressed throughout the life
stages of the parasite is the trisaccharide Lewis X (Galβ1-4(Fucα1-3)GlcNAcβ1, Lex) [2].
As this carbohydrate structure is shared with the host, it was suggested that the Lex
determinant itself and the immune response against Lex play a role in the survival of the
parasite within its host [3-5]. However, hard evidence to support this hypothesis in vivo
has not been reported so far.
Anti-Lex monoclonal antibodies (Mabs) have been shown to react with the oral
sucker of cercariae, and after the transformation of the cercariae into schistosomula, Lex is
expressed in patches on the surface [6]. In adult schistosomes, the anti-Lex Mab stained
the surface of the worms and the gut epithelium of both male and female worms, and Lex
was also found on the egg shell and as a component of soluble egg antigen (SEA) [6,7].
Schistosomes also express polymeric Lex [8]. It has been found that the immunoreactive
part of circulating cathodic antigen (CCA), that is excreted from the gut of adult worms in
relatively high amounts, predominantly consists of repeating Lex trisaccharides [9]. To
date, most people studying the anti-Lex response have used monomeric Lex [10-13] and
for immunolocalization studies antibodies known to bind to monomeric Lex  were used
[6,7]. It is not unreasonable however to assume that the immune response can discriminate
between various oligomeric states of Lex. Therefore, it would be of interest to use
different oligomers of Lex in immunological studies.
In view of the above, a study was undertaken to synthesize Lex in various
oligomeric forms (i.e. mono-, di- and trimeric, Figure 2.1). These synthetic
oligosaccharides will be used as research tools to study whether anti-schistosomal Mabs
can discriminate between different oligomers of Lex (chapter 3). Furthermore, measuring
the antibody response against these different Lex oligosaccharides in serum from mice
with a schistosomal infection will be useful to study the influence of the oligomeric state
of Lex on the humoral immune response in vivo (chapter 6). To allow conjugation to
various carrier molecules, such as labels or resins for use in immunological studies, the
synthesized Lex-glycosides were functionalized with an aminohexyl spacer (21, 31 and 39,
Figure 2.1). In addition, β-O-methylated Lex derivatives 43 and 47 were synthesized to
use in X-ray crystallographic studies as ligands for the Mabs found to interact with these
sugars. The rationale behind this was that the aminohexyl spacer might interfere with co-
crystallization when used in these studies. In addition, the non-fucosylated derivative of
Lex, N-acetyllactosamine 26 (Galβ1-4GlcNAcβ, LacNAc) was synthesized to use as a
negative control in the immunological studies.
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Figure 2.1 Overview of the synthetic LacNAc and Lewis X derivatives.
Synthetic strategy
A straightforward and efficient route to synthesize oligomeric Lex derivatives was
described by Toepfer et al.. [14]. Central in this route is the protected monomeric Lex
building block 12 (Scheme 2.2), which can be selectively deprotected at the reducing or
the non-reducing end, thus allowing selective elongation and functionalization. A key
feature of the synthesis is the selective β-coupling of Lex donors 16 and 35 to various
acceptors (Scheme 2.4). Although the Lex building blocks were provided with the non-
participating azido group as a masked N-acetyl function, execution of the glycosylation
reactions in acetonitrile at low temperatures led selectively to the β-anomers, a result that
can be explained by the nitrile effect [15] [16]. Another important step in this synthesis
was the regioselective coupling of donors 16 and 35 to the C3-OH of Lex acceptors 27, 32
and 44 (Scheme 2.4). As found by Toepfer et al. [14], glycosylation only yielded C3
regioselective coupled products because the protective group pattern of the acceptor
resulted in a higher reactivity of the C3-OH compared to the C2-OH.
In this chapter the synthesis of glycosides 26, 21, 31, 39, 43 and 47 is described
(Figure 2.1). The key glycosylation steps between the Lex building blocks are depicted in
Scheme 2.4. Dimeric Lex derivative 31 was obtained via 3+3 coupling of donor 16 and
acceptor 27 and subsequent deprotection. A 6+3 coupling between donor 35 and acceptor
27 afforded trimeric Lex 39 after removal of the protecting groups. In principle, the

























































































31 R = (CH2)6NH2





39 R = (CH2)6NH2
26 R = (CH2)6NH2
21 R = (CH2)6NH2
43 R = Me
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Results and discussion
The synthesis of the Lex oligosaccharides commenced with the synthesis of monomeric
Lex 12 (Scheme 2.2) that was readily obtained from the protected glycosidic building
blocks 5, 9 and 14 (Scheme 2.1). Glucosamine was converted into its acetylated azido
derivative 1, first by diazotransfer from triflyl azide with Cu2+ as a catalyst [17], followed
by acetylation. Next, the anomeric acetyl group was cleaved with hydrazine acetate in 93
%, followed by protection of the anomeric hydroxyl with a tert-butyldimethylsilyl group
to obtain 3 in 85 % yield. This protecting group at the anomeric position allowed for
selective deprotection of the reducing end of protected 12 and 33 at a later stage of the
synthesis. The synthesis of glucosazido acceptor 5 was completed by deacetylation of 3
under Zemplén conditions [18] and installation of a 4,6-O-benzylidene group with
benzaldehyde dimethylacetal in 4 in the presence of a catalytic amount of p-
toluenesulfonic acid.
Scheme 2.1 Synthesis of protected building blocks of monomeric Lex.
Reagents and conditions: i 2.5 eq. TfN3 in DCM, 1.5 eq. K2CO3, CuSO4 (cat), H2O/MeOH, r.t.,
48h.; Ac2O, pyridine, r.t., overnight; ii 1.06 eq. H2NNH2.H2O, 1.07 eq. HOAc, DMF, r.t., 3h; iii 1.25
eq. TBDMSCl, 2 eq. imidazole, DMF, r.t., overnight; iv NaOMe, MeOH, r.t., 2h; v 1.4 eq.
PhCH(OMe)2, p-TsOH, CH3CN, r.t., 2h; vi MeOH/HCl, reflux, overnight vii 8.5 eq. BnBr, 3.5 eq.
NaH, DMF, r.t., 48h; viii HOAc/HCl, 90-100ºC, 2h. ix 2.5 eq. CCl3CN, Cs2CO3, CH2Cl2, r.t., 3h; x
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The synthesis of  fucose donor 9 started with anomeric methylation of L-fucose
by overnight refluxing in a hydrochloric acid/methanol solution, followed by complete
benzylation using benzyl bromide and sodium hydride as a base. The overall yield over
these two steps was 67 %. Compound 7 was subsequently demethylated in 87 % yield to
give compound 8, which was converted into donor 9 by treatment with
trichloroacetonitrile and cesium carbonate in 93 %.
Galactose derivative 13, obtained by selective anomeric deacetylation of
peracetylated galactose, was transformed into galactosyl donor 14 by treatment with
trichloroacetonitrile and cesium carbonate in an overall yield of 73 % over the two steps.
Scheme 2.2 Synthesis of protected monomeric Lex.
Reagents and conditions: i 0.01 eq. TMSOTf, Et2O, 4 Å MS, r.t., 15 min. under nitrogen
atmosphere; ii 6 eq. BH3NMe3, 7.5 eq. AlCl3, THF, 50 ºC, overnight; iii 0.01 eq. TMSOTf, DCE, 4
Å MS, r.t., 20 min. under nitrogen atmosphere.
Having building blocks 5, 9 and 14 in hand, the assembly of monomeric Lex
building block 12 was undertaken. As fucosyl donor 9 is very reactive, the glycosylation
reaction between donor 9 and acceptor 5 was carried out under inverse procedure
conditions [19], contrary to all other glycosylations, which were carried out by the
standard protocol meaning addition of the catalyst to a mixture of the donor and acceptor.
Imidate 9 was slowly added to a pre-mixed solution of 5 and trimethylsilyltriflate
(TMSOTf) as the catalyst in Et2O to give disaccharide 10 in high yield (89 %). The
regioselective reductive opening of the benzylidene function in compound 10 was met
with difficulties. As acidic conditions were required for this reaction, the rather labile
glycosidic linkage between the fucose and the glucosamine moiety was concomitantly
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presence of HCl in diethylether could not be improved by reduction with BH3NMe3 and
AlCl3 in THF [20]. The latter conditions were used as they were much easier to handle.
Stereoselective coupling of galactose donor 14 and acceptor 11, with 0.01 eq. of TMSOTf
as a catalyst in DCE gave protected monomeric Lex 12 in an overall yield of 33 %, starting
from the protected glucosidic building block 5.
Scheme 2.3 Functionalization of monomeric Lex building block 12.
Reagents and conditions: i 5 eq. TEA.3HF, pyridine, r.t., overnight; ii 6 eq. CCl3CN, Cs2CO3,
CH2Cl2, r.t., overnight; iii 0.05 eq. TMSOTf, CH3CN, 3 or 4 Å MS, -40 ºC, 2-12h.
In first instance, the key-Lex building block 12 was functionalized either with a
spacer or a methyl group (Scheme 2.3), which would allow easy access to functionalized
dimeric Lex derivatives 28 and 45 and trimeric Lex derivative 36 in a later stage of the
synthesis (Scheme 2.4). Donor 16 was readily obtained from 12 by selective anomeric
deacetylation, followed by standard trichloroacetimidate formation. Subsequent
glycosylation of 16 with 6-N-benzyloxycarbonylaminohexanol or MeOH in acetonitrile at
-40º C, using 0.05 eq. TMSOTf as a catalyst, afforded exclusively β-linked glycoside 17
and 40 in 66 and 72 % yield respectively.
To obtain Lex dimers, monomeric Lex building blocks 12, 17 and 40 were
subjected to protective group manipulation to transform them into suitable glycosyl
acceptors (Scheme 2.4). To this end, deacetylation and installation of a 4,6-O-benzylidene
function furnished acceptors 27, 32 and 44. Having both donor 16 and the acceptors in
hand, the stage was set for the glycosylation reaction between the Lex building blocks.
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catalyst furnishing exclusively β-linked dimeric Lex 28, 33 and 45 in 72, 74 and 69 %
yield respectively (Table 2.1 gives an overview of all the glycosylation reactions and their
respective yields).
Scheme 2.4 Synthesis of di- and trimeric Lex conjugates.
Reagents and conditions: i NaOMe, MeOH, r.t., 2h; ii 1.4 eq. PhCH(OMe)2, p-TsOH, CH3CN, r.t.,
2h; iii 0.01-0.05 eq. TMSOTf, CH3CN, 3 or 4 Å MS, -40ºC, 2-12h; iv 5 eq. TEA.3HF, pyridine, r.t.,
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Finally, successful synthesis of dimeric Lex compound 33 allowed further
elongation with monomeric Lex to obtain trimeric Lex compound 36 (Scheme 2.4). To this
end, dimeric Lex conjugate 33 was transformed into the trichloroacetimidate donor 35, as
described previously for the conversion of 12 into 16. Subsequently, coupling of 35 and
27 using similar conditions as described for the other glycosylation reactions between Lex
building blocks gave 36 in 64 % yield.
Table 2.1 Coupling of donor 16 and 35 with various acceptors and the yield.
Donor Acceptor Product Yield (%)
monomeric Lex
16 HO(CH2)6NHZ 17 66
16 MeOH 40 72
dimeric Lex
16 32 33 74
16 27 28 72
16 44 45 69
trimeric Lex
35 27 36 64
In the final stage of the synthesis to the mono-, di- and trimeric Lex glycosides
(Figure 2.1), the protective groups in monomeric 17 and 40, dimeric 28 and 45 and
trimeric 36 Lex derivatives were removed. A similar deprotection route was followed for
all the Lex conjugates and this is illustrated in Scheme 2.5 by the complete deprotection of
the monomeric Lex conjugates 17 and 40. First, the azido-group was reduced with tri-
methylphosphine [21]. Subsequent hydrolysis of the obtained trimethyliminophosphorane
furnished an amine, which was readily acetylated. Toepfer et al. [14] used H2S in
pyridine/water to reduce the azide. These conditions however might leave traces of sulfide
that could complicate the palladium catalyzed hydrogenation in the final deprotection
step, therefore alternative conditions were chosen for the reduction of the azide. The last
deprotection steps entailed deacetylation under Zemplén conditions followed by removal
of the benzyl protecting groups and the benzyloxycarbonyl protecting group in case of the
Lex conjugate 17. In analogy with Kretschmar et al. [22] the latter deprotection step was
carried out by catalytic transfer hydrogenation [23] with formic acid as the hydrogen
donor and Palladium black as the catalyst.
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Scheme 2.5 Deprotection of monomeric Lex derivatives 17 and 40.
Reagents and conditions: i 2 eq. Me3P, THF, r.t., 10 min.; H2O, r.t., overnight; Ac2O, pyridine, r.t.,
overnight; ii NaOMe, MeOH, r.t., 2 h; iii Pd-black (cat), HCOOC, MeOH, r.t., overnight.
As mentioned, the deprotection of both dimeric Lex conjugates 28 and 45 and
trimeric Lex conjugate 36 was carried out as described for the monomeric Lex derivatives.
The yields of the azide reduction and the final deprotection steps of all the compounds are
depicted in Table 2.2. The rather low yield (50 %) of the deprotection of trimeric Lex
conjugate 36 could most likely be attributed to the smaller scale at which this reaction was
performed, compared to the deprotection of the other compounds. Compound 39 was
characterized by 1H NMR and MALDI-TOF mass spectrometry.
Table 2.2 Yields of final deprotection steps.
Compound Azide Reduction (%) Product Final deprotection (%) Product
monomeric Lex
17 77 19 80 21
40 65 41 82 43
dimeric Lex
28 75 29 72 31
45 62 46 68 47
trimeric Lex
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In addition to the preparation of the Lex related glycosides, N-acetyl-lactosamine
conjugated with a linker 26 (LacNAc-spacer) was synthesized. A "one-pot" procedure to
obtain N-acetyl-lactosamine from lactulose [24] could not be reproduced, several attempts
always resulted in a dark mixture of compounds. Therefore, a different synthetic approach
was chosen depicted in Scheme 2.6. Peracetylated N-acetylglucosamine was readily
coupled to 6-(N-benzyloxycarbonylamino)hexanol after the conversion of peracetylated
N-acetylglucosamine into an oxazoline intermediate using an excess of TMSOTf in DCE
at 60 °C. Before addition of the acceptor, the oxazoline was purified by flash
chromatography. This extra purification step was implemented as it was reported by
Kretzschmar et al. [22] that a one-pot procedure resulted in very poor yields (< 20 %).
The glycosylation reaction, carried out in DCE in the presence of 0.1 eq. TMSOTf having
the oxazoline intermediate as a donor and 18 as the acceptor proceeded in 66 % yield.
After deacetylation of compound 22 under Zemplén conditions, protection of the 3' and 6'
hydroxyl groups was established by a benzylation reaction in the presence of a mixture of
barium oxide and barium hydroxide.  The 3,6-dibenzylated compound 23 was obtained in
12.5 % yield, having the mono- and tribenzylated compounds as side products, which
could easily be separated by column chromatography. To prove the regioselectivity, 23
was acetylated to afford the 4-O-acetylated product, as confirmed by a downfield shift in
1H NMR of the C4 proton (δ 4H = 3.6 → δ 4H = 4.9).
Scheme 2.6 Synthesis of LacNAc derivative 26.
Reagents and conditions: i 1.1 eq. TMSOTf, DCE, 60 °C, 3h; 0.1 eq. TMSOTf, 2 eq. 18, DCE, 4 Å
MS, r.t., 48h; ii NaOMe, MEOH, r.t., 2 h. iii 16.5 eq. BaO, 1.6 eq. Ba(OH)2, DMF, r.t., 2 h; 4 eq.
BnBr, r.t., overnight; iv 0.01 eq. TMSOTf, DCM, 4 Å MS, r.t., 20 min. under nitrogen atmosphere;
v NaOMe, MeOH, r.t., 2 h; vi Pd-black (cat), HCOOC, MeOH, r.t., overnight.
i
22 R = Ac
23
R = H
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The coupling of 23 and 14 was performed in dichloromethane with 0.01 eq. TMSOTf as
the catalyst, the reaction proceeded in 70 % yield. The final deprotection steps
encompassed deacetylation under Zemplén conditions and subsequent debenzylation
using a catalytic hydrogen transfer reaction as described previously for the deprotection of
the Lex conjugates.
Conclusions
LacNAc, mono-, di- and trimeric Lex derivatives were successfully synthesized following
a synthetic route as previously described by Toepfer et al. [14]. A key step in the synthesis
was the exclusive β-coupling of Lex donors 16 and 35, which was achieved by performing
the reactions at low temperature in acetonitrile. Synthesized glycosides 26, 21, 31 and 39
contained a versatile linker, which allows for easy and straightforward immobilization to
carrier molecules. The conjugation of the sugars to BSA and their subsequent use in a
surface plasmon resonance (SPR) study to investigate the interaction of a panel of anti-
schistosomal Mabs with these Lex neoglycoconjugates will be discussed in the next
chapter. In addition, mono- and dimeric Lex were synthesized as their respective methyl
glycosides 43 and 47 for use in X-ray crystallographic studies, described in chapters 4 and
5.
Material and methods
General procedures and materials: 1H and 13C-NMR spectra were recorded with a Jeol JNM-FX-
200 (operating at 200 and 50.1 MHz, respectively), a Bruker DPX-300 (300 and 75.1 MHz
respectively) or a Bruker DMX-600 (operating at 600 and 150 MHz respectively) spectrometer. 1H
and 13C Chemical shifts (δ) are given in ppm relative to tetramethylsilane (0.0) or CDCl3 (77.0) as
an internal standard. Mass spectra were recorded with a PE/SCIEX API 165 equipped with an
electrospray interface. MALDI-TOF mass spectrometric analyses were performed on a Reflex III
(Bruker Daltronics) mass spectrometer, operating at a accelerating voltage of 22 kV and equipped
with an N2 laser. Methanol (MeOH, Rathburn, HPLC grade) was stored over 3Å molecular sieves
and used without further purification. N,N-dimethyl formamide (DMF, Baker, p.a.),
dichloromethane (DCM, Baker, p.a.), 1,2-dichloroethane (DCE, Biosolve, HPLC grade), acetonitrile
(CH3CN,  Baker, p.a.), pyridine (Baker, p.a.) were stored over 4Å molecular sieves and used as
received. Tetrahydrofuran (THF, Baker, p.a.) was boiled under reflux with lithium aluminum
hydride for 2h, and distilled immediately prior to use. Toluene was boiled under reflux with CaH2
for 3h, distilled and stored over 4Å molecular sieves. Acetic acid (Baker, p.a.) acetic anhydride
(Baker, p.a.) were used as received.
Column chromatography was performed with silicagel 60, 230-400 mesh (Merck). TLC
analysis was done on DC-fertigfolien (Schleicher & Schull F1500, LS 254) with detection by UV
absorption (254 nm) and by spraying with 20 % H2SO4 in ethanol or a ninhydrine solution or a
solution of (NH4)6Mo7O24.4H2O 25g L-1 and (NH4)4Ce(SO4)4.2H2O 10g L-1 in 10 % sulfuric acid,
followed by charring at ~150C. Superdex gel filtration column chromatography was performed on
a Superdex Peptide PE 7.5/300 column (Amersham Pharmacia Biotech), using 25 mM NH4HCO3 as
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eluent. Reactions were run at ambient temperatures, unless stated otherwise. 13C NMR and 1H NMR
data are in accordance with [14,22] or otherwise given.
Acetyl-O-2-azido-3,4,6-tri-O-acetyl-2-deoxy-/-D-glucopyranoside (1) : 123 mmol NaN3 (8g)
was dissolved in 20mL H2O and 15mL CH2Cl2 in a three neck round bottom flask equipped with a
dropping funnel. The solution was cooled in an ice-bath to 0C and 4.1 mL Tf2O (25 mmol) was
added within half an hour under nitrogen atmosphere. The reaction mixture was stirred for two
hours at 0C, then the organic layer was separated and the aqueous layer was extracted twice with
10 mL CH2Cl2. The combined organic layers were washed with a saturated NaHCO3 solution, brine
and dried on MgSO4. The TfN3 solution was filtered and used without further purification.
D-glucosamine hydrochloride (2g, 9.3 mmol) was dissolved in 30 mL H2O, 1.9 g (13.9 mmol)
K2CO3 and 14 mg (88 mol) CuSO4 were added. Next the solution was diluted with 60 mL MeOH
and the TfN3 solution was added. The reaction mixture was allowed to stir over the weekend at
room temperature.  TLC analysis (30 % MeOH in EtOAc containing 0.5 % TEA) indicated
complete conversion into a less polar product and the solvents were removed in vacuo. Traces of
water were removed from the residue by coevaporation with toluene and the residue was dissolved
in 50 mL pyridine and 25 mL acetic anhydride. The reaction mixture was stirred overnight at room
temperature and concentrated under reduced pressure. The yellowish oil was dissolved in EtOAc
and washed three times with water and with a saturated NaHCO3 solution until no longer acidic. The
organic phase was dried over MgSO4 and filtered, column chromatography (EtOAc/light petroleum
1/4 v/v) yielded 3.1 g (7 mmol, 69 %) of the title compound with a 0.3/0.7 α/ ratio. Rf (EtOAc/light
petroleum 1/1 v/v) 0.80. 13C-NMR (CDCl3, 50.1 MHz): δ 169.5, 169.0, 168.7, 167.8 (CO OAc),
91.6 (C1), 89.2 (C1α), 71.7, 69.9, 68.9, 67.2, 61.8, 59,3 (C2, C3, C4, C5 α/β), 60.7, 59.4 (C6 α/β),
19.6 (4 x CH3 OAc). 1H-NMR (CDCl3, 200 MHz): δ 6.25 (d, 0.3H, H-1α, J 3.7 Hz), 5.51 (d, 0.7 H,
H-1, J 8.6 Hz), 5.41 (dd, 0.3H, H-3α, J 9.4, 10.4 Hz), 5.1-4.9 (m, 1.7H, 0.7H, H-3, 1H H-4α/),
4.25 (dd, 0.7H, H-6, J 4.1, 12.5 Hz), 4.24 (dd, 0.3H, H-6α, J 4.5, 12.4 Hz), 4.12-3.98 (m, 1.3H,
0.7H, H'-6, 0.3H, H-5α, 0.3 H'-6α), 3.76 (ddd, 0.7H, H-5, J 2.2, 4.5, 9.7 Hz), 3.62 (dd, 0.3H, H-
2α, J 3.7, 10.5 Hz), 3.62 (dd, 0.7H, H-2, J 8.6, 9.8 Hz), 2.15-1.98 (4 x s, 12H H-Ac).
2-Azido-3,4,6-tri-O-acetyl-2-deoxy-/-D-glucopyranose (2): 0.35 mL (7.6 mmol) H2NNH2.H2O
was dissolved in 10 mL DMF, 0.42 mL (7.5 mmol) HOAc was added while stirring. This solution
was added to a solution of 3.1 g (7 mmol) of compound 1 in 30 mL DMF. The reaction was stirred
at room temperature until TLC (EtOAc/light petroleum 1/1 v/v) indicated complete conversion of
the starting product. DMF was removed and the residue was taken up in EtOAc, washed with
saturated NaHCO3, dried over MgSO4 and filtered. The title compound was obtained after column
chromatography (EtOAc/light petroleum 1/1 v/v). Yield 2.16 g (6.52 mmol, 93 %). Rf (EtOAc/light
petroleum 1/1 v/v) 0.6. 13C-NMR (CDCl3, 50.1 MHz): δ 169.7, 169.4, 168.5 (CO OAc), 96.0 (C1),
91.9 (C1α), 72.5, 71.7, 70.3, 68.5, 68.6, 67.3, 64.7, 61.3 (C2, C3, C4, C5 α/β), 61.9, 61.8 (C6 α/β),
20.5 (3 x CH3 OAc).
tert-Butyldimethylsilyl-2-azido-3,4,6-tri-O-acetyl-2-deoxy--D-glucopyranoside (3):
Compound 2 (4.4 g, 13.4 mmol) was dissolved in 50 mL DMF. 2 eq. of imidazole (26.8 mmol, 1,83
g) and 1.25 eq. of TBDMSCl (16.75 mmol, 2.52 g) were added. After stirring overnight at room
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temperature the solvent was removed in vacuo and the resulting oil was taken up in EtOAc. The
organic layer was washed with water, saturated NaHCO3 and brine, dried (MgSO4) and filtered. The
pure crystalline compound was obtained in 85 % (6.1 g, 11.4 mmol) after column chromatography
(EtOAc/light petroleum 1/3 v/v). Rf (EtOAc/light petroleum 1/1 v/v) 0.75. 13C-NMR (CDCl3, 50.1
MHz): δ 169.7, 169.2, 168,9 (3 x CO OAc), 96.5 (C1), 71.7, 71.3, 68.4, 66.9 (C2, C3, C4, C5),
61.8 (C6), 25.0 (3 x CH3 tBu), 20.0 (3 x CH3 OAc), 17.4 (Cq tBu), -5.0, -5.8 (CH3 SiMe).
tert-Butyldimethylsilyl-2-azido-2-deoxy--D-glucopyranoside (4): To a solution of 2.1 g (4.7
mmol) silylether 3 in 50 mL dry methanol, NaOMe was added until basic. After completion of the
reaction the solution was neutralized using Dowex-H+, filtered and evaporated, giving 4 in a
quantitative yield without further purification. Rf (EtOAc/light petroleum 1/1 v/v) 0.1. 13C-NMR
(CDCl3, 50.1 MHz): δ 96.9 (C1), 75.2, 74.2, 69.6, 68.1 (C2, C3, C4, C5), 61.4 (C6), 25.3 (3 x CH3
tBu), 17.7 (Cq tBu), -4.5, -5.5 (CH3 SiMe).
 tert-Butyldimethylsilyl-2-azido-4,6-O-benzylidene-2-deoxy--D-glucopyranoside (5):
Compound 4 (1.5 g, 4.7 mmol) was dissolved in 35 mL dry acetonitrile and treated with 1 mL (1.03
g, 6.75 mmol) benzaldehyde dimethyl acetal and 8 mg p-toluenesulfonic acid. After two hours solid
potassium carbonate (0.2 g) was added and the reaction mixture was stirred for another half hour.
After filtration and evaporation the residue was purified using column chromatography (EtOAc/light
petroleum 1/4 v/v), yield 1.55 g (3.8 mmol, 81 %). Rf (EtOAc/light petroleum 1/1 v/v) 0.85. 13C-
NMR (CDCl3, 50.1 MHz): δ 137.0 (Cq benzylidene), 129.1, 128.2, 126.4 (5 x CH arom), 101.6 (CH
benzylidene), 97.3 (C1), 80.6, 71.2, 68.9, 66.1 (C2, C3, C4, C5), 68.3 (C6), 25.5 (3 x CH3 tBu),
17.7 (Cq tBu), -4.4, -5.3 (CH3 SiMe).
Methyl-/-L-fucopyranoside (6): A solution of 1.5 mL chloroacetic acid in 180 mL methanol
was stirred for 10 minutes at room temperature, subsequently 50 mmol (8.2 g) L-fucose was added.
The solution was refluxed overnight, cooled down and neutralized with a 1 M solution of NaOMe in
methanol. The solvents were removed in vacuo and compound 6 was used without further
purification. Rf (10 % MeOH in EtOAc) -glycoside 0.84, -glycoside 0.76.
Methyl-2,3,4-tri-O-benzyl-/-L-fucopyranoside (7): Compound 6 (8.9 g, 50 mmol) was
dissolved in dry DMF (200 mL) and cooled to 0C. NaH (4.4 g, 175 mmol) was added in small
portions, followed by BnBr (50 mL, 420 mmol). The reaction was stirred over the weekend at room
temperature, quenched with MeOH and evaporated. The resulting residue was taken up in EtOAc
and washed with H2O, sat. aq. NaHCO3 and brine, dried (MgSO4) and filtered. Compound 7 was
obtained in 67 % (15.1 g, 33.5 mmol) after column chromatography (EtOAc/light petroleum 1/4
v/v). Rf (EtOAc/light petroleum 1/2 v/v) : 0.79 and : 0.75. 13C-NMR (CDCl3, 50.1 MHz): δ
139.0, 138.7 (3 x Cq arom), 129.1, 128.3, 128.2, 128.0, 127.4 (15 x CH arom), 104.8 (C1), 98.7
(C1α), 79.3, 78.1, 77.7, 70.2 (C2, C3, C4, C5), 77.7, 76.4 (3 x CH2 benzyl), 55.1 (CH3 OMe), 16.6
(CH3).
2,3,4-Tri-O-benzyl-/-L-fucopyranose (8): 33.5 mmol (15.1 g) 7 was dissolved in 150 mL acetic
acid and 50 mL of a 1M solution of hydrochloric acid. The reaction mixture was heated to 90-100C
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for two hours. After cooling down the product was extracted twice with diethyl ether. The organic
layer was washed five times with saturated NaHCO3 until neutral, dried over MgSO4, filtered and
evaporated. Column chromatography (EtOAc:light petroleum 1:3) yielded pure crystalline 8 in 87 %
(29.2 mmol, 12.7 g). Rf (EtOAc:light petroleum 1:4) 0.35. 13C-NMR (CDCl3, 50.1 MHz): δ 138.9,
138.7, 138.5 (Cq arom), 128.4, 128.3, 128.2, 128.0, 127.6 (15 x CH arom), 97.8 (C1), 91.6 (C1α),
82.2, 80.9, 79.0, 77.6, 76.8, 70.5, 66.3 (C2, C3, C4, C5 α/β), 76.5, 75.1, 74.8 (CH2 benzyl), 16.9
(CH3 α/β).
O-(2,3,4-Tri-O-benzyl-/-L-fucopyranosyl) trichloroacetimidate (9): 8 (10 mmol, 4.3 g) was
coevaporated three times with dichloroethane and subsequently dissolved in 100 mL
dichloromethane. 2.5 Eq. (25 mmol, 2.5 mL) trichloroacetonitrile and 50 mg Cs2CO3 were added.
After TLC analysis (EtOAc:light petroleum 1:3 containing 0.5 % TEA) showed completion of the
reaction, the Cs2CO3 was removed by filtration and the solvent was removed under reduced
pressure. After flash chromatography (EtOAc:light petroleum 1:4 containing 0.5 % TEA) 93 % (9.3
mmol, 5 g) of the / mixture  was  obtained in a : ratio of 1:4. Rf (EtOAc:light petroleum 1:3,
0.5 % TEA) -compound is 0.76 and Rf -compound is 0.50. 13C-NMR (CDCl3, 50.1 MHz): δ
161.5, 161.1 (Cq imidate α/β), 138.7, 138.5 (Cq arom), 129.1, 128.4, 128.3 (15 x CH arom), 98.8
(C1), 94.4 (C1α), 91.7, 91.2 (CCl3 imidate α/β), 82.5, 78.3, 77.5, 75.9, 71.6, 69.6 (C2, C3, C4, C5
α/β), 73.1, 72.8 (3 x CH2 benzyl), 16.9 (CH3).
Tert-Butyldimethylsilyl-O-(2,3,4-tribenzyl--L-fucopyranosyl)-(13)-2-azido-4,6-O-
benzylidene-2-deoxy--D-glucopyranoside (10): 5 mmol acceptor 5 was coevaporated three times
with toluene and dissolved in a minimum amount of dry diethyl ether. 4Å molecular sieves were
added and the suspension was stirred for half an hour under nitrogen atmosphere. First a freshly
prepared 0.1M solution of trimethylsilyl trifluoromethanesulfonate in dry diethyl ether was added
(0.7 mL) followed by a concentrated solution of donor 9 (7.2 mmol, 4,14 g) in dry diethyl ether.
After 15 minutes 1 g solid NaHCO3 was added and the solution was filtered. The solvent was
evaporated and disaccharide 10 was purified by silica gel column chromatography (EtOAc:light
petroleum 1:6). Yield 89 % (4.5 mmol, 3.65 g). Rf (EtOAc:light petroleum 1:4) 0.69. 13C-NMR
(CDCl3, 50.1 MHz): δ 139.2, 139.0, 138.7 (4 x Cq arom), 137.1 (Cq benzylidene), 128.2, 127.9,
127.8, 127.5, 127.4, 127.3, 126.7, 126.3, 126.0 (20 x CH arom), 102.0 (CH benzylidene), 97.9
(C1a), 97.4 (C1b), 79.4, 79.3, 77.9, 75.7, 75.5, 69.3, 66.7, 66.4 (C2, C3, C4, C5 a and b), 74.8, 73.0
(3 x CH2 benzyl), 68.6 (C6a), 25.6 (3 x CH3 tBu), 17.9 (Cq tBu), 16.1 (CH3b), -4.4, -5.1 (CH3
SiMe).
Tert-Butyldimethylsilyl-O-(2,3,4-tribenzyl--L-fucopyranosyl)-(13)-2-azido-6-O-benzyl-2-
deoxy--D-glucopyranoside (11): 3.7 mmol (3 g) Disaccharide 10 was coevaporated three times
with dry toluene and subsequently dissolved in 100 mL freshly distilled THF. 6 eq. BH3NMe3 were
added followed by 7.5 eq. aluminium chloride. The reaction was allowed to stand overnight at 50C.
After cooling down, the reaction mixture was poured into a 1M sulfuric acid solution. The product
was extracted two times with EtOAc and washed three times with 1M sulfuric acid, two times with
saturated NaHCO3 and brine. The organic layer was dried on MgSO4, filtered and concentrated in
vacuo. The residue was taken up in EtOAc and purified by column chromatography (10 % EtOAc in
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light petroleum), 49 % yield (1.82 mmol, 1.5 g). Rf (EtOAc:light petroleum 1:4) 0.55. 13C-NMR
(CDCl3, 50.1 MHz): δ 138.6, 138.1 (4 x Cq arom), 128.2, 127.7, 127.4, 127.3 (20 x CH arom), 98.0
(C1a), 97.0 (C1b), 84.4, 78.5, 77.3, 75.4, 74.8, 68.9, 67.7, 66.9 (C2, C3, C4, C5 a and b), 74.7, 73.2,
72.9 (4 x CH2 benzyl), 69.3 (C6a), 25.4 (3 x CH3 tBu), 17.8 (Cq tBu), 16.4 (CH3b), -4.4, 5.4 (CH3
SiMe).
2,3,4,6-Tetra-O-acetyl-/-D-galactopyranose (13): 0.5 mL (10.6 mmol) hydrazinemonohydrate
and 0.62 mL (10.7 mmol) acetic acid were dissolved in 9 mL DMF. This solution was added to a
solution of 4.7 g (10 mmol) of peracetylated galactose in 100 mL DMF. The reaction was stirred at
room temperature until TLC (EtOAc:light petroleum 1:1) indicated complete conversion into a more
polar product. DMF was removed and the residue was taken up in EtOAc, washed with saturated
NaHCO3, dried over MgSO4 and filtered. The title compound was obtained after column
chromatography (EtOAc: light petroleum 3:1). Yield 3.7g (8.9 mmol, 89 %). Rf (EtOAc:light
petroleum 3:1) 0.25. 13C-NMR (CDCl3, 50.1 MHz): δ 170.4, 170.3, 170.2, 170.0 (CO Ac), 95.2 (C1
β), 90.1 (C1α), 70.4, 70.3, 68.2, 67.9, 67.1, 65.5 (C2, C3, C4, C5 α/β), 61.5, 60.2 (C6 α/β), 20.4 (4 x
CH3 OAc).
O-(2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl) trichloroacetimidate (14): 0.7 g (1.7 mmol) 13
was dissolved in 15 mL dry dichloromethane. 0.62 mL (6.2 mmol) Trichloroacetonitrile and 50 mg
Cs2CO3 were added. After 45 minutes the reaction mixture was filtered and the organic solvent was
evaporated. Flash column chromatography (EtOAc:light petroleum 40:60 and 0.5 % TEA) yielded
the pure  compound in 82 % (1.4 mmol, 0.78 g). Rf  (EtOAc:light petroleum 1:1) 0.45. 13C-NMR
(CDCl3, 50.1 MHz): δ 169.3, 169.2, 169.1, 168.9 (CO OAc), 159.8 (Cq imidate) 92.9 (C1α), 90.3
(CCl3 imidate), 68.2, 66.9, 66.4 (C2, C3, C4, C5), 60.7 (C6), 19.7 (4 x CH3 OAc).
Tert-Butyldimethylsilyl-O-(2,3,4,6-tetra-O-acetyl--D-galactopyranosyl)-(14)-[(2,3,4-
tribenzyl--L-fucopyranosyl)-(13)]-2-azido-6-O-benzyl-2-deoxy--D-glucopyranoside (12):
1.82 mmol (1.5 g) acceptor 11 and 2.78 mmol (1.54 g) 14 were coevaporated with dichloroethane
and dissolved in a minimum amount of dry dichloromethane. 4Å Molecular sieves were added and
the slurry was stirred under a nitrogen atmosphere for half an hour. 2.7 mL of a 0.1M solution of
trimethylsilyl trifluoromethanesulfonate in dry dichloromethane was added and after 20 minutes 0.5
mL triethylamine was added and the reaction mixture was filtered and concentrated. Purification by
silica gel column chromatography (EtOAc:light petroleum 1:5) furnished trisaccharide 12 in 75 %
yield (1.35 mmol, 1.56g). Rf (EtOAc:light petroleum 1:4) 0.35. 13C-NMR (CDCl3, 75.1 MHz): δ
169.7, 169.5, 168.4 (4 x CO OAc), 138.8, 138.5, 138.2, 137.5 (Cq arom), 128.4-126.8 (20 x CH
arom), 99.6 (C1c), 97.3 (C1a), 97.1 (C1b), 79.8, 75.3, 75.0, 73.9, 73.7, 70.6, 70.0, 68.5, 68.4, 66.4,
65.9 (C2, C3, C4, C5 a, b and c), 73.5, 73.4, 72.9, 72.5 (CH2 benzyl), 67.2 (C6a), 58.8 (C6c), 25.4
(3 x CH3 tBu), 20.4, 20.3, 20.3, 20.2 (CH3 OAc), 17.8 (Cq tBu), 16.5 (CH3b), -4.5, 5.2 (CH3 SiMe).
ESI-MS: m/z 1178.6 [M+Na]+.
2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl-(14)-[(2,3,4-tribenzyl--L-fucopyranosyl)-
(13)]-2-azido-6-O-benzyl-2-deoxy--D-glucopyranose (15): 0.25 mmol (0.29 g) trisaccharide
12 in 2 mL dry pyridine was treated with 0.2 mL (1.25 mmol, 0.2 g) TEA.3HF complex and stirred
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overnight at room temperature. The reaction mixture was diluted with EtOAc and washed with
water, saturated NaHCO3 and brine. The organic layer was dried on MgSO4, filtered and reduced to
a small volume. After column chromatography (EtOAc:light petroleum 15:10) the product was
isolated in 83 % (0.21g, 0.21 mmol). Rf (EtOAc:light petroleum 3:1) 0.60. 13C-NMR (CDCl3, 50.1
MHz): δ 169.8, 168.5 (4 x CO OAc), 138.9, 138.5, 138.3, 137.4 (Cq arom), 128.6-126.9 (20 x CH
arom), 99.7 (C1c), 97.1 (C1a), 96.6 (C1b), 79.7, 76.4, 75.7, 74.7, 74.3, 70.7, 70.0, 68.7, 66.5, 66.1
(C2, C3, C4, C5 a, b and c), 74.1, 73.5, 73.1, 72.7 (CH2 benzyl), 67.5 (C6a), 59.9 (C6c), 20.4 (4 x
CH3 OAc), 16.5 (CH3b).
O-(2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl)-(14)-[(2,3,4-tribenzyl--L-fucopyranosyl)-
(13)]-2-azido-6-O-benzyl-2-deoxy-/-D-glucopyranosyl Trichloroacetimidate (16): 0.3
mmol (0.31 g) 15 was dissolved in 20 mL dry dichloromethane and 0.18 mL (1.8 mmol)
trichloroacetonitrile and 50 mg Cs2CO3 were added. The reaction mixture was stirred overnight and
after completion the solid Cs2CO3 was filtered off. Flash column chromatography (EtOAc:light
petroleum 10:15 containing 0.5 % TEA) yielded 0.33 g (0.28 mmol, 93 %) 16, / 8/1. Rf 16
(EtOAc:light petroleum 10:15 containing 0.5 % TEA) 0.35, 16 0.25. 13C-NMR (CDCl3, 50.1
MHz): δ 169.8, 168.5 (4 x CO OAc), 160.6 (Cq imidate), 138.8, 138.5, 138.2, 137.2 (Cq arom),
128.7-126.9 (20 x CH arom), 99.6 (C1c, C1a β), 97.1 (C1b), 94.6 (C1a α), 86.9 (CCl3 imidate α/β),
79.6, 76.7, 75.7, 75.3, 75.0, 72.2, 70.7, 70.4, 70.0, 69.4, 68.6, 66.2, 63.9 62.2(C2, C3, C4, C5 a, b




(17): 0.21 mmol (0.25 g) 16 and 0.42 mmol 6-(N-benzyloxycarbonylamino)hexanol (0.11 g) were
coevaporated with acetonitrile, crushed molecular sieves (4 Å) were added and the slurry was stirred
for half an hour under a nitrogen atmosphere. The mixture was cooled to –40 C prior to adding
0.05 eq. TMSOTf from a freshly prepared 0.1M solution in CH3CN (0.1 mL). After two hours 0.5
mL TEA was added to quench the reaction, the slurry was filtered and concentrated. Column
chromatography (EtOAc:light petroleum 1:2) afforded 17 in 66 % (0,175 g, 0.14 mmol). Rf
(EtOAc:light petroleum 1:1) 0.40 13C-NMR (CDCl3, 50.1 MHz): δ 169.9, 169.7, 168.6 (4 x CO
OAc), 156.1 (CO Z), 139.0, 138.6, 138.4, 137.2 (5 x Cq arom), 128.6-126.9 (25 x CH arom), 102.6
(C1a), 99.7 (C1c), 97.3 (C1b), 79.9, 76.8, 75.5, 75.1, 74.3, 70.7, 70.1, 68.7, 66.4, 66.1 (12 x CH C2,
C3, C4, C5 a, b and c), 73.9, 73.6, 73.2, 72.7 (CH2 benzyl), 67.3 (CH2 spacer), 66.6 (C6a), 62.7
(CH2 Z), 59.9 (C6c), 40.9 (CH2 spacer), 29.9, 29.3, 26.3, 25.7 (CH2 spacer), 20.6 (4 x CH3 OAc),
16.7 (CH3b). 1H NMR (CDCl3, 200 MHz) δ 7.5-7.1 (m, 25 H, 5 Ph), 5.53 (d, 1H, J = 3.6, H1b), 5.2
(dd, 1H, J= 2.9, H4c), 5.1 (s, 2H, PhCH2), 5.0-4.7 (m, 15H), 4.6 (d, 1H, J= 8.0, H1c), 4.4 (d, 1H, J =
11.7, H1a), 4.2-3.3 (m, 25 H), 3.14 (m, 2 H, CH2 spacer), 2.1-1.8 (4 s, 12 H, OAc), 1.8-1.4 (m, 2 H,
CH2 spacer), 1.4-1.2 (m, 2 H, CH2 spacer), 1.1 (d, 3 H, J = 8.4, CH3b).
6-(N-Benzyloxycarbonylamino)hexyl-O-(2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl)-(14)-
[(2,3,4-tribenzyl--L-fucopyranosyl)-(13)]-2-acetamido-6-O-benzyl-2-deoxy--D-
glucopyranoside (19): compound 17 (24 mol, 30 mg) was dissolved in THF (2 mL). 2 Eq. Me3P
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(1M sol in THF, 48 mol, 48 L) were added, after 10 minutes TLC analysis (EtOAc/light
petroleum 1/1 v/v) showed the conversion of 17 into a more polar product. Next, 0.5 mL H2O was
added and stirring was continued overnight. The mixture was concentrated in vacuo and traces of
H2O were removed by coevaporating three times with pyridine. The slurry was dissolved in 5 mL
pyridine and 2.5 mL acetic anhydride and stirred for three hours. After removal of the solvents
under reduced pressure, the resulting oil was taken up in EtOAc and washed with a sat. aq. NaHCO3
until neutral. Finally, the solution was washed with brine, dried (MgSO4) and filtered. Column
chromatography (EtOAc/light petroleum 15/10 v/v) yielded 77 % (18.5 mol, 24 mg) 19. Rf
(EtOAc/light petroleum 15/10 v/v) 0.45. 13C-NMR (CDCl3, 50.1 MHz): δ 170.2, 170.0, 169.2 (4 x
CO OAc and CO NAc), 156.1 (CO Z), 138.8, 137.8, 136.6 (5 x Cq arom), 128.5-127.1 (25 x CH
arom), 99.5 (C1a, C1c), 97.3 (C1b), 79.9, 79.8, 76.9, 76.7, 74.9, 74.4, 70.6, 70.6, 68.7, 66.5, 66.4
(12 x CH C2b,c, C3, C4, C5 a, b and c), 73.9, 73.6, 73.2, 72.7 (CH2 benzyl), 69.4 (CH2 spacer), 66.5
(C6a), 62.7 (CH2 Z), 60.3 (C6c), 56.3 (C2a) 40.9 (CH2 spacer), 29.8, 29.1, 26.3, 25.4 (CH2 spacer),
23.1 (CH3 NAc), 20.6 (4 x CH3 OAc), 16.7 (CH3b). 1H NMR (CDCl3, 200 MHz) δ 7.5-7.1 (m, 25 H,
5 Ph), 5.9 (d, 1 H, J = 7.7, NH), 5.3 (d, 1H, J = 3.3, H1b), 5.2 (dd, 1H, J = 3.1, H4c), 5.1 (s, 2H,
PhCH2), 5.0-4.7 (m, 15H), 4.6 (d, 1H, J = 5.9, H1c), 4.5 (d, 1H, J = 11.7, H1a), 4.2-3.3 (m, 25 H),
3.14 (m, 2 H, CH2 spacer), 2.1-1.8 (4 s, 12 H, OAc), 1.7 (s 3H, NAc), 1.7-1.4 (m, 4 H, CH2 spacer),
1.4-1.2 (m, 4 H, CH2 spacer), 1.1 (d, 3 H, J = 6.6, CH3b). ESI-MS: m/z 1313.6 [M+Na]+
6-(N-Benzyloxycarbonylamino)hexyl-O-(-D-galactopyranosyl)-(14)-[(2,3,4-tribenzyl--L-
fucopyranosyl)-(13)]-2-acetamido-6-O-benzyl-2-deoxy--D-glucopyranoside (20):
deacetylation of trisaccharide 19 was established by the addition of NaOMe to a solution of
compound 19 (24 mg,18.5 mol) in 2 mL dry methanol until basic. After completion of the reaction,
the solution was neutralized using Dowex-H+, filtered and evaporated, giving 20 in a quantitative
yield without further purification. Rf (EtOAc) 0.25. ESI-MS: m/z 1123 [M+H]+.
6-Aminohexyl-O-(-D-galactopyranosyl)-(14)-[(--L-fucopyranosyl)-(13)]-2-acetamido-6-
O-benzyl-2-deoxy--D-glucopyranoside (21): 18.5 mol (21 mg) 20 was dissolved in 2 mL
MeOH, 0.13 mL formic acid and a catalytic amount of palladium black were added. The slurry was
allowed to stir overnight at room temperature. The reaction was filtered and taken up in EtOAc, the
product was extracted into the aqueous layer. This layer was washed two times with EtOAc and one
time with DCM. Finally, the water was removed under reduced pressure and the resulting oil was
subjected to gel permeation chromatography to obtain the Lex derivative in 80 % yield (14.8 mol,
8.9 mg). 13C-NMR and 1H NMR spectra are in accordance with [22].
6-(N-Benzyloxycarbonylamino)hexyl-O-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy--D-
glucopyranoside (22): Acetyl-O-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α/-D-glucopyranoside
(5.85 g, 15 mmol) was coevaporated three times with DCE and dissolved in a minimal amount of
DCE. TMSOTf (3.2 mL, 16.5 mmol) was added and the reaction mixture was stirred for three hours
at 60 °C. Upon completion of the reaction, as indicated by TLC analysis (DCM/MeOH/TEA
20/1/0.5 v/v/v), the solution was neutralized by the addition of TEA. Without evaporation, pure
oxazoline was obtained by flash chromatography (toluene/EtOAc/TEA 5/2/0.5 v/v/v) in 95 %.
Oxazoline (14.3 mmol) and (21.5 mmol) 18 were dissolved in toluene and traces of H2O were
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removed from the mixture by coevaporation.  The resulting oil was dissolved in dry DCE (75 mL). 4
Å crushed molecular sieves were added and the slurry was stirred at room temperature for 0.5h
under N2 atmosphere. TMSOTf (0.28 mL, 1.4 mmol) was added dropwise and the reaction was
allowed to proceed 48 hours. After neutralization with TEA, the slurry was filtered and evaporated.
The resulting oil was dissolved in EtOAc and washed subsequently with H2O, sat. aq. NaHCO3 and
brine. The organic layer was dried (MgSO4) and evaporated. Column chromatography (EtOAc/light
petroleum 2/1 v/v) yielded 22 in 63 % over two steps. Rf  (EtOAc/toluene 3/1 v/v) 0.31. 13C-NMR
NMR and 1H NMR spectra are in accordance with [22].
6-(N-Benzyloxycarbonylamino)hexyl-O-(2-acetamido-3,6-dibenzyl-2-deoxy)--D-
glucopyranoside (23): Compound 22 (9.4 mmol, 5.4 g) was deacetylated as previously described
for compound 20. This intermediate was dissolved in 100 mL DMF and treated with 6.5 eq. BaO
(61.4 mmol, 9.4g) and 1.6 eq. Ba(OH)2 (15 mmol, 4.7 g) for 30 minutes. Next, 2 eq. benzylbromide
were added (18.8 mmol, 2.35 mL) dropwise. After stirring overnight another 2 eq. benzylbromide
were added. The reaction was stirred until TLC analysis indicated no further proceeding of the
reaction. EtOAc was added and the slurry was filtered. The filtrate was evaporated under reduced
pressure and the resulting oil was dissolved in EtOAc. This solution was washed with water (2x), a
saturated NaHCO3 solution and brine and dried on MgSO4. Column chromatography (EtOAc:light
petroleum 2:1) yielded 12.5 % (1.18 mmol, 0.75 g) of the desired 3, 6-dibenzylated product. Rf
(EtOAc) 0.45. 13C-NMR (CDCl3, 75.1 MHz): δ 170.7 (CO NAc), 156.4 (CO Z), 138.0, 137.8, 136.5
(3 x cq arom) 128.4-127.5 (15 x CH arom), 99.8 (C1), 80.8 (C3), 74.2 (C5), 73.9, 73.5 (CH2 benzyl)
73.2 (C4), 69.9 (CH2 spacer), 68.2 (C6), 64.7 (CH2 Z), 56.8 (C2) 40.9 (CH2 spacer), 29.8, 29.1, 26.3,
25.4 (CH2 spacer), 23.1 (CH3 NAc). 1H NMR (CDCl3, 300 MHz) δ 7.5-7.2 (m, 15 H, 3 Ph), 6.3 (d, 1
H, J = 8.2, NH), 5.1 (s, 2H, PhCH2), 4.7-4.4 (m, 5 H, H1, 2 x PhCH2), 3.9-3.4 (m, 8 H), 3.24 (br s,
OH), 3.14 (m, 2 H CH2 spacer) 2.8 (s, NAc), 1.6-1.2 (m, 8 H, 4 x CH2 spacer). ESI-MS; m/z 657.7
[M+Na]+.
6-(N-Benzyloxycarbonylamino)hexyl-O-(2,3,4,6-tetra-O-acetyl--D-Galactopyranosyl)-(14)-
2-acetamido-6-O-benzyl-2-deoxy--D-glucopyranoside (24): Compound 23 (0.5 g, 0.79 mmol)
and compound 14 (0.8 g, 1.4 mmol) were dissolved in toluene and traces of H2O were removed by
coevaporation with toluene. The resulting oil was subsequently dissolved in CH2Cl2 (3 mL). 4Ǻ
Molecular sieves were added and the slurry was stirred under a nitrogen atmosphere for half an
hour, followed by the addition of 0.79 mL of a freshly prepared 0.1M TMSOTf in CH2Cl2. The
reaction mixture was stirred for 48 hours, and then neutralized with TEA and filtered. The solvent
was removed under reduced pressure and the residue was redissolved in EtOAc (25 mL). The
organic phase was washed with H2O (20 mL), sat. aq. NaHCO3 (3x 20 mL) and brine (20 mL), dried
(MgSO4) and concentrated. The crude product was applied to a silica gel column and eluted with
EtOAc/light petroleum (1/1→ 4/1, v/v) to give title compound 24 in 70 % (0.53 g) 13C-NMR
(CDCl3, 50.1 Hz): δ 169.9, 169.6, 169.3 (4 x CO OAc and CO NAc), 156.2 (CO Z), 138.3, 137.6,
136.4 (3 x cq arom), 128.1-127.2 (15 x CH arom), 99.8 (C1a), 99.5 (C1b), 80.9, 77.2, 75.4, 74.3,
71.7, 70.3, 68.9 (C2b, C3, C4, C5 a and b), 73.9, 73.4, 73.1 (CH2 benzyl), 73.1 (CH2 spacer), 68.7
(C6a), 64.7 (CH2 Z), 60.4 (C6b), 55.6 (C2) 40.9 (CH2 spacer), 29.8, 29.1, 26.3, 25.4 (CH2 spacer),
23.1 (CH3 NAc), 20.2 (4 x CH3  OAc). 1H NMR (CDCl3, 200 MHz) δ 7.5-7.2 (m, 15 H, 3 Ph), 6.1
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(d, 1 H, J = 8.0, NH), 5.3 (d, 1 H, J = 3.7, H4b), 5.1 (s, 2H, PhCH2 Z), 5.0-4.4 (m, 8 H, H1 a and b, 2
x PhCH2, H2b, H3b), 4.1-3.3 (m, 9 H), 3.14 (m, 2 H CH2 spacer) 2.8, 2.1, 2.0, 1.9 (5 x s, 15 H,
OAc, NAc), 1.6-1.2 (m, 8 H, 4 x CH2 spacer).
6-(N-Benzyloxycarbonylamino)hexyl-O--D-Galactopyranosyl-(14)-2-acetamido-6-O-
benzyl-2-deoxy--D-glucopyranoside (25): Deacetylation of compound 24 (0.12 mmol, 86 mg)
was performed as described for compound 20. Rf (10 % MeOH in EtOAc) 0.6. 13C-NMR (MeOD,
50.1 MHz): δ 173.9 (CO NAc), 156.2 (CO Z), 139.5 (3 x cq arom), 129.7-128.4 (15 x CH arom),
104.0 (C1b), 102.4 (C1a), 82.2, 77.3, 76.0, 74.6, 72.8, (C2b, C3, C4, C5 a and b), 74.0 (CH2
benzyl), 70.3 (CH2 spacer), 69.2 (C6a), 67.0 (CH2 Z), 62.8 (C6b), 56.2 (C2) 41.7 (CH2 spacer), 30.7,
30.3, 27.2, 26.5 (CH2 spacer), 22.9 (CH3 NAc). 1H NMR (MeOD, 200 MHz) δ 7.3 (m, 15 H, 3 Ph),
5.1 (s, 2H, PhCH2 Z), 5.0 (d, 1 H, J = 10.9, H1a), 4.7-4.5 (m, 6 H), 4.4 (d, 1H, J = 8.0, H1b), 4.0-3.3
(m, 12 H), 3.14 (m, 2 H CH2 spacer), 1.9 (s, 3 H, NAc), 1.6-1.2 (m, 8 H, 4 x CH2 spacer).
6-Aminohexyl-O-(-D-Galactopyranosyl)-(14)-2-acetamido-2-deoxy--D-glucopyranoside
(26): Debenzylation of compound 25 was established as described for compound 21 to afford pure
26 in 90 % (0.1 mmol, 52 mg). 13C-NMR and 1H NMR spectra are in accordance with [22]. ESI-
MS: m/z 504.1 [M+Na]+.
6-(N-Benzyloxycarbonylamino)hexyl-O-(4,6-O-benzylidene--D-galactopyranosyl)-(14)-
[(2,3,4-tribenzyl--L-fucopyranosyl)-(13)]-2-azido-6-O-benzyl-2-deoxy--D-glucopyranoside
(27): Compound 17 (50 mg, 45 µmol) was deacetylated as described for compound 20. Followed by
benzylidenation as previously described for compound 5. Column chromatography (EtOAc/light
petroleum 2/1 → 4/1 v/v) afforded compound 27 in 80 % yield. Rf (EtOAc/light petroleum 2/1 v/v)
0.25. 13C-NMR (CDCl3, 50.1 MHz): δ 156.1 (CO Z), 139.4, 138.5, 138.2, 137.5 (6 x Cq arom),
128.9-125.6 (30 x CH arom), 102.7 (C1a), 101.4 (CH benzylidene), 99.9 (C1c), 97.5 (C1b), 78.8,
75.1, 74.7, 73.9, 72.8, 71.8, 66.6, 66.4, 65.9 (12 x CH C2, C3, C4, C5 a, b and c), 74.9, 73.1, 73.0 (4
x CH2 benzyl), 71.7 (CH2 spacer), 70.1 (C6a), 69.1 (CH2 Z), 67.9 (C6c), 40.9 (CH2 spacer), 29.8,
29.3, 26.4, 25.5 (CH2 spacer), 16.3 (CH3b). 1H NMR (CDCl3, 200 MHz) δ 7.5-7.1 (m, 30 H, 6 Ph),
5.6 (s, CH benzylidene), 5.53 (d, 1H, J = 2.2, H1b), 5.1 (s, 2H, PhCH2), 3.14 (m, 2 H, CH2 spacer),





(13)]-2-azido-6-O-benzyl-2-deoxy--D-glucopyranoside (28): Coupling of compound 16 (84
mg, 71 µmol)  to compound 27 (43 mg, 36 µmol) was established as described for compound 17.
Column chromatography (EtOAc/light petroleum 1/2→2/1 v/v) yielded compound 28 in 72 % (59.6
mg, 26 µmol). Rf (EtOAc/light petroleum 1/1 v/v) 0.55. 13C-NMR (CDCl3, 150 MHz): δ 169.9,
169.7, 168.6 (4 x CO OAc), 156.3 (CO Z), 139.5-136.6 (10 x Cq arom), 128.7-126.8 (50 x CH
arom), 102.7 (C1a), 102.3 (C1d), 101.4 (CH benzylidene), 99.8, 99.7 (C1c, C1f), 97.7, 97.4 (C1b,
C1e), 78.9-66.4 (24 x CH C2, C3, C4, C5 a, b, c, d, e and f), 74.8-73.1 (8 x CH2 benzyl), 72.7 (CH2
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spacer), 71.8, 70.1 (C6a, C6d), 69.1 (CH2 Z), 67.9 (C6c), 59.9 (C6f), 40.9 (CH2 spacer), 29.6, 29.3,
26.4, 25.6 (CH2 spacer), 19.1 (4 x CH3 OAc), 16.5, 16.3 (CH3 b and e). 1H NMR (CDCl3, 600 MHz)
δ 7.5-7.1 (m, 50 H, 10 Ph), 5.6 (s, CH benzylidene), 5.53 (d, 1H, J = 3.9, H1b), 5.4 (d, 1 H, J = 3.6,
H1e), 5.2 (d, 1 H, J = 3.2, H4f), 5.1 (s, 2H, PhCH2), 4.9 (d, 1 H, J = 9.2, H1d), 4.6 (d, 1 H, J = 8.5,
H1f), 4.4 (d, 1 H, J = 8.2, H1c), 4.3 (d, 1 H, J = 7.8, H1a), 3.14 (m, 2 H, CH2 spacer), 2.9 (br s, 1 H
OHc), 2.1-1.9 (4 x s, 12 H, OAc), 1.8-1.4 (m, 4 H, CH2 spacer), 1.4-1.2 (m, 4 H, CH2 spacer), 1.1 (2





(29): Compound 28 (49 mg, 22 µmol) was converted into compound 29 in 75 % (38 mg, 16.5 µmol)
as previously described for compound 19. Purification was effected by column chromatography
(EtOAc/light petroleum 5/1→1/0 v/v). Rf (EtOAc/light petroleum 2/1 v/v) 0.65. 13C-NMR (CDCl3
150.1 MHz): δ 170.4-168.7 (4 x CO OAc, 2 x CO NAc), 156.4 (CO Z), 139.5-136.7 (10 x Cq arom),
127.1-126.9 (50 x CH arom), 100.0 (CH benzylidene), 99.8, 99.7, 99.6, 99.2 (C1a,c,d and f), 97.8,
97.7 (C1b, C1e), 80.3-66.2 (22 x CH C2b, c, e and f and C3, C4, C5 a, b, c, d, e and f), 75.0-72.4 (8
x CH2 benzyl), 71.4 (CH2 spacer), 69.4, 69.1 (C6a, C6d), 68.8 (CH2 Z), 68.4 (C6c), 60.1 (C6f), 59.8,
59.6 (C2a and d), 40.8 (CH2 spacer), 29.7, 29.2, 26.2, 25.4 (CH2 spacer), 23.3, 23.2 (CH3 NAc),
20.6 (4 x CH3 OAc), 16.7, 16.0 (CH3 b and e). 1H NMR (CDCl3, 600 MHz) δ 7.5-7.1 (m, 50 H, 10
Ph), 5.6 (2 x d, 2H, J = 7.1, NH), 5.5 (s, CH benzylidene), 5.3 (d, 1 H, J = 3.2, H1b), 5.2 (m, 2 H,
H1e, H4f), 5.1 (s, 2H, PhCH2), 4.4 (d, 1 H, J = 8.9, H1c), 4.3 (d, 1 H, J = 7.2, H1a), 3.14 (m, 2 H,
CH2 spacer), 2.1-1.8 (7 x s, 15 H, OAc, 6 H, NAc), 1.8-1.4 (m, 4 H, CH2 spacer), 1.4-1.2 (m, 4 H,




acetamido-6-O-benzyl-2-deoxy--D-glucopyranoside (30): Quantitative deacetylation of
compound 29 to obtain compound 30 was established as previously described for compound 20. Rf
(EtOAc) 0.25. ESI-MS: m/z 2106.8 [M+Na]+.
6-Aminohexyl-O-(-D-galactopyranosyl)-(14)-[(-L-fucopyranosyl)-(13)]-(2-acetamido-2-
deoxy--D-glucopyranosyl)-(13)-(-D-galactopyranosyl)-(14)-[(-L-fucopyranosyl)-
(13)]-2-acetamido-2-deoxy--D-glucopyranoside (31): Final deprotection of compound 30 (10
mg, 4.7 µmol), as previously described for compound 21, yielded compound 31 in  72 % (4 mg, 3.3
µmol). 1H NMR (D2O, 600 MHz): δ 5.1 (2 x d, 2H, J = 3.9, J = 3.8,  H1b and e), 4.8 (m, 2 H, H5b
and e), 4.7 (2 x d, 2 H, J = 8.1, H1d, H4d), 4.6 (d, 1 H, J = 8.4, H1a), 4.5 (2 x d, 2H, J = 8.2, H1c
and f), 4.0-3.1 (m, 32 H), 2.5 (t, 2 H, CH2 spacer), 2.0 (2 x s, 6 H, NAc), 1.8 (m, 2 H, CH2 spacer),
1.6 (m, 2 H CH2 spacer), 1.4 (m, 2 H CH2 spacer), 1.3 (m, 2 H CH2 spacer), 1.1 (2 x d, 6 H, J = 6.6,
CH3b and e). ESI-MS: m/z 1141.8 [M+H]+, 1167.7 [M+Na]+.
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Tert-Butyldimethylsilyl-O-(4,6-O-benzylidene--D-galactopyranosyl)-(14)-[(2,3,4-tribenzyl-
-L-fucopyranosyl)-(13)]-2-azido-6-O-benzyl-2-deoxy--D-glucopyranoside (32): Compound
12 (81 mg, 69 µmol) was quantitatively deacetylated as previously described for compound 20.
Subsequently, followed by benzylidenation as described for compound 5 to afford pure 32 in 84 %
(62 mg, 58 µmol). Rf (light petroleum/acetone 2/1 v/v) 0.35. 13C-NMR (CDCl3, 50.1 MHz): δ 137.6,
137.3, 137.0, 136.5 (5 x Cq arom), 128.9-125.6 (25 x CH arom), 101.6 (CH benzylidene), 99.9
(C1c), 97.6 (C1a), 97.5 (C1b), 78.8, 75.3, 75.2, 74.5, 74.0, 72.8, 71.8, 68.8, 66.5, 65.9 (12 x CH C2,
C3, C4, C5 a, b and c), 74.8, 73.2, 73.0, 71.7 (CH2 benzyl), 69.1 (C6a), 68.9 (C6c), 25.4 (3 x CH3




(13)]-2-azido-6-O-benzyl-2-deoxy--D-glucopyranoside (33): Compound 33 was prepared from
compound 16 and compound 32 as described for compound 17. Column chromatography (light
petroleum/acetone 2/1 v/v) afforded compound 33 in a 74 % yield (90 mg, 43 µmol). Rf (light
petroleum/acetone 2/1 v/v) 0.65. 13C-NMR (CDCl3, 50.1 MHz): δ 169.9, 169.7, 168.6 (4 x CO
OAc), 139.5-136.6 (9 x Cq arom), 128.6-125.7 (45 x CH arom), 102.3 (C1d), 101.5 (CH
benzylidene), 99.8, 99.7 (C1c, C1f), 97.6, 97.5, 97.4 (C1a, C1b, C1e), 79.9-64.4 (24 x CH C2, C3,
C4, C5 a, b, c, d, e and f), 74.8-73.1 (8 x CH2 benzyl), 71.8, 69.2 (C6a, C6d), 67.6 (C6c), 59.9 (C6f),





deoxy-β-D-glucopyranose (34): Desilylation of compound 33 (90 mg, 43 µmol) was established as
described for compound 15. Column chromatography (EtOAc/light petroleum 2/1→15/10 v/v)
afforded pure 34 in 79 % (68 mg, 34 µmol). Rf (EtOAc/light petroleum 1/1 v/v) 0.25. 13C-NMR
(CDCl3, 50.1 MHz): δ 169.9, 169.7, 168.6 (4 x CO OAc), 139.5-136.6 (9 x Cq arom), 128.6-125.7
(45 x CH arom), 102.3 (C1d), 101.6 (CH benzylidene), 99.8, 99.7 (C1c, C1f), 97.8, 97.4 (C1b, C1e),
96.9 (C1a), 79.9-64.7 (24 x CH C2, C3, C4, C5 a, b, c, d, e and f), 74.8-73.2 (8 x CH2 benzyl), 71.8,





deoxy-/-D-glucopyranosyl trichloroacetimidate (35): Compound 34 (68 mg, 43 µmol) was
converted into compound 35 in 94 % (85 mg ,40 µmol, :1:2) as described previously for
compound 16. Rf  (EtOAc/light petroleum/TEA 1/1/0.05 v/v/v) 35 0.56, 35 0.62.
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Methyl-O-(2,3,4,6)-Tetra-O-acetyl--D-galactopyranosyl-(14)-[(2,3,4-tribenzyl--L-
fucopyranosyl)-(13)]-2-azido-6-O-benzyl-2-deoxy--D-glucopyranoside (40): Compound 16
(0.29 g, 0.25 mmol) was dissolved in CH3CN (2 mL). MeOH (0.5 mL, 12.5 mmol) and 3 Å MS
were added and the slurry was stirred for 0.5h under a N2 atmosphere. Subsequently, the slurry was
cooled to –40 °C and a fresly prepared 0.1 M TMSOTf solution in CH3CN (0.25 mL) was added.
The reaction mixture was slowly warmed up to room temperature and allowed to proceed overnight.
Workup as described for compound 17 yielded 72 % pure 40. Column chromatography EtOAc/light
petroleum 1/3 → 1/1 v/v. Rf (EtOAc/light petroleum 1/1 v/v) 0.40. 13C-NMR (CDCl3, 50.1 MHz): δ
169.9, 169.7, 168.6 (4 x CO OAc), 139.0, 138.7, 138.3, 137.6 (4 x Cq arom), 128.6-126.9 (20 x CH
arom), 103.5 (C1a), 99.6 (C1c), 97.3 (C1b), 79.9, 76.8, 75.5, 75.1, 73.6, 70.7, 70.1, 68.7, 66.5, 66.2,
66.0 (12 x CH C2, C3, C4, C5 a, b and c), 73.9, 73.5, 73.1, 72.7 (CH2 benzyl), 67.2 (C6a), 59.9
(C6c), 57.1 (CH3 OMe), 20.5 (4 x CH3 OAc), 16.6 (CH3b). 1H NMR (CDCl3, 200 MHz) δ 7.5-7.1
(m, 20 H, 4 Ph), 5.53 (d, 1H, J = 3.2, H1b), 5.2 (dd, J = 3.3, 1H, H4c), 5.0-4.7 (m, 10H), 4.6 (d, 1H,
J = 8.2, H1c), 4.4 (d, 1H, J = 7.4, H1a), 4.2-3.3 (m, 13 H), 3.6 (s, 3H OMe), 2.1-1.8 (4 s, 12 H,
OAc), 1.1 (d, 3 H, J = 6.5, CH3b).
Methyl-O-(2,3,4,6-Tetra-O-acetyl--D-galactopyranosyl)-(14)-[(2,3,4-tribenzyl--L-
fucopyranosyl)-(13)]-2-acetamido-6-O-benzyl-2-deoxy--D-glucopyranoside (41): Conversion
of compound 40 (31 mg, 27.5 µmol) into compound 41 was established as described for compound
19. Column chromatography (EtOAc) afforded compound 41 in 65 % yield (23 mg, 20.3 µmol). Rf
(EtOAc) 0.65. 13C-NMR (CDCl3, 50.1 MHz): δ 170.3, 169.9, 169.4 (4 x CO OAc, CO NAc), 138.8,
138.6, 137.9 (4 x Cq arom), 128.4-127.1 (20 x CH arom), 100.6 (C1a), 99.5 (C1c), 96.8 (C1b), 79.8,
76.9, 74.2, 72.7, 70.5, 70.4, 68.8, 66.6, 66.5 (11 x CH C2b and c, C3, C4, C5 a, b and c), 74.4, 73.4,
73.2, 72.5 (CH2 benzyl), 68.5 (C6a), 60.3 (C6c), 57.1 (CH3 OMe), 54.7 (C2a), 23.2 (CH3 NAc),
20.6 (4 x CH3 OAc), 16.7 (CH3b). 1H NMR (CDCl3, 200 MHz) δ 7.5-7.1 (m, 20H, 4 Ph), 6.0 (d, 1H,
J = 7.8, NH) 5.53 (d, 1H, J = 2.6, H1b), 5.2 (dd, 1H, J = 4.0, H4c), 5.0-4.7 (m, 10H), 4.6 (d, 1H, J =
6.9, H1c), 4.4 (d, 1H, J = 6.6, H1a), 4.2-3.3 (m, 13H), 3.6 (s, 3H OMe), 2.1-1.8 (5 s, 15H, OAc,
NAc), 1.1 (d, 3 H, J = 6.6, CH3b).
Methyl-O-(-D-galactopyranosyl)-(14)-[(-L-fucopyranosyl)-(13)]-2-acetamido-2-deoxy-
-D-glucopyranoside (43): Final deprotection of compound 41 (23 mg, 20.3 µmol) was established
as previously described for compound 31. Gel permeation chromatography yielded 82 % of
compound 43 (7.5 mg, 16.6 µmol). 13C-NMR (D2O, 150.1 MHz): δ 175.2 (2 x CO NAc), 101.4
(C1a), 101.3 (C1c), 96.8 (C1b), 76.3, 75.9, 75.6, 75.5, 73.9, 73.6, 72.9, 71.6, 69.8, 68.9, 67.3 (11 x
CH C2b and c, C3, C4, C5 a, b and c), 62.1 (C6a), 60.3 (C6c), 57.8 (CH3 OMe), 56.2 (C2a), 22.8
(CH3 NAc), 16.2 (CH3b). 1H NMR (D2O, 600 MHz) δ 5.2 (d, 1H, J =3.6, H1b), 4.8 (m, H5b), 4.5 (1
x d, 1H, J = 8.4, H1c), 4.4 (1 x d, 1H, J = 7.8, H1a) 4.0 (dd, 1 H, J = 1.9 and 10.3, H6a-A), 4.0-3.5
(m, 14 H), 3.4 (s, 3H OMe), 2.0 (2 x s, 6 H, NAc), 1.1 (d, 3 H, J = 6.6, CH3b). ESI-MS: m/z 566.2
[M+Na]+.
Methyl-O-(4,6-O-benzylidene--D-galactopyranosyl)-(14)-[(2,3,4-tribenzyl--L-
fucopyranosyl)-(13)]-2-azido-6-O-benzyl-2-deoxy--D-glucopyranoside (44): Compound 40
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(25 mg, 22 µmol) was deacetylated as described for compound 20 and followed by installation of a
4,6-O-benzylidene group as previously described for compound 5. Column chromatography
(EtOAc/light petroleum 2/1→4/1 v/v) afforded compound 44 in 80 % yield. Rf (EtOAc/light
petroleum 2/1 v/v) 0.25. 13C-NMR (CDCl3, 50.1 MHz): δ 138.7, 138.5, 138.2, 137.5 (5 x Cq arom),
129.5-125.7 (25 x CH arom), 103.7 (C1a), 101.4 (CH benzylidene), 99.9 (C1c), 97.6 (C1b), 78.9,
75.1, 74.7, 73.9, 73.0, 72.8, 71.8, 66.5, 66.4, 65.9 (12 x CH C2, C3, C4, C5 a, b and c), 74.9, 73.9,
73.1, 71.7 (4 x CH2 benzyl), 69.1 (C6a), 67.9 (C6c), 57.2 (CH3 OMe), 16.3 (CH3b). 1H NMR
(CDCl3, 200 MHz) δ 7.5-7.1 (m, 25 H, 5 Ph), 5.6 (s, CH benzylidene), 5.43 (d, 1H, J = 2.9, H1b),




azido-6-O-benzyl-2-deoxy--D-glucopyranoside (45): Coupling of compound 16 (43 mg, 36
µmol)  to compound 44 (17 mg, 18 µmol) was established as described for compound 17. Column
chromatography (EtOAc/light petroleum 1/2→2/1 v/v) yielded compound 45 in 69 % (25 mg, 12
µmol). Rf (EtOAc/light petroleum 1/1 v/v) 0.40. 1H NMR (CDCl3, 600 MHz) δ 7.5-7.1 (m, 50 H, 10
Ph), 5.6 (s, CH benzylidene), 5.6 (d, 1H, J = 2.9, H1b), 5.4 (d, 1 H, J = 3.6, H1e), 5.2 (dd, 1 H, J =
2.8, H4f), 4.9 (s, 2H, PhCH2), 4.9 (d, 1 H, J = 7.8, H1d), 4.6 (d, 1 H, J = 8.1, H1f), 4.4 (d, 1 H, J =
8.9, H1c), 4.3 (d, 1 H, J = 7.7, H1a), 3.6 (s, 3 H, OMe), 2.9 (br s, 1 H OHc), 2.1-1.8 (4 x s, 12 H,




(13)]-2-acetamido-6-O-benzyl-2-deoxy--D-glucopyranoside (46): Compound 45 (25 mg, 12
µmol) was converted into compound 46 in 62 % (15 mg, 7 µmol) as previously described for
compound 19. Purification was effected by column chromatography (EtOAc/light petroleum
2/1→1/0 v/v). Rf (EtOAc) 0.35. 1H NMR (MeOD, 600 MHz) δ 7.5-7.1 (m, 45 H, 9 Ph), 5.5 (s, CH
benzylidene), 5.3 (d, 1 H, H1b), 5.2 (m, 2 H, H1e, H4f), 5.1 (s, 2H, PhCH2), 4.4 (d, 1 H, H1c), 4.3




acetamido-2-deoxy--D-glucopyranoside (47): Final deprotection of compound 46 (15 mg, 7
µmol), as previously described for the conversion of compound 19 into compound 21, yielded
compound 47 in  68 % (1.8 mg, 4.5 µmol). 1H NMR (D2O, 600 MHz): δ 5.1 (2 x d, 2H, J = 3.9 and
3.8, H1b and e), 4.8 (m, 4 H, H5b and e, H1d and H4d), 4.4 (3 x d, 3H, J = 7.7, 7.5 and 8.7, H1a, c
and f), 4.0-3.6 (m, 30 H), 3.5 (s, 3 H, OMe), 2.0 (2 x s, 6 H, NAc), 1.1 (2 x d, 6 H, J = 6.5, CH3b
and e). ESI-MS: m/z 1077.8 [M+Na]+.






azido-6-O-benzyl-2-deoxy--D-glucopyranoside (36): Coupling of donor 35 (32 mg, 15 µmol) to
acceptor 27 (33 mg, 30 µmol) was established as previously described for compound 17. Column
chromatography (light petroleum/acetone 3/1 v/v) afforded compound 36 in 64 % (30 mg, 9 µmol).
Rf (light petroleum/acetone 2/1 v/v) 0.35. 13C-NMR (CDCl3 150.1 MHz): δ 169.5 (4 x CO OAc),
156.4 (CO Z), 139.6-137.3 (15 x Cq arom), 127.1-126.9 (80 x CH arom), 102.7, 102.4 102.3 (C1a,d
and g), 101.6, 101.4, 101.1 (CH benzylidene), 99.9, 99.8, 99.4 (C1c, f and i), 97.9, 97.7, 97.5 (C1b,
e and h), 80.1-66.6 (36 x CH C2, C3, C4, C5 a, b, c, d, e and f), 75.0-72.4 (12 x CH2 benzyl), 71.8
(CH2 spacer), 70.1, 68.2, 67.9, (C6a, d and g), 67.6 (CH2 Z), 65.6 (C6c and f), 59.9 (C6i), 40.9 (CH2
spacer), 29.8, 29.3, 26.4, 25.6 (CH2 spacer), 20.6 (4 x CH3 OAc), 16.7, 16.2 (CH3 b, e and h). 1H
NMR (CDCl3, 600 MHz) δ 7.5-7.1 (m, 80 H, 15 Ph), 5.6 (2 x s, CH benzylidene), 5.5 (d, 1H, J =
3.1, H1b), 5.4 (2 x d, 2 H, J = 2.9, H1e and h), 5.2 (dd, 1 H, J = 3.2, H4i), 5.1 (s, 2H, PhCH2), 5.0-
4.6 (m, 30 H), 3.14 (m, 2 H, CH2 spacer), 2.9 (2 x br s, 2 H OHc and e), 2.1-1.9 (4 x s, 12 H, OAc),







of compound 36 (10 mg, 3.1 µmol) into compound 37 was established as previously described for
compound 19. Column chromatography (EtOAc/light petroleum 4/1 →8/1 v/v) afforded pure 37 in
61 % (6 mg, 1.8 µmol). Rf (EtOAc) 0.75. 1H NMR (CDCl3, 600 MHz) δ 7.5-7.1 (m, 80 H, 15 Ph),
5.6 (2 x s, CH benzylidene), 5.5 (d, 1H, J = 3.0, H1b), 5.4 (2 x d, 2 H, J = 3.1, H1e and h), 5.2 (dd, 1
H, J = 3.1, H4i), 5.1 (s, 2H, PhCH2), 5.0-4.6 (m, 30 H), 3.14 (m, 2 H, CH2 spacer), 2.1-1.9 (7 x s, 21
H, 4 x OAc and 3 x NAc), 1.8-1.4 (m, 4 H, CH2 spacer), 1.4-1.2 (m, 4 H, CH2 spacer), 1.1 (3 x d, 6




L-fucopyranosyl)-(13)]-2-acetamido-2-deoxy--D-glucopyranoside (39): Deacetylation and
final deprotection of nonasaccharide 37 (6 mg, 1.8 µmol) was established as described for
compound 31. After gel permeation chromatography compound 39 was obtained in 50 % (1.5 mg,
0.9 µmol). 1H NMR (D2O, 600 MHz) δ 5.2 (3 x d, 3H, J = 4.1, 3.8 and 3.9, H1b, e and h), 4.8 (m, 3
H, H5b, e and h),  4.7 (m, 2 H, H1d and g), 4.5 (d, 1 H, J = 7.9, H1a), 4.4 (3 x d, 3 H, J = 7.8, H1c, f
and i), 4.2-3.4 (m, 47 H, 9 2-H, 9 3-H, 9 4-H, 6 5-H, 12 6-H, CH2 spacer), 2.9 (t, 2 H, CH2 spacer),
Synthesis of Lewis X derivatives                                                                                                        65
2.0-1.9 (3 x s, NAc), 1.8-1.6 (2 x m, 4 H, CH2 spacer), 1.4-1.3 (2 x m, 4 H, CH2 spacer), 1.1 (3 x d,
6 H, J = 6.6, CH3b, e and h). MALDI-TOF MS: m/z 1651.8 [M+H}+.
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3
The interaction of anti-
schistosomal monoclonal
antibodies with mono,- di- and
trimeric Lewis X studied by
surface plasmon resonance
Summary
The interaction of a large panel of anti-schistosomal monoclonal antibodies (Mabs) with
mono-, di- and trimeric Lewis X was screened by surface plasmon resonance. Lewis X is
a trisaccharide, which was previously reported to elicit an immune response during a
schistosomal infection. Mabs which interacted differently with the Lewis X structures
were divided into three different groups; group I interacted with all the Lewis X
structures, whereas group II interacted with di- and trimeric Lewis X and group III
interacted solely with trimeric Lewis X. From each group one Mab was selected for
structural studies by X-ray crystallography.
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Introduction
It is generally accepted that the humoral immune response upon a schistosomal infection
is mainly directed against carbohydrate structures [1]. These carbohydrate structures have
been implicated to play a role in the evasion of the parasite from the immune system of its
host [2,3]. One of the carbohydrate structures that is expressed throughout all life cycle
stages of the parasite is Lewis X (Lex, Galß1-4[Fuc1-3]GlcNAc). Several groups have
reported that individuals infected with schistosomes develop an anti-Lex humoral immune
response [2,4-6]. In vitro studies have shown that these anti-Lex antibodies are cytolytic
towards the myeloid cells and granulocytes of the host [2-4]. This effect might play a role
in the escape mechanism of the schistosomes, although it remains to be determined
whether these cytolytic antibodies have a significant effect on the pathology of the
disease.
Previously, a large panel of monoclonal antibodies (Mabs) has been produced
from mice with a schistosomal infection [7]. Some of these Mabs are important tools for
the diagnosis of schistosomiasis, allowing detection of circulating antigens excreted by the
adult worms into the blood of infected individuals. The circulating cathodic antigen
(CCA), which contains multimeric Lex on its immunoreactive part [8], is one of these
immunodiagnostically important antigens. Using the anti-carbohydrate Mabs, CCA can be
quantitatively detected in the serum or urine of infected individuals [9,10].
As both monomeric and oligomeric Lex are expressed by the schistosomes [8,11-
15], we raised the question whether the immune system can discriminate between Lex in
its different oligomeric forms. To be able to study this we have synthesized mono-, di-
and trimeric Lex functionalized with a spacer (chapter 2). A quick and efficient way to
screen the interaction of a large panel of Mabs with different antigenic structures is by
surface plasmon resonance (SPR) analysis using small synthetic oligosaccharides [13,16].
One major advantage of this technique compared to the widely used ELISA is that the
scarce carbohydrate structures can be immobilized via a carrier molecule on the surface of
a sensor chip, which can be regenerated many times. In this case, the Lex derivatives were
conjugated to bovine serum albumin (BSA) ensuring both multivalent presentation and
straightforward immobilization onto a BIAcore sensor chip.
As a result from this SPR study, we could select Mabs with different specificities
for Lex mono- and oligomers, to be used for X-ray structural studies (chapter 4 and 5).
Obtaining a crystal structure of a Mab in complex with Lex will lead to a better
understanding of the binding characteristics of these Mabs for Lex at the molecular level.
This is of importance because Lex and the antibodies elicited against this carbohydrate
structure play an important role in the immunology and the immunodiagnosis of
schistosomiasis. This new information will also aid in the understanding of antibody
carbohydrate interactions in general as to date only a limited number of carbohydrate
structures in complex with a Fab fragment have been solved (chapter 1).
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Results and discussion
Synthesis of the neoglycoconjugates
Having the LacNAc and the Lex derivatives in hand, each functionalized with a spacer
containing a primary amine (chapter 2), the stage was set for conjugation to a carrier
molecule, in this case BSA. A mild, efficient method for this conjugation is to use diethyl
squarate as a linking moiety [17]. The LacNAc and Lex glycosides were readily converted
into their respective squarate adducts by the addition of 1.01-1.05 equivalents of diethyl
squarate to a solution of the sugar in a phosphate buffer/ethanol solution, pH 7.
Purification of the squarate adducts on a C18-column was followed by coupling to BSA in
a 0.1 M carbonate buffer pH 9. The average degree of conjugation of the sugars to BSA
was determined by MALDI-TOF mass spectrometry (Table 3.1). The conjugation degrees
of di- and trimeric Lex are somewhat disappointing. It has been reported that the nature of
the carbohydrate does not effect the outcome of the conjugation [18]. However, in [18]
only monosaccharides were used and the effect of oligomerization of the sugars on
conjugation was not studied. Therefore the lower conjugation degree could be due to the
size of the sugars. At the same time Lex human serum albumin (HSA) neoglycoconjugates
became available (courtesy of Dr. B.J. Appelmelk) with a much higher density of sugar on
HSA. The di- and trimeric Lex derivatives had been conjugated to HSA via an
aminophenylethyl linker using the isothiocyanate coupling method [19]. This implies that
conjugation via diethyl squarate is a good method for the conjugation of monosaccharides,
but is not optimal for oligosaccharides when high degrees of conjugation are desired. Both
the BSA and HSA neoglyconjugates were used in the SPR study. This allowed for the
assessment of the effect of the sugar load on the carrier molecule for the interaction with
the Mabs.












LacNAc-squarate 628.3 [M+Na]+ 70,056 6 6,000
Lex-squarate 775.3 [M+Na]+ 73,423 10 3,000
di-Lex-squarate 1266.2 [M+Na]+ 70,389 3.3 10,000
tri-Lex-squarate 1797.3 [M+Na]+ 70,638 2.3 12,000
aMol sugar per mol BSA
Analysis of the effect of multivalent presentation of sugars for the interaction of Mabs with
the Lex-neoglycoconjugates
To study the effect of the density of the glycosides on BSA or HSA on the interaction
with the Mabs, a sensor chip was prepared containing trimeric Lex-BSA
neoglycoconjugate immobilized to a level of 8,500 RU and its corresponding HSA
neoglycoconjugate immobilized to a level of 1,700 RU. These different immobilization
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levels ensured that a similar amount of sugar was present on the surface of the sensor chip.
A number of Mabs was screened for their interaction with trimeric Lex (Table 3.2). It was
immediately observed that the higher multivalency of the sugar on the carrier protein is
very important for the interaction as most Mabs did not interact with the low-density BSA
neoglycoconjugate, even though it was immobilized in a much higher amount on the
surface of the sensor chip (Figure 3.1). Apparently, the higher density of the BSA
neoglycoconjugate on the sensor chip could not compensate for the higher sugar-density
of the HSA neoglycoconjugate. This was not entirely surprising as it is generally known
that protein-carbohydrate interactions are usually very weak and depend on multivalency
to yield a high overall avidity [20].






a Immobilized to a level of 8,500 RU
b Immobilized to a level of 1,700 RU   
Figure 3.1 The effect of sugar-density on the carrier
molecule for the interaction with Mabs measured by
SPR a) binding of Mab 24-1B2-A and b) Mab 99-3D3-
A to BSA (──) and HSA (──) tri-Lex
neoglycoconjugate. Mabs 24-1B2-A and 99-3D3-A
bind to the high density HSA neoglycoconjugate. No
interaction was observed for Mab 24-1B2-A with the
BSA neoglycoconjugate and the interaction of Mab 99-
3D3-A was approximately 80 % reduced.
Comparison between BSA and HSA neoglycoconjugates
All BSA and HSA neoglycoconjugates were immobilized on CM5 sensor chips. In order
to have similar total levels of sugar on the surface of the sensor chip, the BSA
neoglycoconjugates were immobilized to different levels (Table 3.1). The HSA
neoglycoconjugates contained on average 22 mol sugar per mol HSA and were all
immobilized to a level of 10,000 response units (RU).
First, a group of approximately 100 Mabs was screened for interaction with
LacNAc-BSA, monomeric Lex-BSA and dimeric Lex-BSA and the HSA
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neoglycoconjugates. None of the Mabs interacted with LacNAc-BSA, whereas some did
interact with the other two neoglycoconjugates (data not shown). This finding was in line
with another study measuring the antibody response against Lacto-N-neotetraose
(LNFPIII lacking the fucose, carrying LacNAc at its reducing end) in serum from mice
infected with schistosomes, in which no response was observed against this
neoglycoconjugate [4]. Surprisingly, from the same panel, Mabs have been found to
interact with GalNAcβ1-4GlcNAc (LDN) [13] and with a single GlcNAc (chapter 7). This
might imply that a terminal HexNAc (GlcNAc or GalNAc) is immunogenic whereas a
terminal Hexose, e.g. Galactose in LacNAc, is not.
Furthermore, in this pre-screening the interaction of several Mabs with the
monomeric Lex BSA and HSA neoglycoconjugates was compared. The monomeric Lex-
BSA neoglycoconjugate carried the actual Lex trisaccharide, whereas the HSA
neoglycoconjugate was conjugated with Lacto-N-Fucopentaose III (Galβ1-4(Fucα1-
3)GlcNAcβ1-3Galβ1-4Glcβ, LNFPIII), a pentasaccharide containing Lex at its non-
reducing end. No differences relating to the extra lactose part on LNFPIII-HSA were
observed; all Mabs interacting with Lex also interacted with LNFPIII. Failure of Mabs,
which were screened positive for LNFPIII, to interact with Lex is most likely due to the
lower density of the sugar on BSA (analogous to the results obtained for the trimeric Lex
conjugates). In conclusion, it was decided to use the HSA neoglycoconjugates to study the
interaction of a large panel of Mabs with mono-, di- and trimeric Lex. LacNAc was not
included in this study as no Mabs had been found to bind to this sugar.
Screening of a large panel of Mabs with the HSA-neoglycoconjugates
A set of 831 previously produced anti-schistosome monoclonal antibodies [7,21] was
screened for their interaction with the HSA neoglycoconjugates. 156 Mabs interacted with
one or more of the tested neoglycoconjugates. These Mabs could be divided into three
groups: one group interacting with all the Lex conjugates, a second group interacting with
di- and trimeric Lex and the last group interacting with trimeric Lex (Table 3.3, Figure
3.2). Most Mabs interacting with the Lex oligosaccharides have the IgM isotype, but some
IgGs are also present. This was already noticed in the analysis of anti-CCA Mabs, which
likely recognize one of the Lex oligosaccharides as Lex constitutes the immunogenic part
of this antigen [8]. Other studies have indicated that differently fucosylated carbohydrate
structures (FLDN and LDNDF) primarily induce an IgG response [6,22,23]. An
explanation for the observed isotype restriction might be that Lex antigens give rise to a T-
cell independent immune response resulting in the production of antibodies predominantly
of the IgM isotype [24]. In several studies measuring the anti-Lex response in mice,
chimpanzees and humans infected with schistosomes, IgM antibodies were also primarily
observed [5,6,23], although in some cases IgG has been reported [2,4].
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Table 3.3 Interaction of Mabs with mono-, di- and trimeric Lex.
Mab Isotype LeX di-LeX tri-LeX Mab Isotype LeX di-LeX tri-LeX
Group I
005-100-B nd* ++ ++ ++ 114-5C10-A nd + + ++
005-104-B IgG1 ++ ++ ++ 114-5D12-A nd + + +
005-55-A IgM ++ ++ ++ 114-5F5-A IgG1 + + +
022-2C10-A nd ++ ++ ++ 114-5G3-A IgM + + ++
022-2C2-A nd ++ ++ ++ 114-5G6-A nd ++ ++ ++
022-2F10-A IgM ++ ++ ++ 114-5H8-A IgM ++ ++ ++
022-3A1-E IgM ++ ++ ++ 114-6D11-C IgM + + +
022-3A6-A nd ++ ++ ++ 128-1D9-C IgG1 ++ ++ ++
022-3D1-A nd ++ ++ ++ 128-2G9-A IgG1 + + +
022-4E9-A IgM ++ ++ ++ 128-4F9-A nd ++ ++ ++
022-5G11-E IgM ++ ++ ++ 212-4D2-A nd + + +
024-1B2-A IgM ++ ++ ++ 257-1D11 nd + + +
024-1D12-A IgM ++ ++ ++ 257-4E9 nd ++ ++ ++
024-1G9-A nd ++ ++ ++ 259-3E11-A IgM ++ ++ ++
024-2E5-B IgM + + + 259-3E12-A IgM ++ ++ ++
024-3B8-A IgM ++ ++ ++ 273-1A5-A nd ++ ++ ++
024-4D7-C IgM ++ ++ ++ 273-2G2 IgM ++ ++ ++
024-5E3-A IgM ++ ++ ++ 273-2H1-A IgM ++ ++ ++
024-5G1-A IgM ++ ++ ++ 273-3E7-A IgM ++ ++ ++
025-3E11-A IgM ++ ++ ++ 273-3H2-A nd ++ ++ ++
025-3G9-A IgM + + + 274-1E11-A IgM ++ ++ ++
034-3C6-A nd ++ ++ ++ 274-2G12-A nd ++ ++ ++
034-3E9-A nd + + + 274-3D5-A nd ++ ++ ++
036-2A11-A nd + + + 274-4G4-A IgG1 ++ ++ ++
036-2D8-A nd + + + 275-3H1-A nd ++ ++ ++
036-3G10-A nd ++ ++ ++ 287-2C2 IgM ++ ++ ++
039-1H6-A IgM + + + 287-2D2-A IgM ++ ++ ++
096-5B8-A nd + + + 287-2G9 IgM ++ ++ ++
099-1G3-A IgM + + + 287-2H8-A IgM ++ ++ ++
099-2B9-A IgM ++ ++ ++ 287-5D1-A IgM ++ ++ ++
099-3E11-A IgM ++ ++ ++ 287-5E7 IgG3 ++ ++ ++
100-1F3-A IgM + + + 289-2A5 nd + + ++
100-2A8-A IgM ++ ++ ++ 289-3H5 nd ++ ++ ++
100-2H9-C IgM + ++ ++ 291-1F9-A IgM ++ ++ ++
100-3A1-A nd + + + 291-1G3-A IgM ++ ++ ++
100-3C6-A IgM ++ ++ ++ 291-2G3-A IgG3 ++ ++ ++
100-4A9-E IgM ++ ++ ++ 291-4D10-A IgM ++ ++ ++
100-4G11-A IgM + + + 292-1E7-A nd + ++ ++
100-5A5-A nd + + + 292-1G3-A IgM ++ ++ ++
114-1H1-A IgM ++ ++ ++ 292-2E11-A nd + + +
114-2H6-C IgM ++ ++ ++ 292-5D9-A IgG3 ++ ++ ++
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Mab Isotype LeX di-LeX tri-LeX Mab Isotype LeX di-LeX tri-LeX
114-3A5-A IgG3 + + + 292-5G4-A IgM ++ ++ ++
114-3A7-A IgM + + ++ 292-6D9-A nd ++ ++ ++
114-3C8-A IgG1 + + + 293-1D6 nd + + +
114-3A6-A IgM ++ ++ ++ 293-3A12-A nd + + +
114-3D11-A nd + + + 293-3H11-A IgM ++ ++ ++
114-3E9-A IgM ++ ++ ++ 293-4A7-A nd ++ ++ ++
114-4A6-A IgM ++ ++ ++ 293-4D12-A IgG3 ++ ++ ++
114-4A8-A IgG3 + + + 293-4F9-A nd + + +
114-4B1-A IgG1 ++ ++ ++ 293-4G3-A nd ++ ++ ++
114-4D9-A IgM + + ++ 293-6G5-A nd ++ ++ ++
114-4D12-A IgG3 + + + 295-1B3-A nd ++ ++ ++
114-4E8-A IgM ++ ++ ++ 295-2B2-A nd ++ ++ ++
114-5A2-A IgM ++ ++ ++
Group II
002/7-A nd - ++ ++ 257-5G8 nd - ++ ++
024-2E5-A IgM - ++ ++ 258-2B12-A IgM - ++ ++
096-5D7-A nd - + + 273-1H6 nd - ++ ++
099-3D3-A IgM - ++ ++ 273-2D1-A IgM - ++ ++
114-2B11-A nd - ++ ++ 273-2G4 IgM - ++ ++
114-3E11-A nd - ++ ++ 273-3E1 IgM - ++ ++
114-4B9-A IgM - ++ ++ 274-1B8-A IgM - ++ ++
114-5A10-A IgG1 - ++ ++ 274-2C7-A nd - ++ ++
114-5E7-A IgM - ++ ++ 274-3D7-A IgG1 - ++ ++
179-4B1-A IgG3 - + ++ 291-2F3-A IgM - + +
180-1D9-A IgM - ++ ++ 295-2H1-A nd - ++ ++
257-4A8-A IgM - ++ ++ 297-2G10-A nd - ++ ++
257-5B5-A IgM - ++ ++
Group III
051-4B9-C IgM - - + 179-2G10-A IgG1 - - ++
054-1F6-A IgM - - + 180-1E6-A IgM - - ++
054-5C10-A IgG3 - - ++ 204-2F4-A IgM - - ++
114-2G6-A IgM - - ++ 235-4B1-A IgG3 - - ++
114-3A12-A IgM - - ++ 257-2C1 IgM - - ++
114-3C5-A IgM - - ++ 257-4B4-A IgM - - ++
114-3G5-A IgM - - ++ 257-4E12-A IgM - - ++
114-3H5-A IgG1 - - + 269-5C10-A nd - - ++
114-4B5-A IgG1 - - ++ 274-2A8-A IgG1 - - +
114-4E2-A nd - - ++ 274-3C8-A IgG1 - - ++
128-1G3-D IgM - - ++ 289-4D11-A IgM - - ++
179-1H6-A IgG1 - - ++ 294-3A9-A IgM - - ++
*nd = Isotype not determined;  ++ binding, + weak binding, - not binding
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Figure 3.2 BIAcore sensorgrams. Interaction of Mab a) 114-2B5-A b) 291-2G3-A, c) 179-4B1-A
and d) 54-5C10-A with LNFPIII-HSA (---), di-LeX-HSA (──) and tri-Lex-HSA (──). Mab 114-
2B5-A was found to interact with GlcNAc but does not interact with Lex (chapter 7).
Mabs 99-1G3-A and 99-3D3-A (from group I and II respectively) were next used
in a doublestaining experiment on frozen sections of liver from infected mice. As can be
seen from Figure 3.3 different structures were stained within the miracidium of the
schistosomal eggs. This indicates that the Mabs from different groups can be used to map
the different oligomeric Lex structures within the parasite.
Mabs interacting with monomeric Lex or terminal Lex always interacted with di-
and trimeric Lex as well. Probably they interacted with the terminal Lex moiety in both di-
and trimeric Lex. The exact carbohydrate structure that is recognized by the Mabs which
specifically interacted with the longer Lex structures, is difficult to determine from a
qualitative SPR study. These Mabs might actually need multiple Lex units for interaction
or perhaps an internal Lex in the same or different reading frame. To address this, it would
be of interest to remove the terminal Galactose and/or the Fucose of dimeric Lex and
measure the interaction again. Failure to react could imply that all residues are indeed
required for interaction. Another possibility that should be considered is that multimeric
Lex oligosaccharides could adopt a certain tertiary structure necessary for interaction and
that this structure might not be found in the shorter saccharides.
Definite answers to explain the observed differences in binding to the different
Lex neoglycoconjugates of the Mabs could be provided by X-ray crystallography. Co-
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crystallizing Fab fragments of the Mabs together with their complementary Lex
oligosaccharide would yield structural information about the binding at the molecular
level. Therefore, from each group a Mab was selected for crystallization studies. As it is
much more difficult to prepare Fab fragments from IgM antibodies compared to IgG
antibodies, Mabs with the IgG isotype were selected. From group I, Mab 291-2G3-A was
selected as this Mab had a good interaction with all three neoglycoconjugates. From group
II, Mab 179-4B1-A was selected, which was with hindsighta perhaps not the best choice as
other Mabs bound stronger to di- and trimeric Lex. Finally from group III, Mab 54-5C10-
A was selected. This Mab was selected, as it is diagnostically important. It is used in the
antibody-capture ELISA for detection of CCA employed for the diagnosis of
schistosomiasis [25].
Figure 3.3 Doublestained immunofluorescence
pattern of Mabs 99-1G3-A group I and 99-3D3-A
group II, on frozen sections of adult Schistosoma
mansoni eggs (courtesy of K.K. Van de Vijver).
Different Lex-containing structures are stained
within the miracidium. (For a color picture see
Appendix II).
Conclusions
A panel of anti-schistosomal Mabs was screened for interaction with mono-, di- and
trimeric Lex by SPR and the Mabs were grouped according to their interaction behavior.
Group I contains Mabs reactive with all Lex neoglycoconjugates, group II contains Mabs
interacting with di- and trimeric Lex, whilst Mabs only specific for trimeric Lex are in
group III. From each group, one IgG was selected for structural studies (chapter 4 and 5).
Furthermore, the fact that Mabs can distinguish between Lex in different oligomeric states
indicates that mono-, di- and trimeric Lex are immunologically different entities. These
results have prompted us to study the anti-Lex response upon a schistosomal infection in
vivo, which is discussed in chapter 6.
                                                          
a The large panel of 831 Mabs became available after a smaller selection had already been
screened and used to select the Mabs for structural studies.
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Material and methods
Procedure for the derivatization of spacer glycosides with diethyl squarate
Spacer containing LacNAc, mono-, di- and trimeric Lex conjugates (1-7 mg) were dissolved in a 1:1
solution of 0.1 M phosphate buffer pH 7.0. and MeOH (~ 250 µL total volume). 1.1 Eq. diethyl
squarate was added and the reaction was allowed to stand until TLC analysis (n-
BuOH:MeOH:water:HOAc 4:2:2:0.5) indicated complete conversion of the glycoside into a faster
moving product. After concentration, the crude residue was dissolved in water (0.5 mL) and loaded
onto a C-18 Sep-Pak cartridge. The column was washed with water (3 x 0.5 mL), then the product
was eluted with water/MeOH (75/25 → 25/75 v/v). After TLC analysis, the fractions containing the
squarate adduct were pooled and evaporated. The presence of the final compounds was confirmed
by mass spectrometry using a MALDI-TOF MS (Table 3.1).
Procedure for the preparation of the Bovine Serum Albumin (BSA) neoglycoconjugates
BSA (25 mg mL-1) was dissolved in 0.2 M carbonate buffer pH and stirred for 30 min. Then the
diethyl squarate adduct, dissolved in water (0.5 mg mL-1), was added to the BSA solution (20 mol
eq based on BSA) and the reaction was allowed to proceed for 5 days. The BSA neoglycoconjugates
were purified using gel permeation chromatography. The degree of incorporation of the Lewis X
glycosides onto BSA was determined by MALDI-TOF MS (Table 3.1). The HSA
neoglycoconjugates containing LNFPIII, di- or trimeric Lex were a kind gift of Dr. B.J. Appelmelk
(Amsterdam, The Netherlands). The neoglycoconjugates were originally purchased from Isosep AB
(Tullinge, Sweden). These neoglycoconjugates contained on average 22 mol sugar per mol HSA.
Immobilization of BSA and HSA neoglycoconjugates on CM5 sensor chips
The BIAcore 3000 instrument, CM5 sensor chips and an amino coupling kit were purchased from
BIAcore AB (Uppsala, Sweden). All buffers were filtered and degassed under vacuum before use.
Immobilization of the neoglycoconjugates was performed using the standard amino coupling
procedure according to the instructions of the manufacturer at a flow rate of 5 L min-1. In short, the
carboxymethylated surface of the CM5 sensor chip was activated by a 7 minute pulse of a 1:1
mixture of 0.1M N-hydroxysuccinimide and 0.1M N-Ethyl-N’-(dimethylaminopropyl)carbodiimide,
followed by several injections of the neoglycoconjugate at a concentration of 25 g mL-1 in 10 mM
sodium acetate pH 4.5 until the desired level of immobilization was achieved. The BSA
neoglycoconjugates were immobilized to various levels depending on the sugar load on BSA (Table
3.1). The HSA Lex neoglycoconjugates were immobilized to a level of 10,000 response units (RU).
After immobilization unreacted groups were blocked by the injection of 300 l 1M ethanolamine-
HCl, pH 8.5. The same protocol was followed for the BSA neoglycoconjugates. HSA or BSA
without Lex was coupled on one flow channel as a control.
Binding analysis of monoclonal antibodies to LNFPIII, mono-, di- and trimeric Lex by SPR
Culture supernatant (sup) of 831 anti-schistosomal Mabs was injected over the CM 5 sensor chip
containing the Lex neoglycoconjugates during 2.5 minutes with a flow of 20 µl s-1. After a
dissociation period of 5 minutes, the response was measured. Subsequently, the surface was
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regenerated with 10 µl of 20 mM HCl. At the start of each new cycle, a two minute equilibration
period preceded injection of the sup. Every 10th cycle HBS buffer was injected as a control for the
surface. After subtraction of the response units of the HSA control channel, the binding pattern of
each Mab was interpreted as binding (++), weak binding (+) or not binding (-) to LNFPIII, di- or
trimeric Lex (Table 3.3).
Immunofluorescence assay
IFA was carried out on 6 µm-thick cryostat liver sections of infected mice. The air-dried cold
acetone-fixed (-20 °C) sections were incubated for 2 hrs at 37 °C in a doublestaining procedure with
Mabs 99-1G3-A and 99-3D3-A, which were labeled with Alexa Fluor® 633 (red) and Alexa Fluor®
488 (green) respectively (Molecular Probes, Leiden, The Netherlands). The sections were examined
by K.K. Van de Vijver, Antwerp, Belgium using a conventional fluorescence microscope (Olympus
BX41, Hamburg, Germany) equipped with a dualband filterset (bp 461-500 & 534-588).
References
1. Omer, A.P., Mansour, M., Woody, J.N., Smithers, S.R. and Simpson, A.J. (1989). Antibody to
carbohydrate and polypeptide epitopes on the surface of schistosomula of Schistosoma mansoni
in Egyptian patients with acute and chronic schistosomiasis. Parasitology 98 Pt 3, 417-424.
2. Nyame, A.K., Pilcher, J.B., Tsang, V.C. and Cummings, R.D. (1996). Schistosoma mansoni
infection in humans and primates induces cytolytic antibodies to surface Le(x) determinants on
myeloid cells. Exp. Parasitol. 82, 191-200.
3. Van Dam, G.J., Claas, F.H., Yazdanbakhsh, M., Kruize, Y.C., van Keulen, A.C., Ferreira, S.T.
et al.. (1996). Schistosoma mansoni excretory circulating cathodic antigen shares Lewis- X
epitopes with a human granulocyte surface antigen and evokes host antibodies mediating
complement-dependent lysis of granulocytes. Blood 88, 4246-4251.
4. Nyame, A.K., Pilcher, J.B., Tsang, V.C. and Cummings, R.D. (1997). Rodents infected with
Schistosoma mansoni produce cytolytic IgG and IgM antibodies to the Lewis X antigen.
Glycobiology. 7, 207-215.
5. Richter, D., Incani, R.N. and Harn, D.A. (1996). Lacto-N-fucopentaose III (Lewis X), a target
of the antibody response in mice vaccinated with irradiated cercariae of Schistosoma mansoni.
Infect. Immun. 64, 1826-1831.
6. Van Remoortere, A., Van Dam, G.J., Hokke, C.H., van den Eijnden, D.H., van Die, I. and
Deelder, A.M. (2001). Profiles of immunoglobulin M (IgM) and IgG antibodies against defined
carbohydrate epitopes in sera of Schistosoma-infected individuals determined by surface
plasmon resonance. Infect. Immun. 69, 2396-2401.
7. Deelder, A.M., Van Dam, G.J., Kornelis, D., Fillie, Y.E. and van Zeyl, R.J. (1996).
Schistosoma: analysis of monoclonal antibodies reactive with the circulating antigens CAA and
CCA. Parasitology 112 , 21-35.
8. Van Dam, G.J., Bergwerff, A.A., Thomas-Oates, J.E., Rotmans, J.P., Kamerling, J.P.,
Vliegenthart, J.F. et al. (1994). The immunologically reactive O-linked polysaccharide chains
78                                                                                                                                             Chapter 3
derived from circulating cathodic antigen isolated from the human blood fluke Schistosoma
mansoni have Lewis X as repeating unit. Eur. J. Biochem. 225, 467-482.
9. De Jonge, N., Kremsner, P.G., Krijger, F.W., Schommer, G., Fillie, Y.E., Kornelis, D. et al.
(1990). Detection of the schistosome circulating cathodic antigen by enzyme immunoassay
using biotinylated monoclonal antibodies. Trans. R. Soc. Trop. Med. Hyg. 84, 815-818.
10. Deelder, A.M., Qian, Z.L., Kremsner, P.G., Acosta, L., Rabello, A.L., Enyong, P. et al. (1994).
Quantitative diagnosis of Schistosoma infections by measurement of circulating antigens in
serum and urine. Trop. Geogr. Med. 46, 233-238.
11. Khoo, K.H., Huang, H.H. and Lee, K.M. (2001). Characteristic structural features of
schistosome cercarial N-glycans: expression of Lewis X and core xylosylation. Glycobiology
11, 149-163.
12. Koster, B. and Strand M. (1994). Schistosoma mansoni : immunolocalization of two different
fucose-containing carbohydrate epitopes. Parasitology 108, 433-446.
13. Van Remoortere, A., Hokke, C.H., van Dam, G.J., van Die, I., Deelder, A.M. and van den
Eijnden, D.H. (2000). Various stages of schistosoma express Lewis(x), LacdiNAc,
GalNAcbeta1-4(Fucalpha1-3)GlcNAc and GalNAcbeta1-4(Fucalpha1-2Fucalpha1-3)GlcNAc
carbohydrate epitopes: detection with monoclonal antibodies that are characterized by
enzymatically synthesized neoglycoproteins. Glycobiology 10, 601-609.
14. Wuhrer, M., Dennis, R.D., Doenhoff, M.J., Lochnit, G. and Geyer, R. (2000). Schistosoma
mansoni cercarial glycolipids are dominated by Lewis X and pseudo-Lewis Y structures.
Glycobiology 10, 89-101.
15. Srivatsan, J., Smith, D.F. and Cummings, R.D. (1992). The human blood fluke Schistosoma
mansoni synthesizes glycoproteins containing the Lewis X antigen. J. Biol. Chem. 267, 20196-
20203.
16. Vermeer, H.J., Van Dam, G.J., Halkes, K.M., Kamerling, J.P., Vliegenthart, J.F.G., Hokke,
C.H. et al. (2003). Immunodiagnostically applicable monoclonal antibodies to the circulating
anodic antigen of Schistosoma mansoni bind to small, defined oligosaccharide epitopes.
Parasitol. Res. 90, 330-336.
17. Kamath, V.P., Diedrich, P. and Hindsgaul, O. (1996). Use of diethyl squarate for the coupling
of oligosaccharide amines to carrier proteins and characterization of the resulting
neoglycoproteins by MALDI-TOF mass spectrometry. Glycoconj. J. 13, 315-319.
18. Zhang, J., Yergey, A., Kowalak, J. and Kovac, P. (1998). Studies towards neoglycoconjugates
from the monosaccharide determinant of Vibrio cholerae O : 1, serotype Ogawa using the
diethyl squarate reagent. Carbohydr. Res. 313, 15-20.
19. Kallin, E., Lonn, H. and Norberg, T. (1986). New Derivatization and Separation Procedures for
Reducing Oligosaccharides. Glycoconj. J. 3, 311-319.
20. Lundquist, J.J. and Toone, E.J. (2002). The cluster glycoside effect. Chem. Rev. 102, 555-578.
21. Van Dam, G.J., Kornelis, D., van Zeyl, R.J., Rotmans, J.P. and Deelder, A.M. (1993).
Schistosoma mansoni: analysis of monoclonal antibodies reactive with gut-associated antigens.
Parasitol. Res. 79, 55-62.
22. Naus, C.W.A., Van Remoortere, A., Ouma, J.H., Kimani, G., Dunne, D.W., Kamerling, J.P. et
al. (2003). Specific antibody responses to three schistosome-related carbohydrate structures in
Interaction of anti-schistosomal Mabs with Lewis X                                                                         79
recently exposed immigrants and established residents in an area of Schistosoma mansoni
endemicity. Infect. Immun. 71, 5676-5681.
23. Van Remoortere, A., Vermeer, H.J., Van Roon, A.M., Langermans, J.A., Thomas, A.W.,
Wilson, R.A. et al. (2003). Dominant antibody responses to Fucalpha1-3GalNAc and Fucalpha
1-2Fucalpha1-3GlcNAc containing carbohydrate epitopes in Pan troglodytes vaccinated and
infected with Schistosoma mansoni. Exp. Parasitol. 105, 219-225.
24. Vos, Q., Lees, A., Wu, Z.Q., Snapper, C.M. and Mond, J.J. (2000). B-cell activation by T-cell-
independent type 2 antigens as an integral part of the humoral immune response to pathogenic
microorganisms. Immunol. Rev. 176, 154-170.
25. Van Dam, G.J., Qian, Z.L., Fillie, Y.E., Rotmans, J.P. and Deelder, A.M. (1993). Detection of
IgM antibodies directed against the gut-associated circulating cathodic antigen in sera from
Schistosoma mansoni infected patients. Development and comparison of three enzyme-linked




X-ray analysis of anti-Lewis X Fab
fragments
Anne-Marie M. van Roon, Navraj S. Pannu, Cornelis H. Hokke, André M. Deelder and
Jan Pieter Abrahams
based on Acta crystallographica D 59, 1306-1309 (2003)
Summary
Monoclonal antibodies (Mabs) 291-2G3-A, 179-4B1-A and 54-5C10-A, which were
generated from mice infected with schistosomes, were found to interact with monomers,
dimers and trimers of the Lewis X trisaccharide in different manners. This chapter
describes the production, purification and crystallization of Fab fragments of these Mabs.
The Fab fragment of Mab 291-2G3-A was successfully crystallized using different
conditions, which all contained polyethylene glycol 3350 as a precipitant. Crystallization
trials with the Fab fragments of Mabs 179-4B1-A and 54-5C10-A did not give suitable
crystals. X-ray datasets were recorded for two different 291-2G3-A Fab crystals, both
soaked with Lewis X, to 3.2 and 1.8 Å resolution. In addition a dataset was measured for
the native Fab to 2.05 Å resolution.
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Introduction
In the previous chapter the screening of a selected group of anti-schistosomal Mabs for
interaction with mono-, di- and trimeric Lex by surface plasmon resonance was described.
From this study a number of Mabs was found which interacted differentially with the Lex
structures and were divided into three groups according to their interaction with mono-,
di- and trimeric Lex, di- and trimeric Lex or solely trimeric Lex. From each group one Mab
was selected for X-ray structural studies; from group I Mab 291-2G3-A (IgG3κ), from
group II Mab 179-4B1-A (IgG3κ) and from group III Mab 54-5C10-A (IgG3κ). The
elucidation of the X-ray structure of the Fab fragments of these Mabs with and without
their complementary Lex structure will allow for more insight into the structural
requirements for the binding of these antibodies to the Lex epitope. Moreover, in view of
the limited number of structures investigated so far, it will also provide additional
information concerning carbohydrate recognition by antibodies in general.
As intact Mabs are quite flexible due to a hinge region between CH1 and CH2 they
are rather difficult to crystallize (chapter 1). Therefore, the N-terminal part of the Mab
containing the binding site (Fab fragment) should be cleaved off prior to crystallization. A
straightforward method to directly obtain Fab fragments for all classes of mouse IgG
requires papain digestion in the presence of a thiol such as free cysteine [1,2]. Although a
general protocol has been described, for each IgG the optimal cleavage time and
temperature should be found. After digestion, the Fab fragments can easily be separated
from the undigested IgG and Fc fragments by protein A affinity chromatography, which
specifically retains the IgG and Fc fractions, while the Fabs are recovered in the flow-
through.
It is well known that Fab fragments are heterogeneous, because of minor
modifications during and/or after secretion of the antibody or heterogeneous papain
digestion. This heterogeneity makes crystallization of the Fabs difficult as protein samples
should be as homogeneous as possible for crystallization. Already in 1982 it was
established that the quality of crystals of Fab fragments increased dramatically after
separation of the different isoforms [3,4]. Crystals could be grown from each isoform,
although not all of the same quality. Therefore it is difficult to predict beforehand which
isoform will yield the best crystals. As the different isoforms of  Fab fragments usually
differ in pI, they can easily be analyzed by isoelectric focusing and subsequently,
depending on the pI-range, be separated by cation or anion exchange column
chromatography. After homogeneous protein sample is obtained, crystallization trials may
be set up. Previously, it was shown that a low ionic strength polyethylene glycol (PEG)
3350 screen as described by Harris et al. [5] is a good starting point for finding
crystallization conditions of intact Mabs and their fragments [6]. For the first trial a wide
range of conditions should be tested i.e. 4-24 % PEG 3350 in a pH range of 3-9. After
initial crystals are found the crystallization must be optimized in a narrow range around
the initial conditions.
In order to determine the structure of a complex, the ligand can either be co-
crystallized with the protein or soaked into the crystal afterwards before measuring X-ray
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diffraction. In all previously published structures of Fab fragments with a bound sugar (for
an overview see chapter 1), the ligand was co-crystallized, as soaking cracked the crystals
[7]. However when co-crystallization fails, soaking is the only alternative and optimal
ligand concentrations and soaking times should be explored.
In this chapter we describe the production and purification of the Fab fragments
of anti-Lex Mabs 291-2G3-A, 179-4B1-A and 54-5C10-A and the method of
crystallization. In case of the 291-2G3-A, crystals suitable for X-ray crystallography were
grown. Soaking of these crystals with Lex and the preliminary X-ray diffraction analysis
of both the Fab fragment and the Fab fragment
soaked with Lex are also reported.
Figure 4.1 -O-methyl glycoside of Lex used in
soaking experiments with the Fab of 291-2G3-A.
Results and discussion
Mabs 291-2G3-A, 179-4B1-A and 54-5C10-A were digested with papain and after
purification of the obtained Fab fragments by protein A affinity chromatography and ion
exchange chromatography, crystallization trials were set up. Crystals of 179-4B1-A as
shown in Figure 4.2a were too small for X-ray crystallography and the rather large crystal
of 54-5C10-A (Figure 4.2b) only diffracted to very low resolution (10 Å). In addition,
needle-like crystals of 54-5C10-A were found in 8 % PEG 3350, 0.1 M sodium citrate
(pH 5) (data not shown). Optimization around this condition might yield better crystals for
the 54-5C10-A. The failure to produce high quality crystals of the Fab fragments of 179-
4B1-A and 54-5C10-A is likely due to the inhomogeneity of the solutions, as these protein
samples still contained two isoforms after anion exchange chromatography.
The first attempts to crystallize the Fab fragment of Mab 291-2G3-A used
material that was not further purified after the protein A column. Again the low ionic
strength PEG 3350 screen was set up and sea urchin-like clusters of crystals could be
found in 14-20 % PEG 3350 and 50 mM Tris at pH 8. However, after more extensive
purification of the Fab fragment by anion exchange chromatography, single crystals of
dimensions up to 0.15 x 0.15 x 0.10 mm (Figure 4.2c) could be grown from the same
crystallization conditions. At the same time, the Hampton Crystal Screen Cryo was set up
and a motherliquor containing 25.5 % PEG 4000, 0.17 M ammonium sulfate and 15 %
glycerol yielded small crystals. Replacement of PEG 4000 by PEG 3350 and varying its
concentration between 23 and 26 % yielded single crystals after several days (Figure
4.2d). After two months one crystal with a size of 0.35 x 0.3 x 0.25 mm was found, that
had grown from 26 % PEG 3350, 0.17 M ammonium sulfate and 15 % glycerol. From this
crystal a dataset was recorded to 2.05 Å resolution. The Fab had crystallized in space-
group P1 (for a summary of the processing data see Table 4.1).
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Figure 4.2 Crystals of Fab fragments a) 179-4B1-A grown in 0.16 M ammonium acetate, 0.085 M
sodium acetate, pH 4.6, 25.5 % PEG 4000 and 15 % glycerol b) 54-5C10-A grown in 0.1 M n-(2-
acetamido)iminodiacetic acid, pH 6.5, 1.0 M ammonium sulfate c) 291-2G3-A grown in 14 % PEG
3350, 50 mM Tris pH 8. d) 291-2G3-A grown in 23.5 % PEG 3350, 15 % glycerol and 0.17 M
ammonium sulfate.
Crystallization trials with the Fab fragment in the presence of 10 to 20
equivalents of Lex resulted in phase separation. Various conditions in combination with
additive screen 1 (Hampton Research) failed to co-crystallize the Fab fragment with Lex.
However, soaking experiments with Lex proved more successful. Crystals, grown from 25
% PEG 3350, 0.17 M ammonium sulfate and 15 % glycerol, were soaked in a pre-
equilibrated crystallization condition containing either 50 or 100 mM Lex. Although the
quality of the crystals deteriorated, probably due to the soaking, X-ray diffraction could
still be measured from a crystal soaked overnight in 50 mM Lex, and the data could be
processed. A summary of the statistics is given in Table 4.1. The unit cell parameters of
the crystal with Lex are very similar to those of the crystal without Lex except for a more
elongated b axis, most likely a result of the soaking since the crystal was grown under
similar conditions as the native Fab fragment. The calculated Vm [8] of the native Fab is
2.2 Å3 Da-1 and of the Fab-Lex it is 2.4 Å3 Da-1, which corresponds to a solvent content of
about 50 %, assuming that there are 4 molecules in the asymmetric unit.
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Furthermore, a 100 mM Lex solution was added to a droplet containing crystals
that had grown from 14 % PEG 3350 and 50 mM Tris pH 8. After half an hour of soaking
with Lex, X-ray diffraction was measured. This crystal diffracted to 1.8 Å resolution and
differed in all cell dimensions compared to the crystals grown from 25 % PEG 3350, 0.17
M ammonium sulfate and 15 % glycerol (Table 4.1). Since all the axes are smaller, we
assume that the crystal only contains two Fab molecules in the asymmetric unit. The
calculated Vm [8] of this Fab-Lex crystal is 2.5, corresponding to a solvent content of 50
%. The structure of the Fab fragment of Mab 291-2G3-A with and without Lex was
determined by molecular replacement using the Fab fragment of an anti-Lewis Y antibody
[9] as a model. Clear density was found for Lex in the binding site in case of the Fab
fragments that were soaked with its antigen.









26 % PEG 3350,
0.17 M AS,
15 %  glycerol
25 % PEG 3350,
0.17 M AS,
15 % glycerol
14 % PEG 3350,
50 mM tris pH 8
Beamline APS ID19 APS ID19 ESRF ID14-1
Wavelength (Å) 1.03 1.03 0.934
Space-group triclinic P1 triclinic P1 triclinic P1
Unit cell parameters
a x b x c (Å)
α x β x γ (°)
67.4 x 71.6 x 104.8
86.5 x 71.3 x 83.3
67.4 x 72.4 x 104.8
85.8 x 71.3 x 83.3
45.1 x 60.8 x 91.6
96.0 x 95.4 x 101.8




Unique reflections 103313 27423 87852
Average I/σ (I) 19.7 (2.1) 6.1 (1.6) 11.1 (2.2)
Rmerge (%)b 4.6 (32.9) 14.6 (46.9) 9.4 (38.6)
Completeness (%) 88.1 (38.9) 87.0 (43.4) 87.0 (43.4)
aValues of reflections recorded in the last resolution shell are shown in parentheses.
bRmerge = Σ ( I-<I>) / Σ (I) (scalepack output)
Conclusions
Crystallization trials were set up for Fab fragments of anti-schistosomal Mabs 291-2G3-A,
179-4B1-A and 54-5C10-A. Crystals suitable for X-ray diffraction studies were obtained
for the Fab fragment of 291-2G3-A. In addition, these crystals could successfully be
soaked with monomeric Lex. Datasets were recorded for Fab of 291-2G3-A with and
without Lex. The structure determination is discussed in chapter 5. By improving the
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homogeneity of the protein samples and by optimization of the crystallization conditions,
higher quality crystals for the other two Fab fragments might be obtained.
Materials and methods
Protein production and purification
The murine Mabs 291-2G3-A, 179-4B1-A and 54-5C10-A were purified from hybridoma cell
culture supernatant using protein A affinity chromatography (Protein A Sepharose, Amersham).
Serum free culture medium was used to prevent the introduction of non-specific IgG molecules. The
cell culture supernatant was loaded onto the protein A column. After extensive washing of the
column with a buffer containing 1.5 M glycine, 3 M NaCl pH 8.8, the IgG was eluted from the
column with 0.1 M citrate pH 3. Fab fragments were obtained by papain digestion with immobilized
papain agarose beads (Pierce) following the manufacturers instructions. The digestion buffer
contained 25 mM phosphate, 5 mM EDTA and 10 mM cysteine at pH 7.2 and the Mabs were
digested at 37 °C for 2.5 hours (291-2G3-A and 54-5C10-A) to overnight (179-4B1-A). After
digestion, the Fab fragments were separated from undigested protein and Fc fragments by protein A
affinity chromatography. This was followed by a concentration step with a cation exchange column
using 20 mM citrate pH 3.5 as a running buffer and a 0-1 M NaCl gradient to elute the protein. At
this stage, standard reducing SDS-PAGE showed two closely adjacent bands at 25 kDa, as expected
for the light chain and Fab portion of the heavy chain. Analysis on an isoelectric focusing gel
revealed however that different isoforms of the Fab fragments were still present in the mixture
(Figure 4.3).
291-2G3-A
The protein mixture containing the Fabs was extensively dialyzed against 20 mM Tris-HCl pH 8.8,
0.02 % w/v NaN3 and loaded onto a UNO Q-1 anion exchange column (Biorad). The different Fab
isoforms were eluted with a 0-1 M NaCl gradient. The flow-through of the column, which contained
the isoforms with a pI of 9.1 and 8.2, was dialyzed again and ion exchange column chromatography
under the same conditions yielded a single pure isoform with a pI of 9.1, which was used in
crystallization trials. The sample was concentrated to 8 mg mL-1 in 20 mM Tris-HCl pH 8.8 using
Ultrafree-0.5 Centrifugal Filter Unit (Millipore).
Figure 4.3 Isoelectric focusing gel of the Fab fragment
samples after papain cleavage. For each Fab at least 4 different
isoforms were observed.
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179-4B1-A
The protein mixture containing the Fabs was extensively dialyzed against 20 mM Tris-HCl pH 8.0,
0.02 % w/v NaN3 and loaded onto a UNO Q-1 anion exchange column (Biorad). The different Fab
isoforms were eluted with a 0-1 M NaCl gradient. The flow-through of the column, which contained
the isoforms with a pI of 8.6 and 7.9 and 7.4, was dialyzed again against 20 mM glycine buffer, pH
9. Ion exchange chromatography at pH 9 (0-1 M NaCl) yielded a mixture of isoforms with pI of 8.6
and 7.9 in the flow-through. This was used in crystallization trials. The sample was concentrated to
6 mg mL-1 in 20 mM glycine pH 9 using Ultrafree-0.5 Centrifugal Filter Unit (Millipore).
54-5C10-A
The protein mixture containing the Fabs was extensively dialyzed against 20 mM Tris-HCl pH 8.8,
0.02 % w/v NaN3 and loaded onto a UNO Q-1 anion exchange column (Biorad). The different Fab
isoforms were eluted with a 0-1 M NaCl gradient. The flow-through of the column, which contained
the isoforms with a pI of 9.3 and 7.7, was dialyzed again against 20 mM glycine buffer, pH 9. Ion
exchange column chromatography using a similar elution did not result separate the two isoforms.
The sample was concentrated to 15 mg mL-1 in 20 mM glycine pH 9 using Ultrafree-0.5 Centrifugal
Filter Unit (Millipore).
Prior to crystallization, all samples were filtered through a low protein binding 0.22 µm
filter (Millipore) to remove dust particles and protein aggregates. The amino acid sequence of these
Fab fragments can be found in Appendix I, the procedure of sequencing can be found in the Material
and methods section of chapter 5.
Crystallization trials
Crystallization trials were carried out using the sitting drop vapor diffusion method at 295 K using
equal volumes of protein and reservoir solutions. Crystals were found for each Fab fragment using
different crystallization conditions (see legend of Figure 4.2). Unfortunately, only the Fab fragment
of 291-2G3-A formed crystals suitable for structure determination. These crystals, with an avreage
size of 0.12 x 0.05 x 0.05 mm, were grown by mixing 1 µl of protein solution with 1 µl of reservoir
solution, which contained 23 to 26 % PEG 3350, 0.17 M ammonium sulfate and 15 % glycerol.
Crystals of a similar size could also be obtained from 15 % to 18 % PEG 3350 in 50 mM Tris pH 8
(Figure 4.2).
In order to grow crystals of the Fab fragment of 291-2G3-A in complex with Lex,
crystallization trials were set up around the crystallization conditions of the native Fab fragment but
now in the presence of 10 to 20 equivalents of Lex. In almost all crystallization trials phase
separation occurred and no crystals could be found. Therefore, crystals grown in the absence of Lex
were soaked for varying times in their crystallization buffer containing 50 mM Lex. The crystals
were either transferred to a freshly equilibrated droplet containing 50 mM Lex or 1 µl of a 100 mM
Lex solution was added directly to the droplet containing the Fab crystals, prior to measuring X-ray
diffraction data.
Data collection
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The X-ray diffraction analysis of the 291-2G3-A Fab crystals was carried out at the X-ray
crystallography beamline ID19 at Argonne National Laboratory, Argonne, Illinois, on an ADSC
Q310 CCD detector and at the European Synchrotron Radiation Facility at beamline ID14-1 on a
ADSC Q4 CCD detector. Crystals were either grown in the presence of cryoprotectants so they
could be mounted directly from the crystallization droplet in cryo-loops (Hampton Research) or they
were soaked for five seconds in a solution containing a cryoprotectant prior to mounting, followed
by flash-freezing in a nitrogen-gas stream at 100 K. Data were collected using 1° oscillations and
240 images were recorded per dataset. The collected data were indexed, integrated and scaled with
HKL2000 [10].
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Summary
The Lewis X trisaccharide is pivotal in mediating specific cell-cell interactions.
Monoclonal antibody 291-2G3-A, which was generated from mice infected with
schistosomes, has been shown to recognize the Lewis X trisaccharide. Here we describe
the structure of the Fab fragment of 291-2G3-A, with Lewis X to 1.8 Å resolution. The
crystallographic analysis revealed that the antigen-binding site is a rather shallow binding
pocket and residues from all six complementary determining regions of the antibody
contact all sugar residues. The high specificity of the binding pocket does not result in
high affinity, the KD determined by isothermal calorimetry is 11 µM. However, this
affinity is in the same range as for other sugar-antibody complexes. The detailed
understanding of the antibody-Lewis X interaction revealed by the crystal structure may
be helpful in the design of better diagnostic tools for schistosomiasis and for studying
Lewis X-mediated cell-cell interactions by antibody interference.
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Introduction
The trisaccharide Lewis X (Lex, Galβ1-4(Fucα1-3)GlcNAcβ) is one of the histo-blood
group carbohydrate determinants and is expressed by higher organisms in various tissues,
such as brain, kidney and stomach [1], where it is thought to play an important role in
cell-cell adhesion. Lex has been detected on numerous different tumor cells [2,3] and it
also plays an important role in the immunology of schistosomiasis, a parasitic disease that
affects hundreds of millions of people in the tropics. Throughout the different life cycle
stages of the parasite, Lex and other carbohydrates are abundantly expressed on its outer
membrane or excreted into the circulation of the host [4] (and references cited therein).
The parasite differentially expresses Lex on glycolipids and glycoproteins, both in
monomeric and in multimeric form [5-11]. For example, polymeric Lex is expressed as the
major immunogenic part of the gut-associated circulating cathodic antigen (CCA) [12].
This antigen is excreted into the circulation of the host by the adult worms in abundant
amounts, allowing sensitive immunodiagnostic detection of schistosomiasis [13]. Lex-
containing glycoconjugates have been shown to stimulate B cells to proliferate and to
produce factors that down-regulate the TH1 immune response and up-regulate the TH2
immune response [14,15]. Individuals suffering from schistosomiasis mount an immune
response against Lex [16-19]. Antibodies to the Lex-containing glycans have been reported
to mediate complement-dependent cytolysis in vitro of human granulocytes [20],
suggesting a mechanism for the mild neutropenia sometimes observed during a
schistosome infection [21]. Recent studies have shown that Lex in different oligomeric
states gives rise to the elicitation of different groups of anti-Lex antibodies [22,23, chapter
3 and 6]. To further understand the basis of the specificity of these antibodies for Lex, we
performed an X-ray crystallographic analysis of monoclonal antibody (Mab) 291-2G3-A
that binds monomeric, dimeric and trimeric Lex to gain detailed structural insight in the
protein-Lex interaction. Lex, anti-Lex antibodies and carbohydrate binding proteins
(lectins) that recognize Lex are involved in the activation of the immune system during a
schistosomal infection. Therefore this information will aid in the rational design of better
diagnostics for schistosomiasis and could also be helpful for the development of new
intervention tools.
Previously, structures of bacterial carbohydrates in complex with a Fab fragment
have been solved [24-28]. Recently the structures of a Fab fragment bound to a
disaccharide and an oligosaccharide present on the gp120 envelope glycoprotein from
human immunodeficiency virus were reported [29]. Next to interactions with these
oligosaccharides expressed by invading pathogens, there is considerable interest in the
interactions of endogenous oligosaccharides with antibodies in view of the potential
interference with cell-cell interactions and the immune system. The only example for
which structural information is available is the complex of LewisY with a Fab fragment of
an anti-tumor antibody [30,31]. Lex is of particular interest as it is expressed both by
schistosomes and by the host itself. In this chapter, the crystal structures of a Fab fragment
with and without Lex to 1.8 Å and 2.05 Å resolution respectively are reported.
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Results and discussion
Overall crystal structure of the Fab fragment
The structure of the Fab fragment of anti-Lex Mab 291-2G3-A (IgG3, Vκ) has been solved
with (Figure 5.1) and without its Lex ligand with free-R factors of 24.7 % and 24.3 %
respectively (Protein Data Bank codes 1UZ8 and 1UZ6 respectively).
Figure 5.1 Structure of the two Fab fragments in complex with Lex
present in the asymmetric unit. The picture was produced with the
programs MOLSCRIPT [32] and Raster3D [33]. (For a color
picture see Appendix II).
All residues of the Fab with Lex are well ordered, except for amino acids 128 to 132 of the
heavy chain, which form a flexible loop often disordered in Fab fragments. In the Fab
without Lex in addition to the residues 128 to 132 of the heavy chain, residues 196 to 203
of the light chain were not visible as they are also part of a flexible loop. Both structures
have over 90 % of the residues in the most favored region, having only Met L51 in the
disallowed region. Crystallographic data statistics are given in Table 5.1. Attempts to co-
crystallize the Fab fragment with Lex were unsuccessful, small impurities present in the
Lex solution as a result of the organic synthesis probably interfered with crystal nucleation
by causing phase separation. Fortunately, the Lex trisaccharide could be soaked into
crystals of the Fab fragment, the likely reason for this is that the antigen binding sites of
two Fabs point towards each other in the crystal, with a solvent channel running through
the middle. This facilitates the diffusion of the ligand into the binding pocket of the Fab
fragment to full occupancy and without damaging the crystal.
There is no large conformational change upon binding of the sugar, which is well
ordered in the crystal. Clear electron density is present in the binding site, in which Lex
could be nicely fitted (Figure 5.2).
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Table 5.1 Data Collection and Refinement statistics
291-2G3-A Fab unliganded 291-2G3-A Fab with Lewis
Data Collection
Beamline APS ID19 ESRF ID14-1
Wavelength (Å) 1.03 0.934
Space-group P1 P1
Unit cell parameters
a x b x c (Å) 67.4 x 71.6 x 104.8 45.1 x 60.8 x 91.6
α x β x γ (°) 86.5 x 71.3 x 83.3 96.0 x 95.4 x 101.78
Resolution (Å)a 45-2.05 (2.12-2.05) 45-1.8 (1.86-1.80)
Completeness (%) 88.1 (38.9) 92.9 (72.0)
Measured reflections 256292 951604
Unique reflections 103313 87852
Rmergeb 4.6 (32.9) 9.4 (38.6)
Average I/σ (I) 19.7 (2.1) 11.1 (2.2)
Refinement
R-factor (%) 19.8 (27) 21.0 (25)
Free R-factor (%) 24.3 (31) 24.7 (27)
No of TLS groups 56 28
No of Fabs in the A.U. 4 2
No of protein residues 1628 826
No of solvent molecules 349 288
No of ions/ligands 4 sulfates 6 carbohydrate residues
Average total B-value protein (Å2) 53.2 46.0
Average total B-value Lex (Å2) - 51.1
Average total B-value water (Å2) 47.8 44.7
Validation
Ramachandran plot (%)
most favored region 92.8 91.6
additionally favored region 6.8 8.0
generally allowed region 0.1 0.1
disallowed region 0.3 0.3
RMSD bonds (Å) 0.014 0.005
RMSD angles (°) 1.14 1.15
aValues of reflections recorded in the highest resolution shell are shown in parentheses.
bRmerge  = Σ (| I-<I>| ) / Σ (I) (scalepack output)
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Figure 5.2 2F0-FC electron density for Lex
contoured at 1.2 σ. This picture was
generated with Xtalview [34].
The elbow angle of the Fab fragments with and without Lex are 140.6° and 134.7°
respectively, this small difference is most likely due to different crystal packing as the
crystals were grown under different crystallization conditions [35].
The protein sequence of the Fab fragment was determined (Figure 5.3) and the
structure and sequence of the six complementary determining regions (CDRs) were
analyzed [36]. CDR-L1, CDR-L2 and CDR-L3 belong to the classes 4/16A, 1/7A and
1/9A respectively, and CDR-H1 and CDR-H2 belong to the classes 1/10A and 3/10B
respectively.
Light chain      10                  20     CDR-L1 27 a b c d e    30
D I V M T Q A A F S N P V T L G T S A S I S C R S S K S L L Y S N G I T
               40                  50  CDR-L2          60
Y L Y W Y L Q K P G Q S P Q L L I Y Q M S N L A S G V P D R F S S S G S
   70                  80                  90   CDR-L3        100
G T D F T L R I S R V E A E D V G V Y Y C A Q N L E V P W T F G G G T K
   106a
L E I K R A
Heavy chain      10                  20                  30 CDR-H1
E V K L L E S G G G L V Q P G G S Q K L S C A A S G F D F S G Y W M S W
     40                  50  52 a   CDR-H2     60                  70
V R Q A P G K G L E W I G E I N P D S S T I N Y T P S L K D K F I I S R
             80    82 a b c              90          CDR-H3 100
D N A K N T L Y L Q M S K V R S E D T A L Y Y C A R E T G T R F D Y W G
        110
Q G T T L T V S S
Figure 5.3 Sequence of variable light and heavy chain, complementary determining regions (CDRs)
are depicted in bold. Numbering according to the Kabat numbering scheme and CDR definitions
according to the AbM definitions (http://www.bioinf.org.uk/abs) [36].
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In the case of CDR-H3, the structure was predicted to be a kinked base [37-39] on the
basis of sequence rule i-c.  This rule states that when residue n-1 is Asp (n is the number
of residues of CDR-H3), residue 0 is basic and residue -1 is not basic, the side chain of the
Asp forms a salt bridge with the basic residue at the start of CDR-H3, which is typical for
the kinked base. Although these residues can indeed be found in the sequence of CDR-H3,
the structure forms an extended base (Figure 5.4) because the side chain of Asp H101
forms hydrogen bonds with the side chains of Trp H103 and Tyr L36 and the amide of
Gly H97. Furthermore, three hydrogen bonds stabilizing the loop are present between Oγ1
of Thr H98 with the carbonyl of Glu H95, the amide of Arg 99H and the amide of Phe
100H.  In other structures, a basic residue at position L46 tends to form a salt bridge with
Asp H101 thereby inducing the extended base structure and also prolines in the -hairpin
region can deform the structure into an extended base structure (for examples see Morea
et al., 1998 and Shirai et al., 1996). These residues are not present in our structure
however. A likely explanation for the formation of this extended structure is the presence
of the charge and size of Arg H99 and Phe H100 in the hairpin region. The main chain is
locally deformed and the side chain of Arg H94 now forms a hydrogen bond with the
carbonyl of Phe H100.
Figure 5.4 Stereoview of the CDR-
H3 loop. Asp H101 makes hydrogen
bonds to the side chains of Trp H103
and Tyr L36, forming an extended
base structure. The picture was
produced with the programs
MOLSCRIPT [32] and Raster3D
[33].
Fab sugar interaction
The Fab fragment forms a rather shallow binding pocket, which nicely accommodates the
Lex trisaccharide (Figure 5.6). The pocket is approximately 15 Å long, 13 Å wide and 10
Å deep (distances were measured in Xtalview [34]. Upon binding of Lex, 302 Å2 of the
solvent accessible surface of the Fab fragment is buried. Residues from all six CDRs
contact the sugar, in contrast to other antibodies in which CDR-L2 rarely contributes to
binding of the antigen [40].
Table 5.2 summarizes all the hydrogen bonds between the protein and the sugar
residues. Hydrogen bonds usually contribute most to the stability of protein-sugar
complexes. Amino acids having polar planar side chains are often highly abundant in
binding pockets, as these residues can assist in the formation of stable hydrogen bond
networks. Furthermore, aromatic residues like tyrosine and tryptophan play an important
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role in sugar binding since they are not only capable of forming hydrogen bonds with the
sugar residues but can also stack with the hydrophobic face of the pyranoside rings [41].
Indeed most residues found in the binding site (Figure 5.3) that directly interact with Lex
either have polar or aromatic side chains (Figure 5.5), with only two hydrogen bonds
formed by main chain atoms. In total 11 hydrogen bonds are formed between sugar and
protein residues.
Table 5.2 Hydrogen bonds between sugar and protein or water
Fab residue Atom distance (Å)a
N-acetylglucosamine methyl glycoside Y
O1 Tyr  A27d OH 3.02
O7 Tyr  A27d OH 3.25
N2 Asn  L91 O 3.06
O4 Asn L91 ND2 2.97
O6 Glu  H50 Oε2 2.46
Fucose Y
O4 Gln  L50 Oε1 2.91
O5 Asn L91 ND2 3.15
O4 HOH 242b 3.09
Galactose Y
O2 Glu H50 Oε1 2.71
O2 Trp L96 Nε1 2.90
O2 Thr H96 Oγ1 3.22
O3 Thr H96 N 3.22
O2 HOH 282c 3.13
O3 HOH 203b 2.77
aHydrogen bonds between one Fab fragment and Lex are presented, possible
differences in distance between the atoms in the other Fab-Lex complex present in the
asymmetric unit fall outside the resolution range.
bThese water molecules are absent in the other complex present in the asymmetric
unit.
cPresent as water molecule HOH 280 in the other complex.
Furthermore, three well ordered water molecules are found in the binding pocket bridging
protein and sugar residues. Two water molecules interact with Galactose (Gal) O2 and O3
and fit snugly in a polar binding pocket bridging CDR-H1, CDR-H2 and CDR-H3,
maintaining a stable hydrogen bond network between these CDRs. The third water
molecule bridges between Fucose (Fuc) O4 and the carbonyl of Gly H97. The asymmetric
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unit contains two Fab-carbohydrate complexes and only in one of them the water
molecules interacting with Gal O3 and Fuc O4 are visible. Most likely these water
molecules are also present in the other Fab-sugar complex, but perhaps more disordered or
not fully occupied and therefore not visible. Overlaying the two structures shows no
differences between the binding pockets (data not shown).  The average total B-factor for
the protein, which includes the tls-component used in the crystal structure refinement [42],
is in the same range as the water molecules (Table 5.1).
An extensive hydrogen bond network is present around the binding pocket,
helping to maintain the conformation of the binding pocket. The side chain of Glu H50
bridges the Gal and the N-acetylglucosamine methyl glycoside (Mag) and further
stabilizes the complex. This residue also played a central role in the formation of a stable
hydrogen network in the structure of a Fab fragment in complex with a bacterial
carbohydrate [26]. One striking observation is that the rather long CDR-L1 loop (16
residues) inserts into the binding pocket of the other Fab fragment (Figure 5.1), interacting
with its heavy chain via a hydrogen bond between ND2 of Asn B58 and the carbonyl of
Ser L27e and binding with its sugar. The side chain hydroxyl group of Tyr A27d, located
at the bottom of this loop, forms a bifurcated hydrogen bond with O1 and O7 of the Mag
that is bound to the other Fab molecule in the unit cell. Furthermore, this tyrosine shields
its own binding pocket by making a Van der Waals interaction with the methyl group of
the acetyl function of the Mag residue that is bound to the same Fab molecule.
Figure 5.5 Stereoview of the binding site for Lex. Protein residues and water molecules which are
directly interacting with the Lex trisaccharide are depicted as well as Lex. The picture was produced
with the programs MOLSCRIPT [32] and Raster3D [33]. (For a color picture see Appendix II).
The interaction between Tyr A27d and the Lex bound to the other Fab fragment
may not have biological relevance, but it does help stabilizing the Fab sugar complex in
the crystal. The side chain of residue Gln L50, which is part of CDR-L2, makes a
hydrogen bond with O4 of the Fucose. This could be the reason why the main chain is
slightly distorted at Met L51 according to the Ramachandran plot. This residue however
fits very nicely into the electron density, suggesting that the conformation of CDR L2 is
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the cause of the distortion. Furthermore, Trp H33 forms an aromatic stacking interaction
with a hydrophobic patch (C3, C5 and C6) on the -face of the Gal. This residue is
stabilized by Oε1 of Glu H95 from CDR-H3 by forming a hydrogen bond with the main
chain NH of Trp H33 and NH of Glu H95 donates a hydrogen bond to the carbonyl of Trp
H33.
Comparison between the bound and unbound structure
Upon binding of the sugar, the structure of the binding pocket of the Fab does not change
except for the side chain of Gln L50, which changes slightly to make a favorable
hydrogen bond with Fuc O4. Both the unliganded and the liganded structure have Met
L51 in an unfavorable conformation.
The structure of Lex had been previously determined [43]. The overall
trisaccharide structure is similar to that in the Fab complex (Table 5.3), which is not very
surprising considering the rather rigid structure of Lex. There are however some striking
differences. The Mag has a gauche-trans conformation in the Lex crystals, which is an
energetically favorable conformation [44]. However, bound to the protein it adopts a
gauche-gauche conformation, allowing a hydrogen bond with Glu H50. Furthermore, in
Gal (which has a trans-gauche conformation in the Lex crystals) the 6'-hydroxyl group is
rotated to a gauche-trans conformation. Although in this conformation the primary
hydroxyl group does not form a hydrogen bond, it is orientated parallel to the hydrophobic
face of Trp H33 for optimal aromatic stacking.
Table 5.3. Torsion angles at the glycosidic linkages in Lex
Lex crystala Lex Yc Lex C Ley d
Φ/Ψb Φ/Ψ Φ/Ψ Φ/Ψ
Gal(1-4)Mag (Φ1/Ψ1) -70.5/-107.7 -69.9/-111.1 -66.7/-113.4 -69.8/-103.7
Fucα(1-3)Mag (Φ2/Ψ2) -76.7/139.0 -81.4/139.1 -82.7/136.7 -76.7/131.9
aValues taken from one Lewis X molecule from Perez et al [43]
bTorsion angles at the glycosidic linkages are defined as Φ1 (O5Gal-C1Gal-O4Mag-C4Mag), Ψ1
(C1Gal-O4Mag-C4Mag-C5Mag), Φ2 (O5Fuc-C1Fuc-O3Mag-C3Mag), Ψ2 (C1Fuc-O3Mag-
C3Mag-C4Mag).
cTorsion angles of the two Lex molecules present in the unit cell (Y and C) are given.
dValues taken from BR96-nLey structure (PDB code 1CLZ, [30])
Comparison with anti-Ley Fab BR96
The only other structure of a Fab fragment with a histo-blood group oligosaccharide is the
crystal structure a Fab fragment of Mab BR96 in complex with the nonoate methyl ester
derivative of Lewis Y (Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-(CH2)8COOCH3, nLey) [30].
Ley is a tetrasaccharide containing a Lex moiety. Interestingly, the overall geometry of the
Lex part of Ley is, like the geometry of Lex not bound to a protein, very comparable to Lex
bound to the 291-2G3-A (Table 5.3). Despite this similarity the mode of binding of the
sugars to the protein is very different. In the BR96 structure, the non-reducing end of Ley
points towards CDR-L1, CDR-L3 and CDR-H2, whereas Lex in the 291-2G3-A structure
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sits almost 180° rotated in the binding pocket and is pointing towards CDR-H1 and CDR-
H3 (Figure 5.6). Both antibodies represent a cavity type antibody [45] and have a binding
pocket that fits the complete sugar. In both complexes all sugar residues are involved in
binding. Moreover, it was found that BR96 does not interact with Lex [46]. The binding
pockets of both antibodies have approximately the same size. Upon binding of the sugars,
Lex buries 302 Å2 of the solvent accessible surface, whereas Ley (without the nonoate
methyl ester) buries approximately 337 Å2. Like in the binding pocket of BR96, the
majority of the residues interacting with the Lex in 291-2G3-A has an aromatic or polar
side chain. In the binding pocket of 291-2G3-A Trp H33 aromatically stacks with the
hydrophobic face of the Gal, in BR96 however no aromatic stacking with sugar residues is
observed. Furthermore, CDR-L2 is not involved in interaction with Ley whereas in the
291-2G3-A all CDRs are involved in binding.
Figure 5.6 Comparison between the binding pocket of 291-2G3-A with Lex (left) and the binding
pocket of Mab BR96 with Ley nonoate methyl ester (right). It can immediately be seen that the both
sugars have an opposite direction of binding with the Fabs. Both proteins are displayed as a surface
representation. This picture was generated with GRASP [47].
Isothermal calorimetry
The affinity of 291-2G3-A for Lex has been determined by isothermal calorimetry (ITC), a
sensitive method to determine enthalpy, entropy and binding constant within one
measurement. The thermodynamic parameters for the interaction of 291-2G3-A with Lex
are KA 9.3 ± 1 x 104 M-1, ∆G -6.7 ± 1.1 kcal mol-1, ∆H -5.0 ± 0.2 kcal mol-1, -T∆S -1.7 ±
0.3 kcal mol-1, with the stoichiometry of the interaction determined to be 1.2. This
discrepancy in the stoichiometry of binding is most likely due to the difficulty in
accurately determining the actual binding site concentration. Theoretically this should be
two in the case of an antibody-ligand interaction. The fitting of the isotherm was
performed with a single binding site model, assuming no cooperativity between the
binding sites. Alternative fitting models with multiple sites did not give better results.
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Both a favorable enthalpy and entropy term contribute to the binding of Lex to Mab 291-
2G3-A, which can be explained by the rather large amount of hydrogen bonds and van der
Waals interactions that are formed upon interaction between the protein and all three sugar
residues. Usually, no favorable contribution of entropy is observed for protein-ligand
associations because of greater motional restrictions for both protein and ligand. An
unfavorable change in entropy however, can be overcome by displacement of solvent
from the sugar and/or protein surface [41]. Most likely, the favorable entropy term of the
interaction of Lex with the antibody stems from solvent displacement realized by the close
fit of the sugar at the protein surface. For two structures of bacterial trisaccharides that
have been solved previously, the binding affinities have also been measured by ITC.
Interestingly, the same range of thermodynamic parameters were found. The
thermodynamics of the interaction of a bacterial trisaccharide (Rhaα1-3Rhaα1-3GlcNAcβ-
OMe) with Mab SYA/J6 [26] were determined to be  KA 9.5 x 104, ∆G -6.8 kcal mol-1,
∆H -4.3 kcal mol-1, -T∆S -2.5 and for the interaction of Salmonella serogroup B O-
antigenic trisaccharide epitope (Galα1-2[Abeα1-3]-Manα-OMe) with antibody Se155-4
KA 1.6 x 105, ∆G -7.3 kcal mol-1, ∆H  -4.9 kcal mol-1, -T∆S -2.3 [48,49]. Both of these
interactions also display a favorable contribution from the entropy term. In analogy with
the binding of Lex to 291-2G3-A, these sugars also display a tight fit on the surface of the
Fab fragments.
Basis for the specificity
Although the affinity of 291-2G3-A for Lex is not very high the interaction seems to be
very specific. Generally, protein sugar complexes depend on multivalency to yield an
overall higher avidity compared to single-site affinity. To further understand the basis for
the specificity of this interaction, a surface plasmon resonance (SPR) study was performed
using sugars which are closely related in structure to the Lex trisaccharide, but lack either
the Gal (Fucα1-3GlcNAcβ, FucGlcNAc) or the Fuc (Galβ1-4GlcNAcβ, LacNAc).
Furthermore, the interaction with Lewis A (Galβ1-3(Fucα1-4)GlcNAcβ, Lea) and LewisY
(Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ, Ley) was measured. From the SPR sensorgram
(Figure 5.7) it becomes immediately clear that Mab 291-2G3-A does not interact with any
of these sugars, confirming its very high specificity for Lex. All three residues of Lex form
hydrogen bonds with the Fab, explaining why the intact antibody apparently does not
interact with the disaccharides lacking a Gal or a Fuc. In the case of Lea, modeling studies
have shown that the positions of O6 and N-acetyl have interchanged by turning the
GlcNAc 180º [50]. Most likely, the bulky N-acetyl group would then clash with Glu H50
and several hydrogen bonds will be lost resulting in no binding of Lea to 291-2G3-A.
Furthermore, the rather shallow binding pocket encloses the Gal residue leaving no space
for an extra Fuc residue, as is the case for Ley. By rotating nLey from the BR96 complex
(PDB code 1CLZ) onto Lex in the 291-2G3-A structure, it becomes immediately clear that
there is no space for the extra Fuc bound to the Gal. Mab 291-2G3-A recognizes both
LNFPIII (Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glcβ), a pentasaccharide containing Lex
at its reducing end, and dimeric Lex (Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-
3)GlcNAcβ1, diLex). Whether Mab 291-2G3-A binds more residues than just the terminal
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Lex moiety present in diLex, which contains an additional internal Lex moiety, is difficult
to tell from this crystal structure. A crystal structure of the Fab fragment soaked with
diLex also did not provide a definite answer as no ligand was bound to the Fab. Most
likely the hapten would clash because of the close proximity in the crystal structure of the
binding sites of the two Fabs in the asymmetric unit.
Figure 5.7 SPR sensorgram, binding
pattern of Mab 291-2G3-A with Lex
related HSA-neoglycoconjugates.
In conclusion, Mab 291-2G3-A is highly specific for Lex. This specificity is
gained by involvement of all six CDRs in the interaction with all three residues from Lex.
A binding pocket is formed that snugly fits the trisaccharide.  Higher affinity could
possibly be realized by increasing the number of hydrogen bonds between the sugar and
the protein. Several residues in the binding pocket could be mutated into amino acids with
polar side chains. Improving the hydrogen bonding pattern to the Fuc might increase the
affinity as only one protein residue now interacts with the Fuc. Thr H98, for example, sits
rather closely to the Gal and Fuc, but is unable to make a hydrogen bond. By mutating this
residue into an Arg or a Gln an extra hydrogen bond might be formed, but this mutation
could decrease the stability of the CDR-H3 loop. Another potential amino acid to mutate
would be Tyr L32. Its hydroxyl group is now out of range to form a hydrogen bond with
O2 of the Fuc, a Gln might be able to make this hydrogen bond. The hydrogen bonding
pattern around the Mag and the Gal seems optimized and therefore mutations in this area
will most likely not increase the affinity.
Recently, an article was published describing the structure and thermodynamics
of a peptide carbohydrate-mimic bound to a Fab fragment [51]. The use of peptide mimics
for carbohydrates could be advantageous as the synthesis of a short peptide is rather
straightforward in contrast with the synthesis of a carbohydrate chain. Furthermore,
mimics could be designed that bind the antibody with higher affinity. This new structural
information might therefore also aid in the design of a peptide mimic based on Lex, that
could be used to improve diagnostics for schistosomiasis or possibly as a research tool to
study schistosomiasis or certain cancers.
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Material and methods
Fab fragments, purification and crystallization
Monoclonal antibody production, purification, generation of Fab fragments, crystallization and data
collection were carried out as described in chapter 4 [35]. The -O-methyl glycoside of Lex was
chemically synthesized following a route described by Toepfer et al. [52]. An X-ray dataset to 2.05
Å resolution was measured at beamline ID19 at the APS, Argonne Il (USA) from a crystal without
Lex grown from 25 % PEG 3350, 0.17 M ammonium sulfate and 15 % glycerol. A crystal grown
from 14 % PEG 3350, 50 mM Tris pH 8 was soaked for half an hour with 50 mM Lex and an X-ray
dataset was measured to 1.8 Å resolution at beamline ID14-1 at the ESRF, Grenoble (France). The
data were processed using HKL2000 [53]. Table 5.1 provides a summary of the data processing
statistics.
Structure determination and refinement
The structure of the Fab fragments was solved by molecular replacement using the program Molrep
[54] from the CCP4 program suite [55]. For the native Fab fragment an anti-LewisY antibody (PDB
entry code 1CLZ, [30]) was used as a search model. Rotation and translation searches were
performed for all four monomers in the asymmetric unit at the same time. A solution was found with
an R factor of 49.6 % and a correlation coefficient of 33.3. Several rounds of rigid body refinement
with the program CNS [56] resulted in an R-factor of 44.4 % for the working set and an R factor of
44.5 % for the test set, which contains 5 % of randomly chosen reflections. Grouped B-value
refinement of main chain and side chain atoms using restrained non crystallographic symmetry
(NCS) resulted in an R factor of 33.3 % (Rfree 36.7 %). At this stage of the refinement the correct
amino acids were built in manually using Xtalview [34], omitting loops and side chains that were
not visible in the electron density. The refinement was completed using Refmac5 [57] from the
CCP4 package. During refinement tight NCS restraints were used and translation, liberation and
screw (TLS) parameters were refined [42]. Both the heavy and the light chain were split up in 7 TLS
groups, the variable domain was divided in 6 groups, 3 containing a CDR loop, and the entire
constant domain formed the remaining TLS group. Water molecules were built automatically,
alternated by refinement cycles using ARP/wARP [58]. After the automatic solvent building water
molecules were checked visually and removed if necessary. At the last stage of the refinement, a
new version of Refmac5 was used (version 5.2.000), which resulted in an extra drop in Rfree from
25.5 to 24.3 % for the final model.  The unliganded Fab model containes 1628 protein residues, 349
water molecules and 4 sulfate ions.
The structure of the Fab fragment in complex with Lex was solved by molecular
replacement using the native Fab fragment as a search model. A model for the Lex trisaccharide was
obtained by removal of the Fucose that was bound to the Galactose from a model of LewisY
(obtained from PDB entry code 1CLZ [30]) and  built in the binding site of each Fab fragment at
full occupancy. Refinement and addition of water molecules were carried out similarly as described
for the native Fab fragment, although in the last stages of the refinement the two-fold NCS restraints
were removed. The final model contained 826 protein residues, 6 sugar residues and 288 water
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molecules having an Rfree factor of 24.7 %. The quality of both models was checked by
PROCHECK [59] and WHATIF [60]. Crystallographic statistics are included in Table 5.1.
Neoglycoconjugates
 The human serum albumin (HSA) Lewis neoglycoconjugates, HSA-LNFPIII, HSA-dimeric Lex,
HSA-LewisY and HSA-LewisA, Isosep (Tullinge, Sweden) were a kind gift of Dr. B. Appelmelk
(Amsterdam, The Netherlands). These neoglycoconjugates contained on average 22 mol sugar per
mol HSA. HSA-LacNAc and HSA-FucGlcNAc were synthesized following the route as described
by Toepfer et al. [52]. These neoglycoconjugates contained on average 7 to 10 mol sugar per mol
HSA.
Surface plasmon resonance (SPR) analysis of binding of 291-2G3-A with Lewis-type
neoglycoconjugates
A qualitative study of the binding of Mabs with Lewis-type neoglycoconjugates was carried out
using SPR. The BIAcore 3000 instrument, CM5 sensor chips and an amino coupling kit were
purchased from BIAcore AB (Uppsala, Sweden). All buffers were filtered and degassed under
vacuum before use. Immobilization of the neoglycoconjugates was performed using the standard
amino coupling procedure according to the instructions of the manufacturer at a flow rate of 5 l
min-1. In short, the carboxymethylated surface of the CM5 sensor chip was activated by a 7 minute
pulse of a 1:1 mixture of 0.1 M N-hydroxysuccinimide and 0.1 M N-Ethyl-N’-
(dimethylaminopropyl)carbodiimide, followed by several injections of the neoglycoconjugate at a
concentration of 25 g mL-1 in 10 mM sodium acetate pH 4.5 until the desired level of
immobilization was achieved. The Lex neoglycoconjugates were immobilized to a level of 7,500
RU. After immobilization, unreacted groups were blocked by the injection of 300 l 1M
ethanolamine-HCl, pH 8.5. Unmodified HSA was coupled on one flow channel of each sensor chip
as a control. All analyses were performed at a flow rate of 5 L min-1 using Hepes buffered saline
pH 7.4 containing 3 mM EDTA and 0.005 % surfactant P20 (HBS-EP) as eluent. Five µL of
purified 291-2G3-A (1 mg mL-1 in 0.035 M phosphate-buffered saline, PBS) was injected. After
subtraction of the response units of the HSA control channel, the interaction of the antibody was
interpreted as binding (+) or not-binding (-) with all HSA-neoglycoconjugates. The surface was
regenerated with 5 µl 25 mM HCl.
SPR data analysis
The data were analyzed using the BIA evaluation software (version 3.0). To correct for the
refractive index change and non-specific binding by using the HSA control surface as a blank.
Isothermal calorimetry
ITC was measured using the VP-ITC MicroCalorimeter, Microcal LLC (Northampton, MA, USA).
Protein A purified antibody was dialyzed against PBS and concentrated using Ultrafree-4
Centrifugal Filter Unit with a cutoff of 10 kDa (Millipore). The protein concentration was
determined spectrofotometrically, using a calculated extinction coefficient of 1.63 mg mL-1 [61].
Lex was purchased as a dry powder from Toronto Research Chemicals (North York, On., Canada).
Both protein and trisaccharide were dissolved in the same buffer. The protein solution used had a
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starting concentration of 44 µM, the starting ligand concentration was 1.8 mM. The titrations were
carried out at 22 °C by 5, 10 or 12 s injections of ligand into the protein solution. Three
measurements using different concentrations of protein and ligand were performed. For a typical
measurement see Figure 5.8. Titration of ligand into buffer was used as a control to correct for the
released background heat. The measurements were analyzed by the ORIGIN software package
(Microcal, LLC) and the data were processed using the One Site binding model assuming there is no
cooperativity between the sites. The stated values and standard deviations are derived from data
from three measurements.
Figure 5.8 Calorimetric data of Lex binding to 291-
2G3-A. The top panel shows the raw heat measured
over a series of injections of Lex (915 µM) into 291-
2G3-A (44 µM) at 22 °C. After 23 injections of 5 µL,
the injection volume was increased to 10 µl. Each heat
signal is integrated and shown as data point in the
bottom panel. Data points were fitted to a model
describing a single set of binding sites and the best fit
parameters for Lex was calculated using nonlinear
least-squares fitting. Three measurements have been
performed at different protein and ligand
concentrations. The thermodynamic parameters have
been calculated from these three measurements.
Sequencing of variable domains
Standard molecular biology protocols were used throughout the procedure. Hybridoma cells (106
cells) were sedimented by centrifugation at 300 x g in 5 minutes at room temperature. Total mRNA
was isolated with the Oligotex Direct micro mRNA isolation system (Qiagen Inc., Venlo, the
Netherlands) according to the protocol of the manufacturer. The cell lysates were homogenized
using a 20-gauge syringe, the purified mRNA was eventually eluted in 100 L elution solution. The
mRNA was used as templates for the synthesis of cDNA of the IgG variable regions of the
hybridoma cells. cDNA synthesis and amplification of the synthesized cDNA  was performed in one
step according to the Titan One Tube RT-PCR System (Roche, Basel, Switzerland). The primers
used were obtained from the Mouse Ig-Primer set of the Ig-prime System (Novagen, San Diego,
CA, USA), for primer sequences see protocol. Primer sets MuIgVH5’-F and MuIgGVH3’-2 were
used for the5' and 3’ends of heavy chains respectively. Primer sets MuIgκVL5’-F and MuIgVL3’-1
were used for the 5' and 3’ends of the light chains respectively. Each reaction was performed with 4
L mRNA solution. The reaction was started by incubation at 50 ºC for 30 minutes for the synthesis
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of cDNA. The amplification was performed at 94 ºC for 2 minutes, followed by 35 cycles of 1
minute at 94 ºC, 1 minute at 60 ºC, 2 minutes at 72 ºC followed by a final extension period of 6
minutes at 72 ºC. PCR reaction solutions were screened for DNA fragments of approximately 140
bp with electrophoresis using a 1 % agarose gel. Reaction solutions containing DNA fragments were
extracted with one volume of a chloroform:isoamyl-alcohol (24:1) solution. The fragments were
cloned in the pSTBlue-1 cloning vector according to the protocol of the Perfectly Blunt Cloning Kit
(Novagen) and transformed into NovaBlue Singles Competent cells. Transformants were selected
for the kanamycin resistance marker of the cloning vector and for the vector carrying an insert with
X-Gal (5-bromo-4chloro-3indolyl--galactopyranoside). Sequences were obtained commercially
(Base Clear, Leiden, the Netherlands) by automated dideoxy chain-termination technology using the
T7 and SP6 promoter primers.
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Summary
Individuals suffering from schistosomiasis raise an immune response against Galβ1-
4(Fucα1-3)GlcNAcβ (Lewis X), a trisaccharide that is expressed both in monomeric and
polymeric form in different life stages of the schistosomes. In order to study a possible
immunological discrimination between different presentations of Lewis X, i.e. as a
monomer or as an oligomer (di- or trimer), the levels of antibodies against lacto-N-
fucopentaose III (LNFPIII, a pentasaccharide containing monomeric Lewis X), and
against dimeric and trimeric Lewis X have been measured in sera of mice with a
schistosome infection. The antibody response was predominantly of the IgM type. A
striking difference in intensity of the antibody response against monomeric and
oligomeric Lewis X was observed. Furthermore, the antibody response against circulating
cathodic antigen, a schistosomal antigen containing multimeric Lewis X, was also
measured and the response pattern differed from that of the anti-mono, di- and trimeric
Lewis X responses. Based on the results described in this chapter and in chapter 3, we
suggest that the different presentations of Lewis X give rise to different groups of anti-
Lewis X.
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Introduction
Glycoconjugates are major triggers of the host immune response in schistosomiasis and
play an important role in the pathology. In several studies, the structural complexity of
various carbohydrate chains and their expression in Schistosoma has been extensively
described ([1] and references cited therein). Galβ1-4(Fucα1-3)GlcNAcβ (Lewis X, Lex)
for example (Figure 6.1) is present in various life stages of the parasite but shows different
expression patterns between these life stages. It has been found in whole cercarial extracts
[2], where amongst others it is expressed on glycolipids [3]. At the surface of the cercariae
however, Lex can only be visualized on the oral sucker [4]. Furthermore, Lex is present on
the surface of the schistosomula, on the tegument and in the gut of adult schistosome
worms, and on the shell of the eggs [5-8]. It should be noted that schistosomes not only
express monomeric Lex, but also polymeric Lex [9], e.g. as the major immunogenic part of
the gut-associated antigen circulating cathodic antigen (CCA) [10].
In chapter 3 it has been described that monoclonal antibodies (Mabs) can interact
differentially with mono-, di- and trimeric Lex. In this study we want to investigate
whether mono- and oligomeric Lex also give rise to different humoral immune responses
in murine schistosomiasis in vivo. It has been well established that mice develop an anti-
Lex response upon schistosome infection, which is predominantly of IgM isotype [11],
although in some cases some IgG was observed as well [12]. Anti-Lex antibodies have
been implicated in conferring protection by mediating antibody-dependent cellular
cytotoxicity towards schistosomal larvae [13]. In addition, Lex containing glycoconjugates
have been shown to play an important role in cellular immune responses related to
schistosome infections [14-18]. So far, studies investigating the anti-Lex immune response
in mice infected with schistosomes have only measured the response against LNFPIII
[11,12], a pentasaccharide containing monomeric Lex, and not against oligomeric Lex. We
hypothesize that the humoral immune response can discriminate between Lex in its
different oligomeric states. An internal Lex moiety might lead to a different immune
response than a terminal Lex. To this end, we have measured the antibody responses
against LNFPIII (Figure 6.1a), dimeric Lex (Figure 6.1b), trimeric Lex (Figure 6.1c) and
CCA in serum from mice infected with schistosomes using surface plasmon resonance
(SPR). The combined data from this study and the results described in chapter 3
demonstrate that mono- and oligomeric Lex are different immunological entities.
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Figure 6.1 Lex oligosaccharides
conjugated to human serum albumin
(HSA) with an average of 22 mol
sugar per mol HSA. (a) LNFPIII, (b)
dimeric Lex and (c) trimeric Lex used
in the SPR analysis.
Results
Parasitology
Mice infected with 80 S. mansoni cercariae carried an average of 15.6 adult male and/or
female worms at 24 weeks post infection (p.i.) (range 13-18). Granulomas with extensive
fibrosis were present around embolized schistosome eggs in the liver. Mice infected with
1000 cercariae were sacrificed after 45 days because they were all severely ill. Worm
counts (male and female) varied between 198 and 491 worms per mouse.
Determining the levels of anti-Lex antibodies by SPR
Sera from mice infected with 80 S. mansoni cercariae showed a response against LNFPIII,
di- and trimeric Lex that was detectable from 2 weeks p.i. onwards (Figure 6.2). A striking
difference however was observed in the intensity of the responses. The response against
LNFPIII was much lower than the response against di- and trimeric Lex (Figure 6.2b).
Furthermore, a slight difference in response pattern could be observed; the response
against LNFPIII showed a peak at 8 weeks, after which the response gradually decreased,
the anti-di- and trimeric Lex responses also showed a peak at 8 weeks, but followed by a
rapid decline reaching a steady state level at around 20 weeks. When the relative
contribution of IgG and IgM antibodies to this response was analyzed, a variable IgG
response was measured with each of the Lex neoglycoconjugates. These responses could
not be classed as significant (error bars were in the same range as the measured response)
(Figure 6.2c).
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However, a strong IgM response was measured with di- and trimeric Lex (Figure 6.2d)
following the pattern that was found for the serum response. In addition, a significant IgM
response was detected with LNFPIII, albeit with very low intensity. Sera of uninfected
mice always resulted in blank values (Figure 6.2a).
Figure 6.2 Binding profiles of a) Serum response from uninfected mice b) Serum response from
mice infected with 80 cercariae c) IgG response d) IgM response with LNFPIII (■), dimeric Lex (∆)
and trimeric Lex (). The results show the mean net increase in response units (RU) ± SEM of 12
mouse infection sera.
Sera from mice exposed to 1000 S. mansoni cercariae also showed a response against all
Lex neoglycoconjugates, but with much higher antibody levels (Figure 6.3). The response
pattern for both the serum and the IgM responses followed the pattern of the first weeks of
the less heavily infected mice. Again a signal was detectable from around 2 weeks p.i.,
which started to increase rapidly from 6 weeks onwards. Despite the much higher total
levels again no significant levels of IgG could be measured against any of the Lex
neoglycoconjugates.
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Figure 6.3 Binding profiles of a) Serum response from uninfected mice b) Serum response from
mice infected with 1000 cercariae c) IgG response d) IgM response with LNFPIII (■), dimeric Lex
(∆) and trimeric Lex (). The results show the net increase in RU of pooled sera.
Monitoring the levels of anti-Lex antibodies by SPR with AWA-TCA
Mab 54-5C10-A, a Mab that was previously found to interact with CCA [19], was
immobilized on a BIAcore sensor chip to immunocapture Lex-containing glycoconjugates
from AWA-TCA for subsequent interaction with antibodies from infected mouse serum.
With this assay, the levels of IgM antibodies were found to increase rapidly from 6 weeks
until 10 weeks and then steadily decrease again (Figure 6.4).
Figure 6.4 Binding profile of anti-CCA IgM
response in infection sera, after immunocapturing
CCA from AWA-TCA with anti-CCA Mab 54-
5C10-A in a sandwich assay. The results show the
mean increase in response units ± SEM for 12 mouse
infection sera.
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Blocking study of serum antibodies
In blocking experiments HSA-dimeric Lex did block the anti-dimeric and trimeric Lex
response effectively in serum from mice infected with schistosomes collected at eight
weeks p.i., whereas the anti-LNFPIII response was only partially blocked (Figure 6.5b).
HSA-LNFPIII blocked the anti-LNFPIII, di- and trimeric Lex response for approximately
30 % (Figure 6.5a). As expected, running buffer and bovine serum albumin did not inhibit
any response (data not shown).
Figure 6.5 Inhibition of anti-LNFPIII (■), anti-dimeric Lex (∆) and anti-trimeric Lex () response
in pooled sera from mice, infected with 80 cercariae collected at eight weeks p.i., after incubation
with a) HSA-LNFPIII and b) HSA-dimeric Lex neoglycoconjugates. The serum response was
measured before addition and at several time points after addition of the Lex neoglycoconjugates.
Discussion
There is a large body of evidence that Lex and anti-Lex antibodies play an important role
in the immunology of schistosomiasis [7,13,14,17]. The multimericity of Lex may be an
important factor in the induction of immune responses. This study shows that the serum of
mice infected with 80 or 1000 S. mansoni cercariae contains specific antibodies against
monomeric Lex (as part of LNFPIII), dimeric and trimeric Lex (Figure 6.2 and 6.3),
whereas previously only the presence of anti-monomeric Lex antibodies has been reported
[11-13]. Moreover, we show that there is a striking difference in the antibody response
intensity against monomeric Lex versus that against di- and trimeric Lex. This may
indicate that there is no general anti-Lex response but that in mice infected with
schistosomes different groups of antibodies are evoked, depending on the presentation of
Lex to the immune system. Monomeric Lex contains only terminal Lex whereas di- and
trimeric Lex contain additional internal Lex structures. It is conceivable that the
combination of terminal Lex and internal Lex is recognized by the immune system as a
completely different structure than single terminal Lex. The antibody levels against
LNFPIII are much lower than the levels against di- and trimeric Lex. This might be
explained by the stronger antigenicity of di- and trimeric Lex as the expression of
oligomeric Lex structures has so far never been observed in mice. Expression of terminal
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Lex however, has been reported [20,21]. A similar antibody response observed against
both di- and trimeric Lex suggests that indeed the combination of a terminal with an
internal Lex, such as present in both di- and trimeric Lex, gives rise to a distinctive
immune response. The fact that different groups of antibodies are elicited towards
differently presented Lex is further corroborated by blocking studies; dimeric Lex is
capable of completely blocking the anti-di- and trimeric Lex response but only partially
inhibits the monomeric Lex response. Most likely, some of the anti-monomeric Lex
antibodies are cross-reactive with the terminal Lex present in both di- and trimeric Lex. On
the other hand, addition of LNFPIII-HSA to infected serum only partially inhibited the
LNFPIII, di- and trimeric Lex response, all to a similar extent. Apparently, LNFPIII-HSA
in solution is not able to completely block the antibody interaction with LNFPIII-HSA
immobilized to the surface of the chip. Possibly, a difference in affinity of the antibodies
for immobilized LNFPIII-HSA compared to LNFPIII-HSA in solution might be an
explanation for the incomplete inhibition. Furthermore, the partial inhibition of the di- and
trimeric Lex response by LNFPIII might again be explained by the cross-reactivity of
some of these antibodies with LNFPIII.
To further investigate the influence of the presentation of Lex to the response of
the immune system, the IgM response against CCA, which contains internal polymeric
Lex structures, was measured by SPR. Interestingly, the peak of the anti-CCA IgM levels
(Figure 6.4) appears later and is more prolonged than that of IgM to the Lex
neoglycoconjugates (Figure 6.2d). This suggests that anti-CCA or anti-polymeric Lex
antibodies represent yet another group different from the anti-LNFPIII antibodies and the
anti-di- and trimeric Lex antibodies.
Our hypothesis that differences in presentation of Lex induce the immune system
to elicit different groups of anti-Lex antibodies is further supported by our observations in
a binding analysis of Mabs derived from mice with a schistosomal infection (chapter 3).
From their behavior in SPR analysis, the specificity of these Mabs could be grouped
according to the above proposed different presentations of Lex. Mabs from group I were
shown to interact with all the Lex neoglycoconjugates, thus most likely recognizing
terminal Lex. Mabs from group II interacted with di- and trimeric Lex, being specific for a
terminal Lex linked to internal Lex. Mabs belonging to group III exclusively interacted
with trimeric Lex and might represent the antibodies specific for internal multimeric Lex
(i.e. two or more internal Lex units) as most of these antibodies had previously been
shown to interact with CCA [19]. This corresponds to observations by Dr. B.J. Appelmelk
(unpublished data), who has also found different groups of anti-Lex Mabs reactive with
either short or long chains of Lex in mice immunized with Helicobacter pylori or S.
mansoni.
The observation of different groups of monoclonal and polyclonal anti-Lex
antibodies would lead to the conclusion that the various stages of the schistosome express
Lex-containing structures that differ in their presentation to the immune system. It has
already been shown that antibodies to the Lex-containing glycans mediate complement-
dependent cytolysis in vitro of human granulocytes [12,22,23], which may thus provide a
mechanism for the mild neutropenia sometimes observed during a schistosome infection
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[24]. It might well be that the anti-oligomeric Lex antibodies bind the granulocytes much
stronger as it is known that granulocytes carry multimeric Lex on their surface [25].
A much higher antibody titer was found in sera of mice infected with 1000
cercariae as compared to these of mice infected with 80 cercariae. Although an infection
with 80 cercariae would already correspond to a very high infection compared to a natural
schistosomiasis infection in man, this finding may suggest that even at this high infection
rate there is an antigen-dose dependent humoral immune response.
The antibodies binding to the Lex structures were primarily of the IgM class,
while virtually no IgG could be detected, which corresponds to the results obtained from
similar studies in mice [11,26], humans and chimpanzees [22,27,28]. Likewise, in our
large panel of Mabs that was generated from mice with a schistosome infection the
majority of the anti-Lex antibodies were of the IgM class [19,29] though during the
generation of these monoclonal antibodies attention was paid to the selection of IgG
isotype monoclonal antibodies (A.M. Deelder, unpublished results). However, Nyame et
al. [12] could detect an IgG response against LNFPIII in sera from mice infected with
schistosomes when analyzed by ELISA. A possible difference in sensitivity between the
ELISA and SPR can not explain this finding since the IgG response observed by Nyame
et al.[12] was at least 50 % of the IgM response after 7 weeks and that would have been
easily detectable by SPR. Richter et al. [11] could also not measure an IgG response
against LNFPIII, but they did measure an anti-LNFPIII IgA response. We could not detect
antibodies of the IgA class (data not shown). In our study Swiss OF1 mice have been used
whereas Nyame et al. [12] have used Swiss Webster mice and Richter et al. [11] used
C57BL/6J and CBA/J mice. This could also explain the differences observed in the
isotype of the antibody responses as it is known that the humoral immune response can
show large variations between mice with different genetic backgrounds [30].
Conclusively, we believe that the immune system can distinguish between Lex
that is presented as terminal Lex (Lex), terminal Lex linked to an internal Lex (Lexti) or
multimeric internal Lex (Lexmi). Therefore, we propose to describe Lex, Lexti and Lexmi as
immunologically different entities giving rise to separate groups of antibodies that might
very well play different roles in the immunology and the pathology of the disease. This
discrimination between monomeric and multimeric Lex should be considered in studies
examining Lex-induced immune responses.
Materials and methods
Infection of mice
Twelve 6-weeks old male Swiss mice (OF1, Iffa Credo, St-Germain sur L’Arbresle, France) were
infected with approximately 80 S. mansoni cercariae using the ring method of Smithers and Terry
[31]. Six uninfected, age matched mice were used as controls. Serum samples were taken from the
tail every other week for a period of 24 weeks and the samples were stored at -20C until further
use. The final blood collection was made by cardiac puncture. Infected mice were perfused with
citrated phosphate-buffered saline (PBS) to determine the worm load. A sample of liver tissue was
snap-frozen in liquid nitrogen for use in an IFA. The remainder was formalin-fixed, paraffin-
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embedded and H&E stained to evaluate egg production. In addition, two groups of ten 8 week old
male Swiss mice were infected with 1000 S. mansoni cercariae as described before [32]. Serum
samples were taken from the tails of the mice every day on alternating days per group, starting from
day 0 until day 18 post infection (p.i.); per day the serum samples were pooled. From day 18 p.i.
onwards serum samples were taken every other day. The mice were perfused on day 45 and serum
samples were collected from each individual mouse. The samples were stored at –20 C until use.
All mice were maintained under specific pathogen-free conditions and provided with food and water
ad libitum. All experiments were conducted according to the federal guidelines, approved by the
institution’s ethical committee and supervised by an animal-welfare officer.
Neoglycoconjugates
The human serum albumin (HSA) Lex neoglycoconjugates (Figure 6.1), HSA-LNFPIII, HSA-
dimeric Lex and HSA-trimeric Lex were a kind gift of Dr. B. Appelmelk (Amsterdam, The
Netherlands). The neoglycoconjugates were originally purchased from Isosep AB (Tullinge,
Sweden). These neoglycoconjugates contained on average 22 mol sugar per mol HSA.
Monitoring the levels of anti-Lex antibodies in sera by surface plasmon resonance using Lex
neoglycoconjugates
Antibody detection in the sera was carried out using SPR. The BIAcore 3000 instrument, CM5
sensor chips and an amino coupling kit were purchased from BIAcore AB (Uppsala, Sweden). All
buffers were filtered and degassed under vacuum before use. Immobilization of the
neoglycoconjugates was performed using the standard amino coupling procedure according to the
instructions of the manufacturer at a flow rate of 5 l min-1. In short, the carboxymethylated surface
of the CM5 sensor chip was activated by a 7 minute pulse of a 1:1 mixture of 0.1M N-
hydroxysuccinimide and 0.1M N-Ethyl-N’-(dimethylaminopropyl)carbodiimide, followed by several
injections of the neoglycoconjugate at a concentration of 25 g mL-1 in 10 mM sodium acetate pH
4.5 until the desired level of immobilization was achieved. The Lex neoglycoconjugates were
immobilized to a level of 7,500 response units (RU). After immobilization unreacted groups were
blocked by the injection of 300 l 1M ethanolamine-HCl, pH 8.5. HSA without Lex was coupled on
one flow channel as a control. A dilution series of serum was tested (data not shown) and a 1:40
dilution in Hepes buffered saline containing 3 mM EDTA and 1 % surfactant P-20
(Polyoxyethylenesorbitan, BIAcore, Uppsala, Sweden) pH 7.4 (HBS-EP) was found to be optimal
and used in all experiments. A mixture of rabbit anti-mouse IgG1, IgG2ab and IgG3 (defined as
RaM IgG, Nordic Immunological Laboratories, Tilburg, The Netherlands) diluted 1:50 in HBS-EP
containing 1 % P-20, and peroxidase-conjugated rabbit anti-mouse IgM (RaM IgM, Nordic
Immunological Laboratories) diluted 1:100 in HBS-EP containing 1 % P-20 were used as secondary
antibodies to determine the immunoglobulin subclass. Serum was injected for a period of two
minutes, followed by 3.5 minutes of dissociation. Subsequently, 10 l of RaM IgG was injected and
after a waiting period of 3.5 minutes followed by an injection of 10 l RaM IgM. After each 3.5
minute waiting period the amount of RU was measured. At the end of each cycle the surface was
regenerated by two 1-minute pulses of 50 mM HCl. All analyses were performed at a flow rate of 5
l min-1 using HBS-EP containing 0.005 % P-20 as eluent.
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 Monitoring the levels of anti-Lex antibodies in sera by SPR using adult worm antigen (AWA)
Anti-CCA Mab 54-5C10-A was immobilized on a CM5 sensor chip using the standard amino
coupling method as described above with an average immobilization level of 10,000 RU. A 5-
minute pulse of trichloroacetic acid soluble adult worm antigen (AWA-TCA, 100 µg mL-1 in HBS-
EP) was injected, subsequently followed by 10 µl of serum diluted 1:40 and 10 µl of RaM IgM
diluted 1:100. Each step was followed by a 3.5 minute waiting period. The surface was regenerated
with 5 µl of 50 mM NaOH solution containing 1 M NaCl.
Blocking study of serum antibodies
Sera from 12 mice infected with 80 cercariae were collected at eight weeks p.i. and pooled. As a
control, sera from the same mice had been taken before infection and pooled. To 5 µl of both sera
either 2.5 µl of HBS buffer, bovine serum albumin (1 mg mL-1), HSA-LNFPIII (1 mg mL-1) or
HSA-dimeric Lex (1 mg mL-1) was added. At several time intervals, 1 µl of serum was diluted 1:40
in HBS-EP containing 1 % P-20 and 5 µl was injected, followed by a 2 minute waiting period and
the surface was regenerated with 50 mM NaOH. The antibody levels against LNFPIII, di- and
trimeric Lex were measured immediately after addition of the inhibitors and after one and three hour
periods. The amount of response units measured in infected serum before addition of any inhibitor
was set to 100 % binding.
Data analysis
The data were analyzed using the BIA evaluation software (version 3.0). In the case of the sensor
chip containing the Lex neoglycoconjugates a correction was made for the refractive index change
and non-specific binding by using the HSA control surface as a blank. The serum response is
defined as the total amount of material bound to the surface after injection of serum, which is
expressed in response units (RU), the amount of response units is linearly correlated with the
amount of material bound to the surface of the chip. The amount of response units measured with
serum of mice before infection was set to zero. The relative increase of response units during
infection is presented in the graphs. The IgG and IgM response correspond to the increase of
response units after the injection of RaM IgG and RaM IgM respectively. No change in response
units was observed in the sera from the negative control mice over the time course of the
experiment.
Acknowledgements
We thank Dr. A. van Remoortere for assisting with the SPR measurements and helpful discussions
and D. Kornelis for her excellent assistance with the IFA’s. We are grateful to Dr. B. J. Appelmelk
for supplying the Lex-neoglycoconjugates. Part of this work was supported by the Fund of Scientific
Research (FWO) – Flanders (grant 1.5069.01). K. Van de Vijver is a research assistant of the FWO-
Flanders.
anti-Lewis X antibodies in murine schistosomiasis                                                                          121
References
1. Hokke, C.H. and Deelder, A.M. (2001). Schistosome glycoconjugates in host-parasite
interplay. Glycoconj. J. 18, 573-587.
2. Weiss, J.B. and Strand M. (1985). Characterization of developmentally regulated epitopes of
egg glycoprotein antigens. J. Immunol. 135, 1421-1429.
3. Wuhrer, M., Dennis, R.D., Doenhoff, M.J., Bickle, Q., Lochnit, G. and Geyer, R. (1999).
Immunochemical characterisation of Schistosoma mansoni glycolipid antigens. Mol. Biochem.
Parasitol. 103, 155-169.
4. Köster, B. and Strand M. (1994). Schistosoma mansoni: immunolocalization of two different
fucose-containing carbohydrate epitopes. Parasitology 108, 433-446.
5. Huang, H.H., Tsai, P.L. and Khoo, K.H. (2001). Selective expression of different fucosylated
epitopes on two distinct sets of Schistosoma mansoni cercarial O-glycans: identification of a
novel core type and Lewis X structure. Glycobiology 11, 395-406.
6. Khoo, K.H., Huang, H.H. and Lee, K.M. (2001). Characteristic structural features of
schistosome cercarial N-glycans: expression of Lewis X and core xylosylation. Glycobiology
11, 149-163.
7. Nyame, A.K., Lewis, F.A., Doughty, B.L., Correa-Oliveira, R. and Cummings, R.D. (2003).
Immunity to schistosomiasis: glycans are potential antigenic targets for immune intervention.
Exp. Parasitol. 104, 1-13.
8. Van Remoortere, A., Hokke, C.H., Van Dam, G.J., van Die, I., Deelder, A.M. and van den
Eijnden, D.H. (2000). Various stages of schistosoma express Lewis(x), LacdiNAc,
GalNAcbeta1-4 (Fucalpha1-3)GlcNAc and GalNAcbeta1-4(Fucalpha1-2Fucalpha1-3)GlcNAc
carbohydrate epitopes: detection with monoclonal antibodies that are characterized by
enzymatically synthesized neoglycoproteins. Glycobiology 10, 601-609.
9. Srivatsan, J., Smith, D.F. and Cummings, R.D. (1992). The human blood fluke Schistosoma
mansoni synthesizes glycoproteins containing the Lewis X antigen. J. Biol. Chem. 267, 20196-
20203.
10. Van Dam, G.J., Bergwerff, A.A., Thomas-Oates, J.E., Rotmans, J.P., Kamerling, J.P.,
Vliegenthart, J.F. et al.. (1994). The immunologically reactive O-linked polysaccharide chains
derived from circulating cathodic antigen isolated from the human blood fluke Schistosoma
mansoni have Lewis X as repeating unit. Eur. J. Biochem. 225, 467-482.
11. Richter, D., Incani, R.N. and Harn, D.A. (1996). Lacto-N-fucopentaose III (Lewis X), a target
of the antibody response in mice vaccinated with irradiated cercariae of Schistosoma mansoni.
Infect. Immun. 64, 1826-1831.
12. Nyame, A.K., Pilcher, J.B., Tsang, V.C. and Cummings, R.D. (1997). Rodents infected with
Schistosoma mansoni produce cytolytic IgG and IgM antibodies to the Lewis X antigen.
Glycobiology 7, 207-215.
13. Ko, A.I., Drager, U.C. and Harn, D.A. (1990). A Schistosoma mansoni epitope recognized by a
protective monoclonal antibody is identical to the stage-specific embryonic antigen 1. Proc.
Natl. Acad. Sci. USA 87, 4159-4163.
122                                                                                                                                           Chapter 6
14. Jacobs, W., Deelder, A. and Van Marck, E. (1999). Schistosomal granuloma modulation. II.
Specific immunogenic carbohydrates can modulate schistosome-egg-antigen-induced hepatic
granuloma formation. Parasitol. Res. 85, 14-18.
15. Nutten, S., Papin, J.P., Woerly, G., Dunne, D.W., MacGregor, J., Trottein, F. et al.. (1999).
Selectin and Lewis(x) are required as co-receptors in antibody- dependent cell-mediated
cytotoxicity of human eosinophils to Schistosoma mansoni schistosomula. Eur. J. Immunol. 29,
799-808.
16. Okano, M., Satoskar, A.R., Nishizaki, K. and Harn, D.A., Jr. (2001). Lacto-N-fucopentaose III
Found on Schitosoma mansoni Egg Antigens Functions as Adjuvant for Proteins by Inducing
Th2-Type Response. J. Immunol. 167, 442-450.
17. Velupillai, P. and Harn, D.A. (1994). Oligosaccharide-specific induction of interleukin 10
production by B220+ cells from schistosome-infected mice: A mechanism for regulation of
CD4+ T-cell subsets. Proc. Natl. Acad. Sci. USA 91, 18-22.
18. Velupillai, P., dos Reis, E.A., dos Reis, M.G. and Harn, D.A. (2000). Lewis(x)-containing
oligosaccharide attenuates schistosome egg antigen- induced immune depression in human
schistosomiasis. Hum. Immunol. 61, 225-232.
19. Deelder, A.M., Van Dam, G.J., Kornelis, D., Fillie, Y.E. and van Zeyl, R.J. (1996).
Schistosoma: analysis of monoclonal antibodies reactive with the circulating antigens CAA and
CCA. Parasitology 112 , 21-35.
20. Fox, N., Damjanov, I., Martinez-Hernandez, A., Knowles, B.B. and Solter, D. (1981).
Immunohistochemical localization of the early embryonic antigen (SSEA-1) in
postimplantation mouse embryos and fetal and adult tissues. Dev. Biol. 83, 391-398.
21. Solter, D. and Knowles, B.B. (1978). Monoclonal antibody defining a stage-specific mouse
embryonic antigen (SSEA-1). Proc. Natl. Acad. Sci. USA 75, 5565-5569.
22. Nyame, A.K., Pilcher, J.B., Tsang, V.C. and Cummings, R.D. (1996). Schistosoma mansoni
infection in humans and primates induces cytolytic antibodies to surface Le(x) determinants on
myeloid cells. Exp. Parasitol. 82, 191-200.
23. Van Dam, G.J., Claas, F.H., Yazdanbakhsh, M., Kruize, Y.C., van Keulen, A.C., Ferreira, S.T.
et al.. (1996). Schistosoma mansoni excretory circulating cathodic antigen shares Lewis- x
epitopes with a human granulocyte surface antigen and evokes host antibodies mediating
complement-dependent lysis of granulocytes. Blood  88, 4246-4251.
24. Borojevic, R., Santos-da-Silva, C. and Carvalho, E.A. (1983). Chronic schistosomiasis
mansoni: splenic myelopoiesis and inhibition of neutrophil granulocytopoiesis mediated by the
sera of patients. J. Infect. Dis. 148, 422-426.
25. Spooncer, E., Fukuda, M., Klock, J.C., Oates, J.E. and Dell, A. (1984). Isolation and
characterization of polyfucosylated lactosaminoglycan from human granulocytes. J. Biol.
Chem. 259, 4792-4801.
26. Umeda, M., Diego, I. and Marcus, D.M. (1986). The occurrence of anti-3-fucosyllactosamine
antibodies and their cross-reactive idiotopes in preimmune and immune mouse sera. J.
Immunol. 137, 3264-3269.
27. Van Remoortere, A., Van Dam, G.J., Hokke, C.H., van den Eijnden, D.H., van Die, I. and
Deelder, A.M. (2001). Profiles of immunoglobulin M (IgM) and IgG antibodies against defined
anti-Lewis X antibodies in murine schistosomiasis                                                                          123
carbohydrate epitopes in sera of Schistosoma-infected individuals determined by surface
plasmon resonance. Infect. Immun. 69, 2396-2401.
28. Van Remoortere, A., Vermeer, H.J., Van Roon, A.M., Langermans, J.A., Thomas, A.W.,
Wilson, R.A. et al. (2003). Dominant antibody responses to Fucalpha1-3GalNAc and Fucalpha
1-2Fucalpha1-3GlcNAc containing carbohydrate epitopes in Pan troglodytes vaccinated and
infected with Schistosoma mansoni. Exp. Parasitol. 105, 219-225.
29. Deelder, A.M., van Zeyl, R.J., Fillie, Y.E., Rotmans, J.P. and Duchenne, W. (1989).
Recognition of gut-associated antigens by immunoglobulin M in the indirect fluorescent
antibody test for schistosomiasis mansoni. Trans. R. Soc. Trop. Med. Hyg. 83, 364-367.
30. Richter, D., Incani, R.N. and Harn, D.A. (1993). Isotype Responses to Candidate Vaccine
Antigens in Protective Sera Obtained from Mice Vaccinated with Irradiated Cercariae of
Schistosoma-Mansoni. Infect. Immun. 61, 3003-3011.
31. Smithers, S.R. and Terry, R.J. (1976). The immunology of schistosomiasis. Adv. Parasitol. 14,
399-422.
32. Van Dam, G.J., Bogitsh, B.J., van Zeyl, R.J., Rotmans, J.P. and Deelder, A.M. (1996).
Schistosoma mansoni: in vitro and in vivo excretion of CAA and CCA by developing




studies of a series of parasite-
specific fuco-oligosaccharides
Anne-Marie M. van Roon, Begoña Aguilera, Francisco Cuenca, Alexandra van




Complex multi-fucosylated oligosaccharides are structural elements of glycoprotein and
glycolipid subsets of larval, egg and adult stages of Schistosoma, the parasitic worms that
cause schistosomiasis, a serious disease affecting more than 200 million people in the
tropics. The fucosylated structures are thought to play an important role in the
immunology of schistosomiasis. Defined schistosomal oligosaccharides that enable
immunological studies are difficult to obtain from natural sources. Therefore, we have
chemically synthesized spacer-linked GlcNAc, Fucα1-3GlcNAc, Fucα1-2Fucα1-3GlcNAc
and Fucα1-2Fucα1-2Fucα1-3GlcNAc. This series of linear oligosaccharides was used to
screen a library of anti-schistosome monoclonal antibodies by surface plasmon resonance
spectroscopy. Interestingly, the reactive antibodies could be grouped according to their
specificity for the different oligosaccharides tested, showing that these oligosaccharides
form different immunological entities based on the number and linkage of the fucose
residues. Subsequently, the thus defined monoclonal antibodies were used to visualize the
expression of the corresponding oligosaccharide epitopes by adult Schistosoma mansoni
worms.
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Introduction
Schistosomes are parasitic helminths that cause a chronic, debilitating and sometimes fatal
disease called schistosomiasis, of which at least 200 million people in the tropics suffer.
Schistosomes have a complex life cycle involving a fresh water snail intermediate host
and a vertebrate definitive host. Although the human definitive host develops a strong
immune response after infection, this usually does not lead to elimination of the parasite
or sterile immunity. It is generally accepted that in a schistosomal infection the major
humoral immune response is targeted against carbohydrates (for a review see Hokke and
Deelder)[1]. Furthermore, several studies have provided evidence that carbohydrate
structures also play a role in the pathogenesis of the disease, for instance in granuloma
formation [2-4] and in the characteristic Th2 polarization of the cellular immune response,
for a review see Thomas and Harn [5]. Obviously, it is desirable to determine exactly
which carbohydrate structures are involved in each of these processes. This may lead to an
improvement of current immunodiagnostic methods and possibly to the development of
carbohydrate based therapeutics.
Numerous analytical studies, often based on sensitive mass spectrometric
approaches, have revealed that schistosome glycosylation is extremely heterogeneous and
complex ([6] and references cited therein). Several relatively simple, well studied tri- or
tetrasaccharide elements expressed on schistosome glycoconjugates are the trisaccharide
Lewis X (Lex, Galβ1-4[Fucα1-3]GlcNAc) [7] and the fucosylated LacdiNAc (GalNAcβ1-
4GlcNAc, LDN) derivatives such as GalNAcβ1-4[Fucα1-3]GlcNAc (LDNF) and
GalNAcβ1-4[Fucα1-2Fucα1-3]GlcNAc (LDNDF) [8-10] of which the latter structure
contains a characteristic Fuc1-2Fuc sequence. Using neo-glycoconjugates obtained by
enzyme-assisted synthesis, it has been established that in schistosome-infected individuals
or animals, an intense antibody response is elicited against LDNDF [11,12]. These neo-
glycoconjugates were also used to show that LDNDF is a relatively strong inducer of IL-
10 production in peripheral blood mononuclear cells [13].
Multifucosylated structures containing the unique Fucα1-2Fuc linkage, such as
±Fucα1-2Fucα1-3GalNAcβ1-4[±Fucα1-2Fucα1-2Fucα1-3]GlcNAc, were found on O-
glycans from the glycocalyx of schistosomal cercariae [14]. The major egg glycolipids of
Schistosoma (S.) mansoni contain stretches of multifucosylated structures on a repeating
β1-4 linked GlcNAc backbone [15]. Using defined monoclonal antibodies (Mabs) it has
been determined by immunofluorescence and blotting techniques that, as part of the
LDNDF antigen, also in adult worms the Fuc1-2Fuc element occurs [10,16].
It is extremely difficult to obtain pure compounds from complex, heterogeneous
glycoconjugate mixtures of limited natural sources like schistosome larvae, adult worms
or eggs. Therefore, it is of importance to be able to obtain potentially immunogenic
carbohydrates via chemical synthesis [17,18]. Well-defined synthetic carbohydrate
structures allow direct, detailed studies of their immunogenicity and are useful as probes
in the characterization of antibodies. Previously, we have obtained numerous schistosome-
related anti-carbohydrate Mabs [19-21]. These Mabs are valuable tools in the
immunodiagnosis of schistosomiasis [20,22]. In addition, anti-carbohydrate Mabs can be
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used to visualize the expression of their corresponding antigens throughout the different
life stages of the parasite [10,16,23-25]. Using a stepwise synthetic scheme, we have now
chemically synthesized a series of linearly fucosylated spacer-linked oligosaccharides
containing 0,1 or 2 of the specific α1-2-linked Fuc residues: GlcNAc (Gn 2,), Fucα1-
3GlcNAc  (FGn, 10), Fucα1-2Fucα1-3GlcNAc  (FFGn, 11) and Fucα1-2Fucα1-2Fucα1-
3GlcNAc (FFFGn, 15) (Table 7.1). These oligosaccharides were used to screen a large
library of anti-schistosomal Mabs by surface plasmon resonance (SPR) spectroscopy.
Subsequently, the thus characterized Mabs served as probes to detect their corresponding
antigens in adult S. mansoni worms by fluorescence microscopy.
Table 7.1 Structure and names of synthetic carbohydrates conjugated to BSA via a spacer.
Name Abbreviation Symbol










   GlcNAc,    Fuc,    GalNAc,    Gal,     Glc
Results
Synthesis of the fucosylated carbohydrate structures
The protected oligosaccharides were assembled using a stepwise strategy. Starting from
an appropriately protected glucosamine acceptor, the target di-, tri- and tetrasaccharide
can be obtained by repeated elongation with a suitable fucose donor carrying a temporary
protective group at 2-OH. The selected glucosamine acceptor, 6-[N-
(benzyloxycarbonylamino)hexyl]-2-acetamido-4,6-O-benzylidene-2-deoxy--D-
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conjugation to a carrier protein. The donor of choice was ethyl 2-O-tert-
butyldimethylsilyl-3,4-O-isopropylidene-1-thio--D-fucopyranoside. The TBDMS group
can be selectively removed in the presence of the other protecting groups, after coupling
to the acceptor.
Scheme 7.1 Reagents and conditions: a. 1)
NaOMe, MeOH; 2) H2, Pd/C, EtOH, HCl
1M, r.t. 91 %; b. 1) NaOMe, MeOH, r.t.; 2)
(MeO)2CHPh, p-TsOH, CH3CN, r.t., 92 %.
c. CuBr2, Bu4NBr, DMF-CH2Cl2 (1:1), 5,
85 %; 7, 52 % (/ 12:1); 9, 17 %. d.
TBAF, THF, r.t., 6, 88 %; 8, 94 %. e. 1)
HOAc 60 %, 50 °C; 2) H2, Pd/C, EtOH,
HCl  1M, 10, 68 %; 11, 45 %.
The synthesis of 2 and acceptor 3 was accomplished as follows (Scheme 7.1). 2-N-acetyl-
(3,4,6-tri-O-acetyl-1,2-dideoxy--D-glucopyrano)-[2,1-d]-2-oxazoline [26] was treated
with 6-N-benzyloxycarbonyl-hexanol in the presence of TMSOTf to afford compound 1
(79 %). Subsequent de-O-acetylation, followed by the removal of the 6-N-
benzyloxycarbonyl protecting group by hydrogenolysis, afforded deprotected spacer-
linked 2 (Gn) in 91% yield.
Alternatively, the introduction of a 4,6-O- benzylidene group gave glucosamine
acceptor 3 in 92 % yield. Fucosyl donor 4 was obtained from ethyl 3,4-O-isopropylidene-
1-thio--D-fucopyranoside by silylation with TBDMSCl and imidazole (89 %).
Condensation of acceptor 3 with donor 4 was performed under the Ogawa conditions,
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[27]. Thus, reactions of compound 3 with 4 promoted by copper(II) bromide and
tetrabutylammonium bromide gave disaccharide 5 in 85 %. Removal of the TBDMS
protecting group with TBAF in THF afforded disaccharide acceptor 6 which was
condensed with donor 4 under the same conditions as described above to give
trisaccharide 7 (52 %, / 12:1). In this case, the reaction was not completely
stereoselective and the / mixture could be separated by silica gel chromatography. In
analogy, trisaccharide 7 was partially deprotected to give acceptor 8. Chain elongation of
trisaccharide 8 with donor 4, afforded tetrasaccharide 9 in only 17 % yield. Treatment of
compounds 6 and 7 with acetic acid 60 % at 50 °C and subsequent hydrogenolysis under
Pd/C in the presence of traces of acid, furnished unprotected disaccharide 10 (FGn) and
trisaccharide 11 (FFGn), respectively. Unfortunately, tetrasaccharide 9 decomposed when
treated with acetic acid 60 % at 50 °C.
Therefore, another fucosyl donor, ethyl 2,3,4-tri-O-benzyl-1-thio--D-
fucopyranoside [28] was coupled to trisaccharide 8 under Ogawa conditions (route A,
Scheme 7.2). Under these conditions, tetrasaccharide 13 could be obtained in 16 % yield.
The use of other activators (for instance, Br2, Bu4NBr, or AgOTf) did not afford better
results. Tetrasaccharide 13 could be successfully deprotected by acid treatment followed
by hydrogenolysis to give compound 15 (FFFGn). In order to improve the synthesis of
tetrasaccharide 13, a 2 + 2 block strategy (route B, Scheme 7.2) was considered as
alternative for the stepwise strategy. To this end, coupling of bromide 16, prepared from
thioethyl donor 12, with ethyl 3,4-O-isopropylidene-1-thio--D-fucopyranoside 17
promoted by tetrabutylammonium bromide gave disaccharide donor 18 in 68 % yield.
Donor 18 and disaccharide acceptor 6 were condensed in the presence of copper (II)
bromide and tetrabutylammonium bromide to give tetrasaccharide 13 in 52 % as a
/mixture (2.3:1), which could be separated by column chromatography.  The overall
yield of the preparation of tetrasaccharide 13 using the linear strategy was 7.2 % (starting
from disaccharide 6), while the convergent strategy afforded tetrasaccharide 13 in 24.5 %
overall yield.
Table 7.2 Mass spectrometric data indicating the coupling degree of glycosides to BSA.








Preparation of neoglycoconjugates and coupling to a Biacore sensor chip
Glycosides 2, 10, 11 and 15 were coupled to bovine serum albumin (BSA) to obtain
neoglycoproteins, which could then easily be immobilized onto a SPR chip (CM5 sensor
chip, BIAcore). To this end, glycosides 2, 10, 11 and 15 were transformed into their
corresponding squaric acid amide esters by reaction with diethyl squarate in
MeOH/phosphate (1:1), pH 7. The subsequent coupling to BSA proceeded in 0.1 M
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NaHCO3, pH 9. Twenty molar equivalents of glycoside were added to BSA and the
reaction was allowed to proceed for five days. The average coupling degree of the sugars
to BSA was determined with MALDI-TOF MS (Table 7.2).
The neoglycoconjugates were immobilized on a BIAcore CM5 sensor chip via
the standard peptide chemistry method (BIAcore user manual) to a level of approximately
10.000 response units (RU). BSA was conjugated on one flow channel of each of the
sensor chips to serve as a control for non-specific binding and to correct for the
background signal.
Scheme 7.2 Reagents and conditions: a. CuBr2, Bu4NBr, DMF-CH2Cl2 (1:1), 16 %. b. HOAc 60%,
50 °C, 57 %. c. H2, Pd/C, EtOH, HCl  1M, 70 %. d. 1) 12,  Br2, CH2Cl2, 0 °C; 2) Bu4NBr, DMF-
CH2Cl2, r.t., 68 %.  e. CuBr2, Bu4NBr, DMF-CH2Cl2 (1:1), 52 % (/ 2.3:1).
Binding of Mabs to BSA neoglycoconjugates by surface plasmon resonance
A panel of 831 Mabs, all previously derived from fusions with spleen cells of mice
infected with schistosomes [21], was screened for interaction with the neoglycoconjugates
on the SPR sensor chip. The Mabs, which interacted with one or more of the
neoglycoproteins are listed in Table 7.3. The concentration of each of these Mabs was
determined by ELISA and responses were re-examined at a standardized concentration of
5 µg mL-1 to be able to compare the relative binding capacities. The positive Mabs were
grouped according to their interaction with one or more neoglycoconjugates (Table 7.3).
Mabs from group I specifically interacted with Gn, whereas Mabs from group II
recognized the FGn structure. Furthermore, some Mabs were found that interacted with
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was found that bound only to the tri-fucosyl structure (group IV). None of the Mabs
interacted with BSA (data not shown). As an additional control, each of the Mabs of
group I-IV was tested for interaction with lacto-N-fucopentaose III (LNFPIII, Table 7.1), a
fuco-pentasaccharide containing the Lex trisaccharide at its terminus. None of the Mabs in
Table 7.3 interacted with LNFPIII (data not shown).
Immunofluorescence assays
Next, the identified Mabs were used to locate their corresponding natural antigens in the
schistosome. To this end, frozen liver sections that contain eggs and worms, prepared
from hamsters infected with S. mansoni, were probed with Mabs of each of the four
groups in an immunofluorescence microscopy assay. Typical staining patterns for each
group are presented in Figure 7.1. Interestingly, Mab 294-4C4-A only interacted with the
tegumental outer region of the adult worm, in contrast to the other Mabs, which stained
structures inside the parasite. The staining patterns for Mabs from group II and III are
rather similar and resemble the duct-related patterns specified in a previous study by
Thors and Linder [29]. It seems that the staining of Mab 291-3A4-A is more defined than
that of Mab 258-3E3. Finally, staining with Mab 114-5B1-A resulted in completely
different fluorescence patterns of canal like structures which have been previously
described as part of the excretory system of the adult worms [30].
Figure 7.1 Immunofluorescence staining of frozen sections of S. mansoni-infected hamster livers
incubated with Mabs from the four different groups. a) 294-4C4-A, b) 291-3A4-A, c) 258-3E3 and
d) 114-5B1-A. Different structures within the worms were stained by Mabs from the different
groups. Staining patterns of Mabs from group II and III are rather similar, however not identical. It
cannot be determined from these pictures which exact cellular structures the two Mabs 291-3A4-A
and 258-3E3 bind. In contrast, staining with Mab 114-5B1-A  (group IV) resulted in a completely
different fluorescence pattern. Canal like structures were stained, which have previously been
described as part of the excretory system of the adult worms [30]. Incubation with fresh culture
medium as a negative control did not result in fluorescence of the sections (data not shown).
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Table 7.3 Interaction of Mabs with neoglycoconjugates by surface plasmon resonance.
Maba Isotype Gn FGn FFGn FFFGn
Group I
114-2B5-A ndb ++ - - -
114-4C1-A IgM +++ - - -
292-6G2-A nd + - - -
294-4C4-A IgM +++ - - -
314-1G5-A IgM +++ - - -
Group II
128-1E7-Cc IgM - + - -
128-3G12-A IgG3 - + - -
291-3A4-Ac IgM - + - -
Group III
257-4D8 IgM - - ++ +
258-3E3 IgM - - ++ ++
Group IV
114-5B1-Ad IgG1 - - - +++
a The Mabs were screened at a concentration of 5 µg mL-1, + represents 100-500 RU after a 5 min
dissociation period, ++ represents 500-1000 RU and  +++  represents > 1000 RU.
b Isotype of the antibody has not been determined.
c Also interacts with Fucα1-3GalNAcβ1-4[Fucα1-3]GlcNAc (FLDNF) (H.J. Vermeer, personal
communication).
d Also interacts with GalNAcβ1-4[Fucα1-2Fucα1-3]GlcNAc (LDNDF) [10].
Discussion
Schistosomes produce a wide variety of immunogenic fucosylated carbohydrate structures
[1]. Thus far it is not well known where and when these structures are expressed and, most
importantly, which elements exactly confer the different immunogenic properties to the
glycoconjugates. This is especially true for particular multifucosylated oligosaccharides
that contain Fucα1-2Fuc and Fucα1-2Fucα1-2Fuc elements that are α1-3-linked to a
GlcNAc moiety, which seem to be characteristic for schistosomes [14,15]. We have
synthesized a set of linear oligosaccharides containing this Fucα1-2Fuc element and
investigated the interaction with a large panel of anti-schistosomal Mabs.
A stepwise synthetic approach was used successfully to synthesize the desired
mono- and difucosylated compounds FGn and FFGn. For the synthesis of the final target
structure FFFGn, a 2 + 2 block synthetic strategy showed to be more efficient. In both
strategies thioglycoside donors were activated with CuBr2/Bu4NBr, a method shown to be
very selective for the formation of α-glycosidic linkages [27], although in our hands this
method was not always completely stereoselective.
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 Interestingly, for all of the tested structures one or more Mabs were found (Table
7.3). The Mabs could be divided into four groups. Mabs from group I selectively
interacted with Gn, suggesting that terminal GlcNAc is an antigenic structure. This is
somewhat surprising since GlcNAc is ubiquitously expressed in higher as well as lower
organisms. In mammals however, GlcNAc usually occurs as an internal monosaccharide
rather than a terminal residue. Mabs from group II bound to FGn (for an overview of the
discussed carbohydrate structures see Table 7.1). The disaccharide Fucα1-3GlcNAc is
also part of the Lex trisaccharide antigen. However, none of the FGn-positive Mabs bound
to Lex (in the context of LNFPIII), suggesting that the additional 1-4-linked Gal in Lex
blocks the interaction of the Mabs with Fucα1-3GlcNAc. The third group of Mabs binds
to oligosaccharides with at least two terminal fucoses in Fucα1-2Fuc linkage, the common
element in FFGn and FFFGn. These Mabs did not interact with the Fucα1-3GlcNAc
structure, indicating that in this structural context a single terminal fucose is not sufficient
for binding. Moreover, the fucoses should be at a terminal position in a linear structure as
these Mabs did not interact with branched LDNDF either (H.J. Vermeer, personal
communication). Mab 114-5B1-A from group IV significantly interacted only with the
trifucosylated FFFGn, indicating that this Mab requires two consecutive α1-2 linked
fucoses.
Some of the presented Mabs have been found to bind to other carbohydrate
structures as well. Mabs 128-1E7-C and 291-3A4-A from group II cross-react with
FLDNF (H.J. Vermeer, personal communication), suggesting they recognize a fucose α1-
3 linked to HexNAc, since both Fucα1-3GalNAc (terminal disaccharide of FLDNF) and
Fucα1-3GlcNAc (FGn) are bound. However, it may be expected that clear quantitative
differences in the binding of these cross-reacting Mabs to their respective antigens occur.
Unfortunately, we cannot obtain quantitative SPR data with the current experimental
setup, and therefore it is not possible to elaborate on the affinity and kinetic characteristics
of the Mabs with respect to their different possible binding partners. However, in a direct
comparison of the binding to FLDNF- and FLDN-conjugates by SPR, 128-1E7-C gave an
at least 3-fold better response for FLDNF than for FLDN, which indicates that F-LDN-F
is the more accurate representation of the epitope of 128-1E7-C. This conclusion is further
supported by the observation that pre-incubation with keyhole limpet haemocyanin
(KLH), which expresses the F-LDN-F element [31], inhibits the binding of 128-1E7-C to
schistosome glycolipids [16]. Notably, Mab 114-5B1-A was previously shown to bind to
LDNDF [10]. In the current study, Mab 114-5B1-A interacted with FFFGn. Initial binding
of 114-5B1-A to FFGn could also be observed, but the SPR response returned to
backgrounds levels within the five-minute equilibration period before measurement,
indicating that 114-5B1-A has an insignificant, but detectable affinity for FFGn. From the
primary carbohydrate sequence these characteristics are difficult to explain. Therefore we
have examined the spatial orientation of these carbohydrate structures using a web-based
tool (Sweet [32]) designed to construct 3-dimensional models of carbohydrates.
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Figure 7.2 Overlay of modeled structures of
FFFGn (grey) and LDNDF (black). The
Fucα1-2Fuc moiety of LDNDF overlays
almost perfectly with the terminal Fucα1-
2Fuc moiety of FFFGn, this might be the
explanation for the binding of Mab 114-
5B1-A to both these structures. The picture
was created using PyMol Molecular
Graphics System (DeLano, W.L. 2002,
http://www.pymol.org).
The overlay of the models of each structure (Figure 7.2) suggests clearly that the terminal
Fucα1-2Fuc moiety in the linear, curve-shaped FFFGn is oriented similarly as the Fucα1-
2Fuc element in the branched LDNDF, thus explaining why Mab 114-5B1-A can bind
both FFFGn and LDNDF. In FFGn however, this terminal Fucα1-2Fuc moiety may not be
well available for binding by 114-5B1-A since the model of FFGn overlays with only the
first three reducing-end residues of FFFGn (not shown).
By combining the data obtained from this and previous studies using related
oligosaccharide structures, the epitopes of a number of anti-schistosomal monoclonal
antibodies could be mapped and fine-tuned. It should be noted that neoglycoconjugate
structures might only be limited representations of the natural glycoprotein and -lipid
structures expressed by the parasites. The Mabs described in this study are however very
useful tools to discriminate between different fucosylated structures with small but
relevant structural and (immuno)biological differences.
The expression of the fucosylated carbohydrate structures within the adult worms
was studied by immunofluorescence assays, similar to previous studies on other sets of
related fucosylated and non-fucosylated glycoconjugates [10,16,23,30,33]. The results of
the current microscopic study show major differences between the staining patterns
obtained with Mabs from each of the groups, except group II and III (Figure 7.1). The
Mabs may for instance be applied as immuno-affinity tools to purify glycoproteins or
glycolipids carrying predefined glycosylation patterns from crude schistosome extracts. In
conclusion, the presented results provide a good starting point for further studies to assess
the role of these carbohydrate structures in the immunology of schistosomiasis, utilizing
both the synthesized structures and the corresponding Mabs.
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Material and methods
General
TLC analysis was performed on Merck Alumina silica gel F254 plates, with detection by means of
UV absorption (254 nm) and/or charring with ammonium molybdate (25g L-1) and ceric ammonium
sulfate (10 g L-1) in 10 % aq. H2SO4 or a ninhydrine solution or 0.2 % orcinol in 20 % methanolic
H2SO4. Column chromatography was performed with Fluka Silica Gel (230-400 mesh). Unless
otherwise indicated, all the reagents were purchased from commercial sources and used without
further purification. EtOAc and Pet- Ether 60-80 were of technical grade and distilled before used.
CH2Cl2 was distilled over CaH2 , the rest of the solvents were of p.a. grade (Baker) and stored over
molecular sieves. 1H and 13C NMR spectra were recorded on a Bruker AC 200 (200 and 50 MHz),
Bruker AV 400 (400 and 100 MHz) or Bruker DMX 600 (600 and 150 MHz) as indicated. Optical
rotations were measured on a Propol automatic polarimeter (sodium D line  = 589 nm). High
resolution mass spectra were recorded on a Q-star Applied Biosystems Q-TOF instrument (TOF-
section). MALDI-TOF mass spectrometric analyses were performed on a Reflex III mass
spectrometer or an Ultraflex TOF/TOF mass spectrometer (Bruker Daltonics).
6-[N-(benzyloxycarbonylamino)hexyl]-2-acetamido-3,4,6-tri-O-acetyl-2-deoxy--D-
glucopyranoside (1). A mixture of known [26] 2-methyl-(3,4,6-tri-O-acetyl- 1.2-dideoxy--D-
glucopyrano)-[2,1-d]-2-oxazoline (4.67 g, 14.2 mmol) and 6-(N-(benzoyloxycarbonylamino)-1-
hexanol (5.3 g, 21.11 mmol) was coevaporated  three times with 1,2-dichloroethane, and then
dissolved in dry CH2Cl2 (170 mL). Molecular sieves 4Å were added and the mixture stirred at r.t.
for 15 min. Then TMSOTf (0.52 mL, 2.82 mmol) was added and stirring was continued for 40h.
The reaction mixture was then neutralized with triethylamine and washed with aq. sat. NaHCO3 and
water, dried (MgSO4), filtered and evaporated. The crude was purified by column chromatography
(Pet. Ether-EtOAc 1:1) to give 1 (6.53 g, 79 %). Rf (CH2Cl2-MeOH 10:1): 0.65.  []D= 13.4 (c =
2.5, CH2Cl2). Lit. []D= 12.7 (c = 1, CH3Cl).  1H-NMR (400 MHz, CDCl3): δ 7.35-7.28 (m, 5H,
Ar), 6.28 (d, 1H, J = 8.7 Hz, NHAc), 5.29 (t, 1H, J = 9.9 Hz, H-3), 5.15-5.05 (m, 4H, CH2Ph, H-4,
NHZ), 4.63 (d, J = 8.2 Hz, H-1), 4.24 (dd, 1H, J = 4.6 Hz ,  J = 12.3 Hz , H-6), 4.10 (bd, 1H, J =
12.1 Hz, H-6), 3.83 (m, 2H, CH2O, H-2), 3.63 (m, 1H, H-5), 3.46 (m, 1H, CH2O),  3.18 (m, 2H,
CH2NH), 2.07 (s, 3H, Ac), 2.01 (s, 6H, 2 Ac), 1.92 (s, 3H, Ac), 1.53 (m, 4H, (CH2)2), 1.32 (m, 4H,
(CH2)2). 13C-NMR (CDCl3):  170.5, 170.2, 169.2 (CO), 156.4 (CONH), 136.4, 128.2, 127.7, 127. 6
(Ar), 100.2 (C-1), 77.2, 71.3, 68.5 (C-3, C-4, C-5), 69.0, 66.2 (C-6, CH2Ph), 61.9 (OCH2), 54.3 (C-
2), 40.3 (CH2NH), 29.4, 28.7, 25.7, 24.9 ((CH2)4), 22.9 (Ac), 20.4 (Ac).
6-Aminohexyl-2-acetamido-2-deoxy-β-D-glucopyranoside (2). Compound 1 (25 mg, 0.043
mmol) was treated with NaOMe in MeOH (0.033M, 3 mL) at r.t. for 15h. The mixture was then
neutralized with Amberlite-H, filtered and evaporated. The crude was dissolved in EtOH 90 % in
water (1.5 mL) and HCl 1M (38 L), Pd/C 10 % (36 mg) was added and the reaction mixture was
stirred overnight under H2 atmosphere. The reaction was filtered over Hyflo® and evaporated. The
crude was purified by Gel permeation chromatography on a Superdex Peptide PE 7.5/300 column
(NH4HCO3 0.025 M in water) to give 2 (11 mg, 73 %). 1H-NMR (600 MHz, D2O): δ 4.48 (d, J = 8.5
136                                                                                                                                           Chapter 7
Hz, 1H, H-1 GlcNAc), 3.91-3.86 (m, 2H, H-6, OCH2), 3.72-3.70 (m, 1H, H-2), 3.69 (dd, 1H, J = 5.2
Hz, J = 9.8 Hz, H-6 GlcNAc), 3.60 (t, 1H, J = 8.7 Hz, H-3), 3.55 (m. 1H, OCH2), 3.48 (t, 1H, J =
8.7 Hz, H-4), 3.42 (m, 1H, H-5 GlcNAc), 2.95 (t, 2H, J = 7.6 Hz, CH2NH), 1.99 (s, 3H, Ac) 1.52 (
m, 2H, CH2), 1.45 (m, 2H, CH2), 1.30 (m, 4H, (CH2)2). 13C-NMR (200MHZ, D2O): δ 175.2 (CO),
102.6 (C-1 GlcNAc), 77.6, 75.7, 71.8 (C-3, C-4, C-5 GlcNAc), 70.2 (CH2O), 62.5 (C-6 GlcNAc),
57.1 (C-2 GlcNAc), 40.4 (CH2NH), 29.9, 28.2, 26.8, 26.4 ( (CH2)4), 22.8 (Ac). MALDI-TOF m/z:
321. 3 [M + H]+, 343.2 [M + Na]+.
6-[N-(benzyloxycarbonylamino)hexyl]-2-acetamido-4,6-O-benzylidene-2-deoxy--D-
glucopyranoside (3). Compound 1 (6.53 g, 11.25 mmol) was treated with NaOMe in MeOH
(0.033M, 300 mL) at r.t. for 15h. The mixture was then neutralized with Amberlite-H, filtered and
evaporated. The crude was dissolved in CH3CN (8.5 mL) and benzaldehyde dimethyl acetal  (0.7
mL, 4.64 mmol) and p-TsOH (90 mg, 0.49 mmol) were added. The reaction mixture was stirred
overnight at r.t. and then neutralized with triethylamine and evaporated. The crude was purified by
column chromatography (CH2Cl2-MeOH 30:1) to give 3 (0.86 g, 92 %). Rf (CH2Cl2-MeOH 10:1):
0.65. []D= 50.2 (c = 1, DMF). Lit. []D= 49.2 (c = 1.5, DMF). ). 1H-NMR (400 MHz, CDCl3): δ
7.51-7.31 (m, 10H, Ar), 5.55 (s, 1H, CHPh), 5.55 (bs, 1H, NHAc), 5.08 (bs, 2H, CH2Ph), 4.61 (d,
1H, J = 8.3 Hz, H-1 GlcNAc), 4.32 (dd, 1H, J = 4.9 Hz, J = 10.4 Hz , H-6), 3.92-3.37 (m, 7H,
OCH2, H-2, H-3, H-4, H-5, H-6), 3.16 (m, 2H, CH2NH), 1.99 (s, 3H, Ac), 1.59-1.48 (m, 4H,
(CH2)2), 1.34 (m, 4H, (CH2)2). 13C-NMR (CDCl3-CD3OD 10:1):  136.8, 128.9, 128.2, 127.9, 127.8,
127.6, (Ar), 101.5 (CHPh), 101.1 (C-1), 81.4, 70.9, 65.9 (C-3, C-4, C-5), 70.0 (C-6), 68.4 (CH2Ph),
66.3 (OCH2), 57.1 (C-2), 40.5 (CH2NH), 29.4, 28.6, 25.9, 22.5 (-(CH2)4-), 22.5 (CH3).
Ethyl-2-O-tert-Butyldimethylsilyl-3,4-O-isopropylidene-1-thio--L-fucopyranoside (4).  A
solution of ethyl 3,4-O-isopropylidene-1-thio--D-fucopyranoside [34] (1.71g, 6.89 mmol),
imidazole (1.09g, 16.18 mmol) and TBDMSCl (1.62 g, 10.75 mmol) in DMF (10 mL) was stirred at
r.t. for 16h and then evaporated. The residue was dissolved in EtOAc (200 mL) and washed with aq.
sat. NaHCO3 and brine, dried (MgSO4), and evaporated. The crude was purified by column
chromatography (Pet. Ether-EtOAc 30:1) to give 4 (2.24 g, 89 %). Rf (Pet. Ether-EtOAc 20:1): 0.55.
[]D= +18.7 (c = 1.1, CH2Cl2). 1H-NMR (200 MHz, CDCl3):  4.27 (d, 1H, J = 9.5 Hz, H-1), 4.02
(dd, 1H, J = 5.8 Hz, J = 2.2 Hz, H-3), 3.93 (m, 1H, H-4), 3.80 (m, 1H, H-5), 3.54 (q, 1H, J = 9.5 Hz,
J = 5.8 Hz, H-2), 2.64 (m, 2H, CH2 SEt), 1.50 (s, 3H, CH3 iPr), 1.38-1.27 (m, 9H, CH3 iPr, CH3 Fuc,
CH3 SEt).13C-NMR (50 MHz, CDCl3):  109.1 (Cq iPr), 84.7 (C-1), 80.3, 76.3, 73.5, 72.01 (C-2, C-
3, C-4, C-5), 27.8, 26.2 (CH3 iPr), 25.7 (CH3 tBuSi), 24.0 (CH2 SEt), 17.9 (Cq tBuSi), 16.6 (CH3
Fuc), 14.6 (CH3 SEt).
6-[N-(benzyloxycarbonylamino)hexyl]-2-acetamido-4,6-O-benzylidene-2-deoxy-3-O-(2-O-tert-
butyldimethylsilyl-3,4-O-isopropylidene--L-fucopyranosyl)--D-glucopyranoside (5).
Acceptor 3 (334 mg, 0.63mmol) and donor 4 (280 mg, 0.77 mmol) were coevaporated together three
times with toluene, dissolved in DMF:CH2Cl2 (1:1, 8 mL) and stirred at r.t. in the presence of
activated molecular sieves 4Å for 1h. Bu4NBr (656 mg, 2.04 mmol) was added and 1h later CuBr2
(456 mg, 2.04 mmol), and stirring was continued for 48 h at r.t.. The reaction mixture was diluted
with CH2Cl2, filtered over Hyflo, washed three times with aq. sat. NaHCO3 and brine, dried
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(MgSO4), filtered and concentrated. The crude was purified by column chromatrography (Pet.
Ether-EtOAc 20:1	1:1) to give 5 (454 mg, 85 %). Rf (DCM:MeOH 40:1): 0.5. []D=-85.6 (c =
0.53, CH2Cl2). 1H-NMR (400 MHz, CDCl3): δ 7.49-7.33 (m, 10H, Ar), 5.93 (d, 1H, J = 7.5 Hz,
NHAc), 5.50 (s, 1H, CHPh), 5.10 (s, 2H, CH2Ph), 4.98 (d, 1H, J = 2.9 Hz, H-1 Fuc), 4.86 (m, 1H,
NHZ), 4.73 (d, 1H, J = 8.0 Hz, H-1 GlcNAc), 4.40 (m, 1H, H-5 Fuc), 4.32 (m, 2H, H-6 GlcNAc, H-
3 GlcNAc ), 4.08 (t, 1H, J = 6.5 Hz, H-3 Fuc), 3.91 (dd, 1H, J = 2.5 Hz , J = 5.7  Hz,  H-4 Fuc),
3.83 (m, 1H, OCH2), 3.73 (m, 2H, H-6 GlcNAc, H-2 Fuc), 3.59 (m, 2H, H-2 GlcNAc, H-4
GlcNAc), 3.46 (m, 2H, OCH2, H-5 GlcNAc), 3.18 (m, 2H, CH2N), 1.98 (s, 3H, Ac), 1.49 (m, 4H,
(CH2)2), 1.46 (s, 3H, CH3 iPr), 1.32 (s, 3H, CH3 iPr), 1.30 (s, 3H, CH3), 1.08 (d, 1H, J = 6.6 Hz, CH3
Fuc), 0.92 (s, 9H, tBuSi),  0.14 (s, 3H, CH3Si),  0.11 (s, 3H, CH3Si). 13C-NMR (CDCl3): δ170.1
(CO), 137.1, 128.7, 128.3, 127.9, 127.8, 125.8 (Ar), 108.4 (Cq iPr), 101.1 (CHPh), 100.9 (C-1), 97.8
(C-1’), 80.6, 76.1, 75.8, 74.3, 71.9, 65.9, 63.6, (C-3, C-4, C-5, C-2’, C-3’, C-4’, C-5’) 57.1 (C-2),
69.4, 68.6 (CH2Ph, C-6), 66.2 (OCH2), 40.5 (CH2NH), 28.9 (CH2), 25.7 (tBuSi, CH3 iPr), 25.1
(CH2), 19.5 (Ac), 17.9 (Cq Si), 16.3 (CH3 Fuc). HRMS m/z: calcd for C44H67N2O12Si [M + H]+:
843.4463; found 843.4464.
6-[N-(benzyloxycarbonylamino)hexyl]-2-acetamido-4,6-O-benzylidene-2-deoxy-3-O-(3,4-O-
isopropylidene--L-fucopyranosyl)--D-glucopyranoside (6). Disaccharide 5 (372 mg, 0.44
mmol) was treated with TBAF (1M in THF, 0.9 mL) under N2 for 16 hours at r.t. The reaction
mixture was then evaporated, the residue dissolved in EtOAc and washed with NaHCO3 and brine,
dried (MgSO4), filtrated and evaporated. The crude was purified by column chromatography
(EtOAc-MeOH 30:1	15:1) to give 6 (285 mg, 88 %). Rf (DCM:MeOH 25:1): 0.25. []D= 105.6
(c = 1.2, CH2Cl2). 1H-NMR (400 MHz, CDCl3): δ 7.47-7.26 (m, 10H, Ar), 6.75 (d, 1H, J = 8.3 Hz,
NHAc), 5.46 (s, 1H, CHPh), 5.11 (m, 2H, CH2Ph), 4.95 (bs, 1H, NHZ), 4.87 (d, 1H, J = 3.3 Hz, H-1
Fuc), 4.68 (d, 1H, J = 8.1 Hz, H-1 GlcNAc), 4.32 (m, 2H, H-5 Fuc, H-6 GlcNAc), 4.06 (m, 2H, H-3
Fuc, H-3 GlcNAc), 3.87-3.73 (m, 4H, OCH2, H-2 GlcNAc, H-4 Fuc, H-6 GlcNAc), 3.57 (m, 2H, H-
2 Fuc,  H-4 GlcNAc), 3.48-3.42 (m, 2H, H-5 GlcNAc, OCH2), 3.19 (m, 2H, CH2NH), 1.98 (s, 3H,
Ac), 1.50 (m, 4H, (CH2)2), 1.46 (s, 3H, CH3 iPr), 1.32 (m, 4H, CH2)2), 1.29 (s, 3H, CH3 iPr), 0.79 (d,
1H, J = 6.6 Hz, CH3 Fuc). 13C-NMR (CDCl3): δ170.6, 156.5 (CO), 137.0, 129.1, 128.4, 128.1,
127.9, 127.7, 126.2, 126.1 (Ar), 108.7 (Cq iPr), 101.9 (CHPh), 100.3 (C-1 GlcNAc), 99.7 (C-1 Fuc),
80.1, 77.4, 76.4, 75.9, 70.2, 66.1, 63.3 (C-3, C-5, C-5 GlcNAc, C-2, C-3, C-4, C-5 Fuc), 69.0, 68.7
(C-6, CH2Ph), 66.5 (OCH2), 56.8 (C-2 GlcNAc), 40.4 (CH2NH), 29.6, 28.7, 25.6, 24.8 ((CH2)4),
28.1, 26.1 (CH3 iPr), 23.2 (Ac), 15.5 (CH3 Fuc). HRMS m/z: calcd for C38H53N2O12 [M + H]+:
729.3598; found 729.3640.
6-Aminohexyl-2-acetamido-2-deoxy-3-O-(α-L-fucopyranosyl)-β-D-glucopyranoside (10).
Disaccharide 5 (25 mg, 0.044 mmol) was treated with acetic acid 60 % (10 mL) at 50 ºC for 6h. The
reaction mixture was then concentrated coevaporating with toluene. The crude was dissolved in
EtOH 90 % in water (1.5 mL) and HCl 1M (38 L), Pd/C 10 % (36 mg) was added and the reaction
mixture was stirred overnight under H2 atmosphere. The reaction was filtered over Hyflo® and
evaporated. The crude was purified by HW-40 (NH4HCO3 0.15M in water) to give 10 (14 mg, 68
%). 1H-NMR (600 MHz, D2O): δ 4.96 (d, J = 4.1 Hz, 1H, H-1 Fuc), 4.48 (d, J = 8.6 Hz, 1H, H-1
GlcNAc), 4.30 (m, 1H, H-5 Fuc), 3.91-3.86 (m, 2H, H-6 GlcNAc, OCH2), 3.81-3.76 (m, 3H, H-3
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Fuc, H-4 Fuc, H-2 GlcNAc), 3.72 (dd, 1H, J = 5.7 Hz, J = 12.2 Hz, H-6 GlcNAc), 3.67 (dd, 1H, J =
4.1 Hz, J = 10.4 Hz, H-2 GlcNAc), 3.60 (t, 1H, J = 8.7 Hz,, H-3 GlcNAc), 3.55 (m. 1H, OCH2),
3.48 (t, 1H, J = 8.7 Hz, H-4 GlcNAc), 3.44 (m, 1H, H-5 GlcNAc),  2.64 (t, 2H,  J = 7.1 Hz,
CH2NH),  1.99 (s, 3H, Ac) 1.52( m, 2H, CH2), 1.45 (m, 2H, CH2), 1.30 (m, 4H, (CH2)2), 1.13 (d, J =
6.6 Hz, 3H, CH3 Fuc). 13C-NMR (D2O): δ 175.2 (CO), 101.7 (C-1 GlcNAc), 100.7 (C-1 Fuc), 81.2,
76.6, 72.6, 70.3, 69.4, 68.8, 67.7 (C-2, C-3, C-4, C-5 Fuc, C-3, C-4, C-5 GlcNAc), 71.3 (CH2O),
61.6 (C-6 GlcNAc), 56.1 (C-2 GlcNAc), 41.7 (CH2NH), 29.3, 26.4, 25.6 ( (CH2)4), 23.0 (Ac), 15.9
(CH3 Fuc). MALDI-TOF m/z: 467.25 [M + H]+, 489.26 [M + Na]+.
6-[N-(benzyloxycarbonylamino)hexyl]-2-acetamido-4,6-O-benzylidene-2-deoxy-3-O-[3,4-O-
isopropylidene-2-O-(2-O-tert-butyldimethylsilyl-3,4-O-isopropylidene--L-fucopyranosyl)--
L-fucopyranosyl]--D-glucopyranoside (7). Acceptor 6 (430 mg, 0.59 mmol) and donor 4 (278
mg, 0.77 mmol) were coevaporated together three times with toluene, dissolved in DMF:CH2Cl2
(1:1, 7.5 mL) and stirred at r.t. in the presence of activated molecular sieves 4Å for 1h. Bu4NBr (643
mg, 1.99 mmol) was added and 1h later CuBr2 (444 mg, 1.99 mmol), and stirring was continued for
4 days at r.t.. The reaction mixture was diluted with CH2Cl2, filtered over Hyflo, washed three times
with aq. sat. NaHCO3 and brine, dried (MgSO4), filtered and concentrated. The crude was purified
by column chromatrography (Pet. Ether-EtOAc 7:1	0:1) to give -7 (291 mg), -7 (24 mg), Yield
52 %, / =12:1). Rf (DCM:MeOH 40:1): 0.45. []D= 96.5 (c = 1.5, CH2Cl2). 1H-NMR (400 MHz,
CDCl3): δ 7.5-7.2 (m, 10H, Ar), 6.0 (bs, 1H, NHAc), 5.5 (s, 1H, CHPh), 5.09 (s, 2H, CH2Ph), 5.03
(d, 1H, J = 2.7 Hz, H-1 Fuc), 4.94 (d, 1H, J = 3.3 Hz, H-1 Fuc), 4.74 (d, 1H, J = 8.3 Hz, H-1
GlcNAc), 4.50 (m, 1H, H-5 Fuc), 4.45 (m, 1H, H-5 Fuc), 4.33 (m, 1H, H-6 GlcNAc), 4.19-4.09 (m,
4H, H-3 Fuc, H-3 GlcNAc, H-4 Fuc, F-4 Fuc), 3.95 (m, 1H, H-4 Fuc), 3.85-3.74 (m, 4H, OCH2, H-
6, H-2 Fuc, H-2 Fuc), 3.64 (m, 1H, H-2 GlcNAc), 3.53 (m, 1H, H-4 GlcNAc), 3.46 (m, 2H, H-5
GlcNAc, OCH2), 3.18 (m, 2H, CH2NH), 2.01 (s, 3H, Ac), 1.49-1.30 (m, 15H, 4 CH3 iPr, CH3 Fuc),
1.08 (d, 3H, J = 6.6 Hz, CH3 Fuc), 0.89 (s, 3H, tBuSi), 0.14 (s, 6H, CH3Si). 13C-NMR (50 MHz,
CDCl3): δ 170.6, 156.1 (CO), 137.1, 128.8, 128.4, 128.0, 127.9, 126.0 (Ar), 108.6, 108.4 (Cq iPr),
101.2 (CHPh, C-1 GlcNAc), 97.3 (C-1 Fuc), 97.1 (C-1 Fuc), 81.0, 76.4, 75.9, 74.5, 72.1, 66.0, 63.7,
63.4 (C-3, C-4, C-5 GlcNAc, C-2. C-3, C-4, C-5 Fuc, C-2. C-3, C-4, C-5 Fuc), 69.7, 68.6 (CHPh, C-
6), 66.0 (OCH2), 56.8 (C-2 GlcNAc), 40.7 (CH2NH), 29.6, 29.1, 25.3, ((CH2)2), 28.2 (CH3 iPr), 26.1
(CH3 iPr), 23.6 (Ac), 18.4 (Cq tBuSi),  16.1, 16.0 (CH3 Fuc), -3.8 (CH3Si), -4.2 (CH3Si). HRMS m/z:
calcd for C53H84N3O16Si [M + NH4]+: 1046.5620; found 1046.5668.
6-[N-(benzyloxycarbonylamino)hexyl]-2-acetamido-4,6-O-benzylidene-2-deoxy-3-O-[3,4-O-
isopropylidene-2-O-(3,4-O-isopropylidene--L-fucopyranosyl)--L-fucopyranosyl]--D-
glucopyranoside (8). Trisaccharide 7 (52.8 mg, 0.05 mmol) was treated with TBAF (1M in THF,
100 l) under N2 for 6 hours at r.t. The reaction mixture was then evaporated, the residue dissolved
in EtOAc and washed with NaHCO3 and brine, dried (MgSO4), filtrated and evaporated. The crude
was purified by column chromatography (Pet.Ether-EtOAc 1:4) to give 8 (42 mg, 94 %). Rf
(DCM:MeOH 20:1): 0.5. []D= 128.9 (c = 0.7, CH2Cl2). 1H-NMR (400 MHz, CDCl3): δ 7.46-7.34
(m, 10H, Ar), 5.47 (s, 1H, CHPh), 5.10 (bs, 2H, CH2Ph), 5.03 (bs, 1H, H-1 Fuc), 4.89 (s, 1H, H-1
Fuc), 4.58 (m, 1H, H-5 Fuc), 4.43 (m, 2H, H-5 Fuc, H-1 GlcNAc), 4.33 (m, 1H, H-6 GlcNAc), 4.22
(m. 1H, H-3 Fuc), 4.12 (m, 3H, OCH2, H-3 Fuc, H-4 Fuc),  3.89-3.73 (m, 7H, H-2 Fuc, H-2 Fuc, H-
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4 Fuc, H-3 GlcNAc, H-4 GlcNAc, H-6 GlcNAc, OCH2), 3.52 (m, 2H, H-2 GlcNAc, H-5 GlcNAc),
3.20 (m, 2H, CH2NH), 1.95 (s, 3H, Ac), 1.49-1.25 (m, 23H, 4 CH3 iPr, CH3-Fuc, (CH2)2), 0.91 (d,
3H, J = 5.1 Hz, CH3-Fuc). 13C-NMR (50 MHz, CDCl3): δ 170.5, 156.5 (CO), 137.1, 128.9, 128.4,
128.1, 128.0, 127.9, 126.1 (Ar), 108.8, 108.4 (Cq iPr), 101.5 (CHPh), 99.9 (C-1 GlcNAc), 95.7 (C-1
Fuc), 95.3 (C-1 Fuc), 80.7, 76.4, 76.1, 75.9, 74.5, 74.1, 73.6, 71.0, 65.7, 62.7 (C-3, C-4, C-5
GlcNAc, C-2. C-3, C-4, C-5 Fuc, C-2. C-3, C-4, C-5 Fuc), 69.7, 68.8 (CHPh, C-6), 66.6 (OCH2),
58.7 (C-2 GlcNAc), 40.5 (CH2NH), 29.5, 28.9, 25.7, 25.1 ((CH2)2), 28.3 (CH3 iPr), 26.3 (CH3 iPr),
23.3 (Ac), 15.9, 15.6 (CH3 Fuc). HRMS m/z: calcd for C47H67N2O16 [M + H]+: 915.4490; found
915.4450.
6-Aminohexyl-2-acetamido-2-deoxy-3-O-[2-O-(-L-fucopyranosyl)--L-fucopyranosyl]--D-
glucopyranoside (11). Compound 8 (38 mg, 0.04 mmol) was treated with AcOH 60 % (2.4 mL) at
50 ºC for 8h, and then evaporated to dryness with the aid of toluene. The crude was dissolved in
EtOH 90 % in water (2.7 mL), and HCl 1M (60 L), Pd/C 10 % was added and the reaction mixture
was stirred under H2 atmosphere for 4h, filtrated over Hyflo and evaporated. The residue was
purified by gel filtration chromatography HW-40 (NH4HCO3 0.15M in H2O) to give 11 (11 mg, 45
%). []D= 126. 4 (c = 0.5, CH3OH). 1H-NMR (400 MHz, CD3OD): δ 5.25 (d, 1H, J = 2.7 Hz, H-1
Fuc), 4.94 (d, 1H, J = 3.1 Hz, H-1 Fuc), 4.45 (d, 1H, J = 8.3 Hz, H-1 GlcNAc), 4.32 (m 1H, H-5
Fuc), 4.27 (m, 1H, H-5 Fuc), 3.88-3.39 (m, 14H, H-2, H-3, H-4, H-4, 2 H-6 GlcNAc, H-2, H-3, H-4
Fuc, H-2, H-3, H-4 Fuc), 2.90 (t, 1H, J = 7.4 Hz, CH2NH ), 2.00 (s, 3H, Ac), 1.63 (m, 2H, CH2),
1.54 (m, 2H, CH2), 1.39 (m, 4H, (CH2)2), 1.17 (m, 6H, 2 CH3 Fuc).  13C-NMR (50 MHz, CD3OD): δ
173.6 (CO), 102.3 (C-1 GlcNAc), 97.4 (C-1 Fuc), 97.3 (C-1 Fuc), 80.3, 77.5, 73.9, 73.6, 73.5, 71.6,
71.0, 70.1, 69.2, 68.1, 67.4, 62.4 (C-3, C-4, C-5 GlcNAc, C-2, C-3, C-4, C-5 Fuc, C-2, C-3, C-4, C-
5 Fuc), 69.7 (C-6 GlcNAc), 62.4 (OCH2), 56.6 (C-2 GlcNAc), 40.5 (CH2NH), 29.8, 28.1, 26.7, 26.4
((CH2)2), 23.2 (Ac), 16.3 (CH3-Fuc). MALDI-TOF m/z: 613.30 [M + H]+, 635.32 [M + Na]+.
Ethyl-3,4-O-isopropylidene-2-O-(2,3,4-tri-O-benzyl--L-fucopyranosyl)-1-thio--L-
fucopyranoside (18). Bromine (45 L, 0.88 mmol) was added to a solution of ethyl 2,3,4-tri-O-
benzyl-1-thio--L-fucopyranosyl (382 mg, 0.8 mmol) in CH2Cl2 (7.7 mL) at 0 ºC. After 10 min, the
mixture was evaporated, coevaporating twice with CH2Cl2 to give crude bromide 16. Acceptor 17
was coevaporated with toluene (3 times), dissolved in DMF (3.7 mL) under N2 and stirred in the
presence of activated molecular sieves 3Å for 15 min at r.t. Bu4NBr (159 mg, 0.49 mmol) was
added followed by the crude bromide dissolved in CH2Cl2 (2 mL), and stirring was continued
overnight at r.t. The mixture was filtrated, and the filtrated washed with aq. sat. NaHCO3, water and
brine, dried (MgSO4) and evaporated. The crude was purified by column chromatography Pet.
Ether-EtOAc 6:1	3:1 (1% Et3N), to give 18 (178 mg, 68 %). []D= 90 (c = 1.1, CH2Cl2).  1H-
NMR (400 MHz, CDCl3):  7.42-7.26 (m, 15H, Ar), 5.51 (d, 1H, J = 3.6 Hz, H-1’), 4.99- 4.62 (m,
6H, 3 CH2Ph), 4.43 (d, 1H, J = 10.2 Hz, H-1), 4.24 (bq, 1H, J = 6.1 Hz, J = 12.7 Hz, H-5), 4.15 (t, J
= 5.7 Hz, H-3), 4.08 (dd, 1H, J = 3.7 Hz, J = 10.2 Hz, H-2’), 4.01 (dd, 1H, J = 1.9 Hz, J = 5.4 Hz,
H-4), 3.96 (dd, 1H, J = 2.7 Hz, J = 10.2 Hz, H-3’), 3.81-3.70 (m, 3H, H-2, H-4’, H-5’), 2.70 (m, 2H,
CH2 SEt), 1.54-1.11 (m, 15H, 2 CH3 iPr, 2 CH3 Fuc, CH3 SEt). 13C-NMR (CDCl3):  138.9, 138.6,
138.4 (C-ipso), 128.2, 128.0, 127.3, 127.2 (Ar), 109.3 (Cq iPr), 96.7 (C-1’), 83.5 (C-1), 79.1, 78.8,
77.7, 76.1, 74.1, 72.9, 72.1, 66.3 (C-2, C-3, C-4, C-5, C-2’, C-3’, C-4’, C-5’), 74.6, 73.1 (CH2Ph),
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29.5 (CH2 SEt), 26.4, 24.1 (CH3 iPr), 16.7, 16.3 (CH3 Fuc, CH3 Fuc’), 14.5 (CH3 SEt). HRMS m/z:




Route A: Acceptor 8 (60 mg, 0.065 mmol) and donor 12 (47 mg mg, 0.097 mmol) were
coevaporated together three times with toluene, dissolved in DMF:CH2Cl2 (1:1, 1 mL) and stirred at
r.t. in the presence of activated molecular sieves 4Å for 1h. Bu4NBr (81.3 mg, 0.25 mmol) was
added and 1h later CuBr2 (58.8 mg, 0.25 mmol), and stirring was continued for 48 h at r.t.. The
reaction mixture was diluted with CH2Cl2, filtered over Hyflo, washed three times with aq. sat.
NaHCO3 and brine, dried (MgSO4), filtered and concentrated. The crude was purified by column
chromatrography (Pet. Ether-EtOAc 2:1	1:1) to give 13 (14 mg, 16 %) and recovered acceptor 8
(75 %).
Route B: Acceptor 6 (42 mg, 0.057 mmol) and donor 18 (50 mg, 0.075 mmol) were coevaporated
together three times with toluene, dissolved in DMF:CH2Cl2 (1:1, 710 L) and stirred at r.t. in the
presence of activated molecular sieves 4Å for 1h. Bu4NBr (62 mg, 0.19 mmol) was added and 1h
later CuBr2 (43 mg, 0.19 mmol), and stirring was continued for 5 days at r.t.. The reaction mixture
was diluted with CH2Cl2, filtered over Hyflo, washed three times with aq. sat. NaHCO3 and brine,
dried (MgSO4), filtered and concentrated. The crude was purified by column chromatrography (Pet.
Ether-EtOAc 3:1	1:1) to give -13 (27 mg, 36 %), -13 (12 mg, 16 %), Yield 52 %, / = 2.3:1.
[]D= 89.0 (c = 0.2, CHCl3). 1H-NMR (600 MHz, CDCl3):  7.35-7.16 (m, 25H, Ar), 6.64 (d, 1H,
J = 7.2 Hz, NHAc), 5.38 (s, 1H, CHPh), 5.19 (bs, 1H, H-1 Fuc), 5.11-5.07 (m, 4H, H-1 Fuc, H-1
Fuc, CH2Ph), 4.93-4.61 (m, 8H, 3 CH2Ph, H-1 GlcNAc, NHZ), 4.56 (m, 1H, H-3 GlcNAc), 4.45-
4.43 (m, 2H, 2 H-5 Fuc), 3.20 (m, 1H, H-3 Fuc), 4.25 (dd, 1H, J = 10.4 Hz , J = 4.6 Hz), 4.14 (m,
4H, H-2 Fuc, H-3 Fuc, H-4 Fuc, H-5 Fuc), 3.95 (dd, 1H, J = 10.1 Hz, J = 2.7 Hz, H-3 Fuc), 3.83 (m,
1H, H-4 Fuc), 3.79-3.64 (m, 5H, H-2 Fuc, H-2 Fuc, H-6 GlcNAc, H-4 Fuc, OCH), 3.48-3.43 (m,
2H, H-5 GlcNAc, H-4 GlcNAc), 3.33 (m, 2H, H-2 GlcNAc, OCH), 3.12 (m, 2H, CH2NH), 1.97 (s,
3H, Ac), 1.60-1.21 (m, 23H, (CH2)4, 4 CH3 iPr , CH3 Fuc), 1.13 (d, 1H, J = 6.4 Hz, CH3 Fuc), 0.95
(d, 1H, J = 6.6 Hz, CH3 Fuc). 13C-NMR (CDCl3):  171.0 (CO), 138.6, 138.4, 138.3, 137.1, 128.9,
128.3, 128.2, 128.0, 127.6, 127.3, 127.0, 126.1 (Ar), 108.7, 108.4 (Cq iPr), 101.6 (CHPh), 100.1 (C-
1 GlcNAc), 95.8 (C-1 Fuc), 95.9 (C-1 Fuc), 93.7 (C-1 Fuc), 81.1, 79.1, 75.9, 75.7, 75.2, 74.6, 74.2,
74.1, 66.7, 65.9, 62.2 (C-3, C-4, C-5 GlcNAc, C-2, C-3, C-4, C-5 Fuc1, 2, 3), 72.5, 72.3, 69.2, 68.7
(CH2Ph, C-6), 60.2 (OCH2) 58.0 (C-2 GlcNAc), 40.7 (CH2NH), 29.5, 29.1, 26.1 (CH2), 28.3, 28.1,




(14). Compound 13 (16 mg, 0.01 mmol) was treated with AcOH 60 % (700 L) at 50 ºC for 8h, and
then evaporated to dryness with the aid of toluene. The crude was purified by column
chromatography (CH2Cl2-MeOH 25:1	15:1) to give 14 (8 mg, 57 %). []D= 92 (c = 0.16,
MeOH). 1H-NMR (600 MHz, CD3OD):  7.85-7.22 (m, 20H, Ar), 5.42 (s, 1H, H-1 Fuc), 5.34 (s,
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1H, J = 3.5 Hz, H-1 Fuc), 5.31 (s, 3H, J = 3.1 Hz, H-1 Fuc), 5.06 (bs, 2H, CH2Ph), 4.81-4.52 (m,
7H, 3 CH2Ph, H-1 GlcNAc), 4.41 (m, 1H, H-5 Fuc), 4.20 (m. 1H, H-5 Fuc), 4.09-3.35 (m, 17H, H-
2, H-3, H-4, H-5, 2 H-6 GlcNAc, 3 H-2, H-3, F-4 Fuc, OCH2), 3.07 (m, 2H, CH2NH), 1.91 (s, 3H,
Ac), 1.68-0.94 (m, 17H, (CH2)2, 3 CH3-Fuc). 13C-NMR (CD3OD):  129.5, 129.1, 128.9, 128.5,
128.3 (Ar), 101.7 (C-1 GlcNAc), 96.4 (C-1 Fuc), 94.9 (C-1 Fuc), 94.0 (C-1 Fuc), 79.9, 79.1, 77.6,
76.8, 73.3, 73.0, 70.5, 69.6, 69.5, 68.1, 68.0 (C-3, C-4, C-5 GlcNAc, C-2, C-3, C-4, C-5 Fuc1, 2, 3),
75.9, 73.7, 70.5, 67.0 (CH2Ph, C-6), 62.7 (OCH2), 57.7 (C-2 GlcNAc), 41.5 (CH2NH), 30.6, 30.2,
27.2, 26.5 (CH2), 23.3 (Ac), 16.7, 16.2 (CH3 Fuc). HRMS m/z: calcd for C61H83N2O20 [M + H]+:
1163.5539; found 1163.5562.
6-Aminohexyl-2-acetamido-2-deoxy-3-O-{2-O-[2-O-(-L-fucopyranosyl)--L-fucopyranosyl]-
-L-fucopyranosyl}--D-glucopyranoside (15). Compound 14 (8 mg, 0.007 mmol) was dissolved
in EtOH 90 % in water (0.5 mL), and HCl 1M (12 L), Pd/C 10 % was added and the reaction
mixture was stirred under H2 atmosphere for 4h, filtrated over Hyflo and evaporated to give 15 (3.7
mg, 70 %). 1H-NMR (600 MHz, D2O): δ 5.50 (d, J = 3.6 Hz, 1H, H-1 Fuc), 5.18 (d, J = 3.8 Hz, 1H,
H-1 Fuc), 5.14 (d, J = 3.4 Hz, 1H, H-1 Fuc), 4.40 (d, J = 8.4 Hz, 1H, H-1 GlcNAc), 4.30 (bq, 1H, H-
5 Fuc), 4.25 (bq, 1H, H-5 Fuc), 4.06 (bq, 1H, H-5 Fuc), 4.00 (m, 2H, H-6 GlcNAc, OCH2), 3.93-
3.78 (m, 11H, C-2, C-3 GlcNAc, C-2, C-3, C-4 Fuc 1, 2, 3), 3.58 (t, 1H, J = 9.1 Hz, H-4 GlcNAc),
3.51 (m, 1H, OCH2), 3.44 (m, 1H, H-5), 2.95 (t, 2H, J = 7.5 Hz, CH2NH), 2.00 (s, 3H, Ac), 1.61 (m,
2H, CH2), 1.51 (m, 2H, CH2), 1.31 (m, 4H, CH2), 1.19 (m, 9H,  3 CH3 Fuc). 13C-NMR (D2O): 
174.9 (CO), 102.3 (C-1 GlcNAc), 96.9 (C-1 Fuc), 93.6 (C-1 Fuc), 92.4 (C-1 Fuc), 76.3, 75.8, 72.9,
72.7, 72.4, 71.1, 70.6, 68.9, 68.8, 68.6, 68.5, 67.8, 67.7, 67.5 (C-3, C-4, C-5 GlcNAc, C-2, C-3, C-4,
C-5 Fuc1, 2, 3), 71.2.(C-6), 61.5 (OCH2), 56.2 (C-2 GlcNAc), 40.2 (CH2NH), 29.2, 27.5, 26.1, 25.5
(CH2), 23.2 (Ac), 16.1, 16.1, 16.0 (CH3 Fuc). MALDI-TOF m/z: 759.4 [M + H]+, 781.4 [M + Na]+.
General procedure for the derivatization of glycosides with diethyl squarate
Spacer containing 2, 10, 11 and 15 (1-7 mg) were dissolved a 1:1 solution of 0.1 M phosphate buffer
pH 7.0 and MeOH (~ 250 µL total volume). 1.1 Eq. diethyl squarate was added and the reaction was
allowed to stand until TLC analysis (n-BuOH:MeOH:water:HOAc 4:2:2:0.5) indicated complete
conversion of the glycoside into a faster moving product. After concentration, the crude residue was
dissolved in water (0.5 mL) and loaded onto a C-18 Sep-Pak cartridge. The column was washed
with water (3 x 0.5 mL), then the product was eluted with water/MeOH (75/25 → 25/75 v/v). After
TLC analysis, the fractions containing the squarate adduct were pooled and evaporated.
General procedure for the preparation of the Bovine Serum Albumin (BSA) neoglycoconjugates
 BSA was dissolved in 0.2 M carbonate buffer pH 9 (25 mg mL-1) and stirred for 30 min. Then the
diethyl squarate adduct, dissolved in water (0.5 mg mL-1), was added to the BSA solution (20 mol
eq. based on BSA) and the reaction was allowed to proceed for 5 days. The BSA-
neoglycoconjugates were purified using gel permeation chromatography. The average degree of
incorporation of the glycosides onto BSA was determined by MALDI-TOF MS (Table 7.2). The
LNFPIII-HSA neoglycoconjugate was a kind gift of Dr. B.J. Appelmelk (Amsterdam, The
Netherlands). The neoglycoconjugate was originally purchased from Isosep AB (Tullinge, Sweden)
and contained on average 22 mol LNFPIII per mol HSA.
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Immobilization of BSA neoglycoconjugates on CM5 sensor chips
The BIAcore 3000 instrument, CM5 sensor chips and an amino coupling kit were purchased from
BIAcore AB (Uppsala, Sweden). All buffers were filtered and degassed under vacuum before use.
Immobilization of the neoglycoconjugates was performed using the standard amino coupling
procedure according to the instructions of the manufacturer at a flow rate of 5 L min-1. In short, the
carboxymethylated surface of the CM5 sensor chip was activated by a 7 minute pulse of a 1:1
mixture of 0.1M N-hydroxysuccinimide and 0.1M N-Ethyl-N’-(dimethylaminopropyl)carbodiimide,
followed by several injections of the neoglycoconjugate at a concentration of 25 g mL-1 in 10 mM
sodium acetate pH 4.5 until the desired level of immobilization was achieved. The BSA
neoglycoconjugates were immobilized to a level of approximately 10,000 response units (RU). After
immobilization unreacted groups were blocked by the injection of 300 L 1M ethanolamine-HCl,
pH 8.5. The same protocol was followed for the LNFPIII-HSA neoglycoconjugate. Unconjugated
BSA was coupled on one flow channel as a control.
Binding analysis of monoclonal antibodies to fucosylated glycosides by SPR
Hybridoma culture supernatant (sup) containing the Mab of interest was injected on the different
CM5 sensor chip channels containing immobilized neoglycoconjugates during two minutes with a
flow of 20 µL s-. After a dissociation period of five minutes following the end of the injection, the
response unit (RU) value was measured. Subsequently, the surface was regenerated with 20 µL of
20 mM HCl. At the start of each new cycle, a three-minute equilibration period preceded injection
of the sup, during this period 5 µL HBS buffer was injected as a control for the surface. After
subtraction of the response units of the BSA control channel, the binding pattern of each Mab is
represented in Table 7.3 as + (100-500 RU), ++ (500-1000 RU) or +++ (> 1000 RU).
Immunofluorescence assay (IFA)
IFAs were carried out on 6 µm-thick cryostat liver sections of infected hamsters. These sections
were incubated with Mabs (Figure 7.1), washed and then incubated with an FITC labeled conjugate
of RaM immunoglobulin antibodies (Nordic Immunological Laboratories) diluted 1:50 in PBS
(0.035 M phosphate, 0.15 M NaCl, pH 7.8) containing 0.1 mg mL-1 Evan’s blue. The slides were
observed with a Leica DM RBE fluorescence microscope with the appropriate filter combination for
FITC fluorescence. A negative control consisted of incubation with fresh culture medium followed
by staining with the FITC labeled conjugate. Fluorescence was interpreted visually (Figure 7.1).
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Summary
Empty capsids (artificial top component) of turnip yellow mosaic virus were co-
crystallized with an encapsidation initiator RNA hairpin. No clear density was observed
for the RNA, but there were clear differences in the conformation of a loop of the coat
protein at the opening of the pentameric capsomer (formed by five A-subunits) protruding
from the capsid, compared to the corresponding loop in the intact virus. Further
differences were found at the N-terminus of the A-subunit. These differences have
implications for the mechanism of decapsidation of the virus, required for infection.
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Introduction
Turnip yellow mosaic virus (TYMV) is a non-enveloped plant RNA virus and is the type
member of the genus Tymovirus. The virion is an icosahedral particle with T=3 symmetry
and the protein shell consists of 180 identical subunits. The viral capsid is mainly
stabilized by protein-protein interactions [1], hence the ability of the virus to produce
empty capsids (natural top component, NTC) [2]. Viral RNA can also be separated from
the intact virus by various methods leaving the protein shell largely intact, such as
incubation in the presence of a high concentration of urea or formamide, alkaline
treatment, heating or freezing and thawing (reviewed by Kaper [1]). Over the past years
TYMV, NTC and artificially obtained empty capsids (artificial top component, ATC)
have been extensively studied using many different techniques. Low resolution diffraction
studies have been performed on TYMV, ATC and NTC. From these studies it was
concluded that the structures of these particles are most likely very similar [3,4]. In
addition, TYMV and NTC could also be indistinguishably co-crystallized [2], with several
cryo-electron microscopy studies (Cryo-EM) corroborating the findings of a high
similarity between the intact virus and empty particles [2,5-8]. Furthermore, from cryo-
EM studies in combination with analytical ultracentrifugation, X-ray scattering and X-ray
diffraction and orientation in a magnetical field it was concluded that the RNA leaves the
virus via a hole in the capsid left by the dissociation of at least one pentameric capsomer,
whereas the rest of the capsid remains intact [9]. A high resolution structure of TYMV has
been reported by Canady et al.[10]. To date, however, no high resolution structure of the
empty capsids of TYMV is available. For another virus belonging to the genus Tymovirus
both the structure of the intact virus and its empty capsid are available [11,12].
Comparison of the two structures proved helpful in providing indirect evidence for
protein-RNA interactions as parts of the N-termini of the A, B and C subunits were visible
in the presence of viral RNA, whereas in the absence of RNA they were disordered.
Presently, not much is known about protein-RNA interactions in TYMV. The
organization of RNA in TYMV was studied using small angle neutron scattering [13].
Results indicated that the RNA is organized within the interior of the protein capsid with
little or no penetration into the coat protein. On the other hand, crosslinking studies have
demonstrated that interactions should occur between RNA and protein [14]. However, the
X-ray structure of TYMV could not provide direct evidence to corroborate these findings
[10]. No clear electron density in the vicinity of the coat protein was found that could be
ascribed to RNA. However, strong density organized around the five-fold axis in the
interior of the virus capsid was found but with no apparent interactions with the coat
protein. On the contrary, in a cryo-EM study ordered regions of RNA were found
touching the coat protein at the three-fold axis rather than at the five-fold axis [7].
Furthermore, from in vitro binding assays and gel mobility shift electrophoresis it was
concluded that a 5' proximal hairpin HP1 of TYMV RNA specifically binds to the interior
of an empty TYMV capsid under slightly acidic conditions and in the presence of
spermidine, whereas no interaction was observed at neutral conditions [15]. In TYMV, as
well as in other members of the genus Tymovirus, the 5' untranslated region (UTR) of the
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genomic RNA was shown to contain hairpins with internal loops consisting solely of C•C
and C•A oppositions [16]. Extensive studies revealed that the conserved C-C and C-A
pairs in the stem-loop structure are of major importance for its function in encapsidation
initiation [17]. It was postulated that under acidic conditions protonation of cytosines and
adenines occurs, thereby forming C+•C and A+•C basepairs. These C+•C and A+•C pairs
may share a proton with carboxylic side chains of acidic amino acids, which then would
represent a novel type of RNA-protein interaction [15]. Recently, it has been suggested
that the whole TYMV viral RNA genome can form 20-30 hairpins, containing the C+•C
and A+•C base pairs. The protonation and deprotonation of these C•C and A•C base-pairs
is proposed to be a driving force for encaspidation and disassembly of the TYMV virion
(Bink et al., manuscript in preparation).
Previously, a study was performed on bacteriophage MS2 that was soaked with
an RNA hairpin, which is thought to play a role in assembly of the phage capsid [18]. The
X-ray structure showed binding of specific RNA bases of the hairpin to conserved
residues of the coat protein. Later, in a cryo-EM study, the interaction of viral RNA with
the MS2 coat protein was visualized confirming the binding of the hairpin was not just an
artefact of the crystallization [19]. In analogy with these studies, we co-crystallized the 5'
proximal hairpin HP1 with ATC and solved the structure of this capsid complex.
Although no density was observed for the RNA hairpin, differences were observed
between the intact TYMV particles and the ATC capsids, which may provide further clues
in the elucidation of the nature of the interaction between viral RNA and the protein
capsid.
Results
Data collection and structure of empty capsids of TYMV
Most X-ray data from virus crystals are obtained at room temperature as it is often
difficult to find suitable freezing conditions. However, freezing reduces the radiation
induced decay and allows for a complete dataset to be measured from a single crystal.
ATC crystallizes in the presence of high salt concentration (1.2 M ammonium phosphate).
Therefore we investigated freezing conditions with cryosalts rather than with the more
traditional organic cryoprotectants, such as glycerol [20].
Several different saturated solutions of salts in various ratios with 1.2 M ammonium
phosphate pH 4.5 were tested (Table 8.1). These salts had to be compatible with the high
concentration of phosphate already present in the solution and should not affect the pH of
the solution, which is important for the eventual binding of the RNA hairpin to the capsid
protein. Crystals frozen in a 4:1 lithium sulfate:ammonium phosphate solution gave the
best diffraction images.
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Table 8.1 Cryosalt solutions used to test for suitable freezing conditions for ATC crystals
Cryoprotectant (sat. solutions) Ratioa Freezingb
Lithium Fluoride 9:1 Clear
Lithium Fluoride 4:1 Clear
Lithium Fluoride 1:1 Precipitate
Ammonium Fluoride 3:2 Clear
Sodium Chloride 1:1 Precipitate
Lithium Sulfate 9:1 Clear
Lithium Sulfate 4:1 Clear
Lithium Sulfate 1:1 Precipitate
aRatio of cryosalt solution with 1.2 M ammonium phosphate pH 4.5.
bThe frozen drops were visually inspected to see if they were clear and one diffraction image was
taken to check for ice-rings.
A complete dataset was measured from one ATC crystal and the structure of
these empty capsids of turnip yellow mosaic virus was solved to 3.75 Å resolution. The
crystals belong to space-group F4132, with cell dimensions of 688.5 Å. This space-group
and cell dimensions were also reported for crystals grown from 0.7 M ammonium sulfate
[3]. A summary of the refinement statistics is given in Table 8.2. The rather high Rmerge is
caused by the weakness of the data, yet, because of the high multiplicity, acceptable
values for the I/σ could be obtained.
Figure 8.1 a) Pentamer of subunits A, B and C present in the asymmetric unit. b) Secondary
structure of the subunits, the beta-strands of the jellyroll beta-barrel are labeled. The nomenclature
for the BIDG and CHEF strands follows Harrison et al.[21]. The picture was created using PyMol
Molecular Graphics System (DeLano, W.L. 2002, http://www.pymol.org). (For color picture see
Appendix II).
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Resolution (Å)a 25-3.75 (3.98-3.75)
Completeness (%) 100 (99.3)
Measured reflections 1267930
Unique reflections 141239
Rmergeb (%) 20.4 (59.5)
Average I/σ (I) 10.7 (2.7)
Refinement
R-factor (%) 24.5 (28.6)
Free R-factor (%) 25.1 (28.4)
No of particles in unit cell 8
No of atoms in asymmetric. unit 20470
Average total B-value (Å 2) 44.0
Validation
Ramachandran plot (%)
most favored region 71.3
additionally favored region 27.2
generally allowed region 0.9
disallowed region 0.7
RMSD bonds (Å) 0.008
RMSD angles (°) 1.50
aValues of reflections recorded in the highest resolution shell are shown in parentheses.
bRmerge  = Σ (| I-<I>| ) / Σ (I) (scalepack output)
The structure was solved by molecular replacement using the structure of the
intact virus [10], (PDB accession code 1AUY) after establishing that the asymmetric unit
contains five of the three icosahedrally independent subunits designated A, B and C (Fig.
8.1), which are chemically identical (following the nomenclature used by Harrison et al.
[21]) due to the symmetry imposed by the space-group. The unit cell contains 8 virus
particles, with a lattice of a diamond type. The structure was refined to a final R factor of
24.5 % (Rfree 25.1 %). The overall structure is of good quality, with 98 % of the residues
lying in the most favored and additionally allowed regions in the Ramachandran plot [22].
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The rms-deviation in bond distances is 0.008 Å and the rms-deviation in bond angles is
1.50º from the Engh and Huber values [23]. The overall structure of the A, B and C
subunits is very similar (Figure 8.1), having a topology as found in virtually all spherical
plant viruses, the beta-barrel motif. Like in other T=3 virus structures, the A-subunits
form the pentamers around the icosahedral five-fold axis, the B and C subunits together
form the hexamers, and are related by quasi
six-fold symmetry (Figure 8.2). The
subunits A, B and C are related by quasi
three-fold symmetry. The pentamers and
hexamers protrude from the surface leaving
a deep depression at the quasi three-fold
axis surrounded by the A, B and C
subunits.
Figure 8.2 Schematic representation of T=3
viral architecture. Picture was taken from the
VIPER website [24].
Electron density map
After the molecular replacement solution was obtained, several rigid body refinements
and grouped B-factor refinement cycles were performed using strict non-crystallographic
symmetry and electron density maps were calculated. These maps were of such good
quality that there was no need for real space averaging over the five-fold non-
crystallographic symmetry of the asymmetric unit. We attempted to co-crystallize the
ATCs with an RNA encapsidation initiation hairpin HP1 by growing crystals of the ATC
the presence of an RNA initiator hairpin at pH 4.5, as it has been shown that this is the pH
Figure 8.3 The integrity of the RNA HP1 during co-crystallization.
RNA from crystallization droplets with various salt concentrations was
analyzed with a 10 % polyacrylamide gel electrophoresis under
denaturing conditions (8 M urea), after two months of crystallization at
room temperature. Lane 1: 1.18 M ammonium phosphate. Lane 2: 1.22
M ammonium phosphate. Lane 3: 1.24 M ammonium phosphate. In the
lane with the reference, intact RNA HP1 was loaded. The gel was
stained with toluidine blue.
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optimum for binding of the RNA hairpin to the coat protein [15]. Binding of RNA to the
coat protein under the conditions used for crystallization has never been shown, as these
conditions are unsuitable for performing the standard binding assay (based on a shift in
electrophoretic mobility), due to the high salt concentration. However, the integrity of the
RNA hairpin during co-crystallization was analyzed and after two months of
crystallization at room temperature under various salt conditions the hairpin was still
intact in the crystallization drops (Figure 8.3).
Figure 8.4 2Fo-Fc electron density map
contoured at 1σ. Extra electron density, perhaps
of the poorly ordered RNA hairpin, is observed
in a cavity formed by H68 and H180, R67, R140
and D143. In this orientation R67 lies exactly
behind H68 and can therefore not be observed in
this picture. The picture was created with
Xtalview [25].
No clear electron density was observed for the RNA hairpin. Some extra electron
density was found in the vicinity of two histidine residues H68 and H180 (Figure 8.4),
which are accompanied by residues R67, R140 and D143. These residues are located in a
cavity surrounded by R12-E135 and K32-E72 (Figure 8.5). All these residues are located
at the interior surface of the capsid close to the interface between subunits A, B and C at
the bottom of the depression.
Previously, these residues were implicated to play a role in RNA binding
[10,14,26]. The RNA hairpin does not likely coincide with the viral symmetry, hence its
electron density would not be seen. Modeling ions such as phosphate or magnesium into
this difference density as an alternative for RNA was not successful. Additional extra
density was also present along beta-strand G of subunit A, which could be ascribed to part
of the N-terminal region of the A-subunit (data not shown). By overlaying subunit B onto
A, part of the N-terminus of the B-subunit approaches this density. As a result amino
acids 10-15 of the A subunit could be built into the density and refined. This loop is rather
flexible as shown by the high average B-factor for this region.
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Figure 8.5 Surface representation of
subunits A, B and C viewed along the quasi
three-fold axis from the interior of the
capsid. The histidines 68 and 180 are
located close to the interface between
subunits A, B and C. The cavities
containing the Histidines 68 and 180,
accompanied with Arg 67. Arg 140 and Asp
143 are surrounded by a Arg-Glu and a Lys-
Glu couple (R12/E135 and K32/E72). The
side chain of these residues point towards
the interior of the capsid. (For color picture
see Appendix II).
Comparison with TYMV
We have crystallized the ATC using similar crystallization conditions as used for the
intact virus and to our surprise ATC crystallized in a different space-group (F4132 rather
than P6422, Table 8.3). In the empty particles, crystal contacts between the particles occur
at the quasi six-fold positions only. At the top of the hexamer, a loop from residue 161 to
165 "kisses" the same loop in a neighboring particle. In the intact virus however, a more
efficient packing exists (Figure 8.6).
Table 8.3 Comparison of TYMV and ATC crystals
TYMVa ATC
Crystallization conditions 1.11-1.15 M ammonium
phosphate, 100 mM MES, pH 3.7
1.16 M ammonium
phosphate,  pH 4.5
Space-group P6422 F4132




aCrystallization data were obtained from Canady et al. [27].
An ATC particle takes up to 1.5 times more space in the unit cell than the intact virus
particles. Both pentamers and hexamers are involved in the packing for TYMV. A
pentamer from one particle snuggles up into the depression in between the pentamer and
the hexamer, making numerous contacts via the beta-strands of the protruding pentamers
and hexamers. In order to release genomic RNA from the intact virus particles by freezing
and thawing it has been suggested that the particles must lose a pentamer [7,9].
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Figure 8.6 Stereoview of crystal packing of a)
ATC and b) TYMV. A difference in packing
can be observed immediately. ATC interacts
via tips of the hexamers, whereas in TYMV a
pentamer protrudes into the depression
formed by A, B and C at the quasi three-fold
axis. The difference in packing may be
explained by the loss of a single capsid
pentamer in the ATC.
Although this hole cannot be observed by X-ray crystallography, as it gets averaged out
due to the random orientations of the particles in the crystal, it could be the reason that the
empty particles only pack at the hexamers and not at the pentamers. These observations
may also explain the reduction in crystalline order in the ATC crystals (diffracting to 3.75
Å) compared to crystals of the intact virus (diffracting to 3.2 Å).
In contrast to the general similarity of the capsid structures of ATC and TYMV, a major
difference was found in a loop of subunit A at the opening in a depression of the pentamer
(Figure 8.7).
The residues in this loop in both the TYMV and the ATC structures have high B-
factors suggesting that this loop is very flexible. Despite this, difference density did
clearly indicate a different conformation of the loop in ATC rather than disorder. The loop
starts at amino acid G120 running to L128 in the A subunit. Significantly, this loop with
I122 at the tip is pointing towards the interior of the pentamer in TYMV, while in ATC
this loop is rotated about 90° towards the top of the pentamer; I122 is now pointing
outwards, leaving a smaller opening in the depression of the pentamer. The distance
between opposite side chains of the ILE is about 3.5 Å, whereas in TYMV the distance
between the side chains of this ILE is approximately 4.8 Å. Because of the large
conformational change in this loop, the opening at the depression of the pentamer lies
approximately 9 Å deeper in TYMV than in ATC. The fact that both structures have high
non-crystallographic symmetry of trimers, formed by subunits A, B and C, 5-fold in case
of ATC and 15-fold in the case of TYMV, suggests that the differences observed between
the loops are not likely due to crystal packing.
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Figure 8.7 a) Top view along the five-fold axis of an overlay of a loop containing residues 117 to
135 of subunit A from ATC (grey) and TYMV (black), with the loops containing G120 to L128
highlighted. b) 90° rotated side view of the overlay. The side chain of I122 is shown in both models.
From this picture it becomes clear that this loop in ATC has flipped in an upward direction,
changing the opening of the pentamer. (For color picture see Appendix II).
Earlier biochemical and cryo-EM studies had established that the diameter of the
full and empty particles is similar [6,7]. When pentamers or hexamers lying on exactly
opposite sites in the capsids of ATC are overlayed on top of the TYMV capsid, the
diameter is 2.1 Å shorter for the pentamer and 1.5 Å shorter for the hexamers. At a
resolution of 3.75 Å these are small, but significant differences, which could not have
been observed from cryo-EM studies.
Finally, the association energies and the buried surface areas between the
subunits have been calculated using the Virus Particle Explorer (VIPER, Fig. 8.2, Table
8.4, [24]). The data for TYMV were available from the VIPER website
(http://mmtsb.scripps.edu/viper/). As expected for very similar structures, no major
differences were found. Except for the increase of buried surface area and association
energy between subunits at the icosahedral five-fold and at the quasi three-fold axis
between subunit A and B, which can be explained by the presence of part of the N-
terminus of the A subunit in ATC. This N-terminus, which is not modeled in the TYMV
structure, interacts with the A2 and B subunits and hence increases the association energy
and the buried surface area. Furthermore, the influence of the conformational change in
the loop at the opening in the apex at the icosahedral five-fold axis was checked. The
surface area and the association energy of ATC were recalculated with residues 10 to 15
of the A subunit left out of the model. Similar values were found as for TYMV (data not
shown), showing that this conformational change in the loop of subunit A does not have
an effect on the stability of the capsomer.
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Table 8.4 Comparison of association energies and buried surface area between subunits around







Buried surface area (Å2)
ATC TYMV ATC TYMV
A1-A2 icos. 5-fold -40 -33 2075 1794
A1-B1 quasi 3-fold -34 -25 1751 1410
A2-B1 quasi 2-fold -30 -31 1676 1755
A1-C1 quasi 3-fold -33 -32 1728 1700
B1-C1 quasi 3-fold -44 -44 2196 2217
B1-C2 quasi 6-fold -48 -50 2461 2604
B1-C6 quasi 6-fold -50 -49 2495 2531
C1-C6 icos. 2-fold -32 -32 1779 1812
Discussion
Crystals of TYMV grown from 1.11-1.15 M ammonium phosphate at pH 3.7 (Table 8.3)
belong to the hexagonal space-group P6422 [27], whereas crystals of ATC, described in
this paper, grown from 1.16 M ammonium phosphate at pH 4.5 belong to the cubic space-
group F4132. Interestingly, Klug et al. [3] also found that both TYMV and ATC
crystallize in the cubic space-group with similar cell dimensions using 0.7 M ammonium
sulfate. Therefore, the presence of a hole of at least one pentamer in the ATC capsids
versus its absence in the intact virus may not be sufficient to explain this difference.
Perhaps the binding of RNA to the coat protein induced this difference. TYMV was
grown in ammonium phosphate at pH 3.7 by Canady et al. [27], whereas crystals obtained
by Klug et al.[3] were most likely grown at a higher pH, as the pH of 0.7 M ammonium
sulfate solution is around 5.5, which might have an influence on RNA binding. In our
structure no viral RNA is present. The major difference found between TYMV and the
ATC is located in a loop from amino acid G120 to L128 in the A subunits, which is
located at the opening within a pentamer. It has been suggested that the viral RNA leaves
the virus particles via a hole in the capsid, generated by the loss of at least one pentamer.
Perhaps subunit A undergoes some structural rearrangement to facilitate the loss of a
pentamer, which is reflected in the differences between the A subunit of ATC compared to
that of TYMV. Most likely, the changes in these loops are not caused by crystal packing
interactions, since both structures have a high degree of non-crystallographic symmetry
and the multiple copies of the trimers present in the asymmetric unit have different
surroundings. Thus the different loop conformations appear to be a biological feature of
the viral capsids.
It would not be surprising that some interaction occurs between the viral RNA
and the A-subunits. It was suggested that a unique RNA sequence will interact with a
particular group of residues from the protein capsid [9]. Furthermore, binding studies
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between the viral coat protein and the RNA-hairpin HP1, located at the 5' terminus of the
genomic RNA have shown that the interaction only occurs at low pH [15]. Although the
loop in the A-subunit that changes its conformation does not contain any residues that
might directly interact with RNA, the conformational change might be caused by
interaction with the N-terminus of the A-subunit, which we show here to have a different
conformation compared to the intact virus. Contrary to what was found in the higher
resolution TYMV structure, in the ATC structure we did observe part of the N-terminus of
the A-subunit. This may suggest that the N-terminus of subunit A in TYMV interacts in a
non-unique way with the TYMV genomic RNA. The electron density maps of TYMV
showed, in agreement with earlier cryo-EM studies, regions of ordered RNA within the
particles at a radius of 90 Å, although no direct interaction with the coat protein was
observed. However, along the five-fold axis pronounced projections of RNA extending to
approximately 75 Å were observed [10]. Perhaps some RNA interacts with the coat
protein, but not according to the crystallographic and icosahedral symmetry, which would
explain why it is not visible in the electron density maps of the intact TYMV. We propose
that in the absence of viral RNA the N-terminus of the A subunit, which is very flexible,
undergoes structural rearrangements and then interacts with the beta-strand G in ATC,
thereby becoming partially visible in the symmetrized structure. From RNA crosslinking
studies at pH 4.8 it is clear that along with two other regions, the N-terminus is involved
in binding the RNA [14]. Similar UV crosslinking studies at pH 7.3 did not introduce any
crosslinks, indicating that at this higher pH the RNA does not interact with the coat
protein.
Another region (residues 132-152) indicated by Ehresmann et al. [14] to
crosslink with RNA is located close to the N-terminus and in the TYMV structure extra
density around these residues was observed. Moreover, two histidines 68 and 180, which
are exposed at the interior of the virus capsid are located very closely to both the N-
terminus and residues 132-152 and were also already suggested as potential candidates for
interaction with the RNA [10]. Mutagenesis of these histidines to alanines has a strong
effect on virus transport in the infected plant, which supports a role for these residues in
RNA encapsidation [26]. It may be the case that RNA discriminates between the
chemically identical subunits A, B and C because of the difference in the size of the apex
of the pentamer compared to the hexamer, which are formed by the A or the B and C
subunits respectively. As the N-termini of the B and C subunits are already involved in
stabilization of the hexamers, they would not be available anymore to engage in RNA
binding.
Despite the differences in crystal packing and in the loop of subunit A, the
overall structure of TYMV and ATC is very similar. This confirms that the capsid is
mainly stabilized by protein-protein interactions and not protein-RNA interactions [1].
From very early X-ray diffraction studies [3] structural  similarity between TYMV, NTC
and ATC was already established. Moreover, the same results have been obtained by cryo-
EM studies [5-7].
In the TYMV structure extra density was observed around residues H68, H180,
R67 and R140. Therefore, it is not unreasonable to expect the RNA initiator hairpin HP1
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to bind in this area. In the ATC containing a short RNA hairpin, extra density was
observed in this region (Figure 8.4). However, it was not possible to ascribe this extra
density to any particular nucleic acid moiety. Most likely, the RNA hairpin does not obey
the icosahedral symmetry present within the virus particles, hence its electron density gets
averaged out. The observed bit of extra density might be the result of alignment of part of
the hairpin at this position within the capsid and therefore visible, whereas the rest of the
hairpin is out of register with the symmetry. Furthermore, because of the high symmetry
present within the virus capsid, the hairpin may be distributed equally among the five or
six equivalent positions in a capsomer. The latter may also seriously hamper a successful
elucidation of the RNA-protein interactions in TYMV. Yet, there is also a possibility that
under the crystallization conditions used, this hairpin did not fully bind to the coat protein.
Therefore, new crystallization conditions will be explored, which are more suitable for
binding of the hairpin to the coat protein.
In conclusion, the structure of the coat protein of TYMV is affected by the
presence or absence of genomic RNA inside the virus. No interaction was observed
between the coat protein and an RNA hairpin that contains the proposed capsid
recognition motif. As yet, further studies will be required to establish whether there are
conditions in which this interaction becomes sufficiently ordered to be visualized by X-
ray diffraction techniques. A clearly different conformation was found for a loop in the A
subunit located at the opening of the pentamer and part of the N-terminus of the A subunit
is visible in the ATC structure. These differences may confirm evidence for interactions
between the coat protein and viral RNA at the N-terminus at the icosahedral five-fold axis,
depending on the pH and state of the virus. We propose that this RNA-protein interaction
plays a role in encapsidation or decapsidation of the virus, as it has been described that the
virus on decapsidation loses at least one pentamer through which the viral RNA can
escape.
Materials and methods
Production and purification of empty capsids
TYMV was isolated from infected leaves of Chinese cabbage (Brassica pekinensis) plants three
weeks after inoculation. Inoculation of the plants was performed with in vitro transcribed and
capped genomic TYMV RNA. The infectious cDNA clone of the Blue Lake strain of TYMV,
pBL16 [28] was used as template. Conditions of plant growth and inoculation were as described
earlier [15]. Isolation of TYMV from the infected leaves was done using the bentonite procedure, as
described by Dunn and Hitchborn [29]. On average, 40 infected plants provide 350-400 gram of
infected leaf material after the major vein material was discarded. The virus preparation obtained
after the various centrifugation steps was resuspended in 10 mM Tris·HCl pH 7.0 with a final
concentration of 80-90 mg.mL-1. The virus yield is about 1 mg per gram of infected leaf material.
Artificial top component (ATC) was prepared from TYMV virions using the freeze-thaw method as
described by Katouzian-Safadi et al. [8] Aliquots of 0.4 mL of virus suspension in 30 mM sodium
acetate pH 7.0 and a concentration of 8 mg mL-1 were frozen in liquid N2 for 2 min and thawed at
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room temperature. The aliquots were pooled and supplemented with cesium chloride (1.90 g mL-1)
and sodium acetate buffer (10 mM pH 6.0). Before centrifugation the initial density of the cesium
chloride mixture was 1.26 g mL-1. Centrifugation was done for 16 hr at 60,000 rpm at 10°C in a
Beckman NVT-65 rotor. Two layers of protein formed of which the upper layer was taken for
further processing. The second layer primarily contains NTC complexed with cesium (as described
by Noort et al. [30] Genomic RNA and undegraded B-component (filled virions) were present at the
bottom of the tube. The samples were dialyzed for 24 hr against 10 mM sodium acetate pH 6.0 at
4°C with regular buffer exchanges (with 2 liters, at least 5 times). The dialyzed ATC suspension
was filtered over a 0.24 µm filter (Schleicher and Schuell). Finally, ATC was pelleted (60 min at
45,000 rpm at 4°C in a 75 Ti-rotor) and resuspended in 10 mM sodium acetate pH 6.0 (final
concentration of 15 mg mL-1). The quality of the ATC preparation was analyzed using agarose gel
electrophoresis and in vitro binding assays (data not shown).
The RNA fragment corresponding to the TYMV encapsidation initiation hairpin HP1 (5'
CCAGC UCUCU UUUGA CAACU GG 3') was chemically synthesized as described earlier [15].
Crystallization
Prior to crystallization, the sample was filtered through a low protein binding 0.22 µm filter
(Millipore). Crystals of ATC were grown in 1.16-1.22 M ammonium phosphate pH 4.5 at room
temperature, using the sitting-drop vapor diffusion method (as described previously for TYMV)
[27]. A large number of small crystals appeared within a few days from mixing 5 L of protein
solution with an equal volume of precipitant solution. Crystals of ATC with the RNA hairpin were
obtained by crystallization with a protein to ligand molar ratio of 1:50. 10 mM MgCl2 was added to
the precipitant solution to replace the spermidine, which is naturally present in TYMV [31].
Spermidine is subject to oxidation and therefore not suitable for this type of experiment.
Furthermore, RNase inhibitor (RNA Guard, Pharmacia) was added in a 1:50 dilution to the
crystallization droplet to prevent the RNA oligonucleotide from degradation. Mixing equal volumes
of protein solution, in the presence of 50 equivalents of RNA hairpin, with reservoir solution, again
resulted in a large amount of rather small crystals, which were not suitable for X-ray
crystallography. In order to grow larger crystals the protein concentration was lowered to 10 mg mL-
1 and 5 L of this protein solution was mixed with an equal volume of precipitant solution. After
equilibration, macroseeds obtained from previous crystallization trials were washed in reservoir
solution and transferred to the new crystallization droplets. In these drops, no spontaneous
nucleation had occurred and the macroseeds grew into large crystals with dimensions up to 0.6 x 0.4
x 0.25 mm.
Data collection and processing
X-ray diffraction data of the ATC crystals grown in the presence of the RNA fragment were
measured at the protein X-ray crystallography beamline ID29 at the European Synchrotron
Radiation Facility in Grenoble, France on an ADSC Q210 CCD detector. The crystals were soaked
for a few seconds in a cryoprotectant solution containing a saturated lithium sulfate solution and a
1.2 M ammonium phosphate solution pH 4.5, mixed in a 4:1 ratio, and 0.45 mM RNA, followed by
flash-freezing in a nitrogen gas stream at 100 K. Data were collected using 0.25° oscillations and
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200 images were recorded per dataset. The collected data were indexed, integrated and scaled with
HKL2000 [32]. A summary of the processing statistics is given in Table 8.2.
Structure determination and refinement
A complete data set was taken from one crystal at 100 K and the data were processed to 3.75 Å
resolution. The structure was solved by molecular replacement using the structure of the intact
TYMV (PDB accession code 1AUY) [10] as a search model in Molrep [33]. The molecular
replacement solution had an R-value of 48 % (Rfree 49.9 %) for data to 5 Å. The asymmetric unit
contains a pentamer of A, B and C subunits. Several cycles of rigid body refinement, followed by
alternating energy minimization and grouped temperature factor refinement runs, using strict five-
fold non-crystallographic symmetry (NCS) constraints in the CNS program [34], the R-value
dropped to 24.5 % with an Rfree of 25.1 % for data to 3.75 Å. Electron density maps were calculated
and where necessary, the model was rebuilt.
Protein Data Bank accession code
The coordinates and structure factors have been deposited in the Protein Data Bank, under accession
code 1W39.
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General discussion and future
prospects
It is well known that individuals infected with schistosomes elicit an immune response
against the monomeric Lewis X (Lex) antigen. It remained to be studied however whether
different oligomers of Lex, which the parasite produces, can induce a different immune
response. To investigate this, the interaction of a large panel of schistosome derived
monoclonal antibodies (Mabs) with mono-, di- and trimeric Lex structures was studied and
the antibody levels against these Lex structures were studied in vivo in a time course study
using serum of infected mice. Furthermore, the structural aspects of Lex-antibody
interaction at the molecular level were examined by X-ray crystallography.
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Synthesis of Lex derivatives
To enable the immunological and structural studies, mono-, di- and trimeric Lex and the
non-fucosylated derivative LacNAc were successfully synthesized. The chemical
synthesis is described in chapter 2. The synthesis of the Lex oligomers was based on a key
monomeric Lex building block. This building block could readily be deprotected at the
reducing or non-reducing end and converted into a glycosyl donor or acceptor,
respectively. This allowed for straightforward oligomerization of the Lex building blocks
to obtain di- and trimeric Lex. Exclusively β-linked glycosides were obtained by coupling
the Lex building blocks in acetonitrile at low temperatures (nitrile effect).
The Lex oligosaccharides were functionalized with a spacer ensuring easy
conjugation to a carrier protein (BSA) for binding studies via a diethylsquarate linker as
described in chapter 3. BSA neoglycoconjugates were obtained in various densities (n
from 2.5 to 10 mol sugar per mol BSA). At the same time higher density (n ~ 25) Lex-
HSA neoglycoconjugates became available. Having both high and low density
neoglycoconjugates, containing the same sugar, allowed us to study the relevance of
multivalent presentation for the interaction of Mabs with these carbohydrates by surface
plasmon resonance (SPR). It was found that the multivalency of the sugar is an important
factor for binding. In the case of the lower density trimeric Lex-BSA neoglycoconjugate (n
~ 2.5), the binding of Mabs was either completely absent or greatly reduced compared to
the interaction of the same Mab with the high density HSA neoglycoconjugate.
The influence of antigen presentation
The importance of a multivalent presentation of the Lex antigen allowing e.g. cooparative
binding is in line with other studies. It is recognized more and more that not only the
oligosaccharide itself but also its presentation is of crucial importance for interaction with
antibodies or components of the cellular or innate immune system. For instance in a study
performed by Velupillai et al. [1], LNFPIII (a pentasaccharide carrying Lex at its non-
reducing end) conjugated to BSA was able to induce IL-10 to down-regulate the host's
protective immune response, whereas the free oligosaccharide did not. Remarkably free
LNFPIII was found to reduce the IL-10 production stimulated by soluble egg antigens
(known to contain Lex). These results might suggest that a lectin type receptor on the cell
surface of the peripheral blood mononuclear cells requires multivalent interaction with the
sugar to activate the cell to start producing IL-10. In another paper it was suggested that
DC-SIGN could discriminate between self and non-self oligosaccharides on the basis of a
higher multivalent presentation of the pathogenic sugars [2]. The fact that anti-Lex
antibodies are elicited upon a schistosomal infection might stem from the same principle.
Because of the multivalent presentation of Lex by the parasite, it is recognized as non-self
by the immune system and an immune response is elicited. In another study, a panel of
Mabs which had been characterized as anti-monomeric Lex Mabs by SPR, was used in an
immunofluorescence assay on Rossman fixed sections of adult worms [3]. A different
staining pattern was found for Mab 291-2G3-A compared to most other Mabs within the
same panel. All the Mabs stained the gut of the worms whereas the 291-2G3-A did not.
Furthermore, both parenchyma and tegument were only stained by 291-2G3-A. An
Discussion                                                                                                                                         167
explanation could be that these Mabs can differentiate between Lex expressed on a lipid or
protein backbone. This provides further evidence that the presentation of the antigen is
very important for its immunogenicity.
In chapter 3 a large panel of anti-schistosomal Mabs was screened for interaction
with the high-density mono-, di- and trimeric Lex-HSA neoglycoconjugates by SPR.
Interestingly, not only the multivalency of the sugar was important for immunogenicity
but also a difference in oligomericity was found to induce different humoral immune
responses. Mabs were found which interacted with mono-, di- and trimeric Lex (group I),
whereas others exclusively interacted with di- and trimeric Lex (group II) or solely with
trimeric Lex (group III). It would also be of interest to study whether these different anti-
Lex Mabs have different effector functions. It is known that Mabs against CCA
(containing poly-Lex on its immunoreactive part) and antibodies from serum of infected
humans mediate complement-dependent lysis of granulocytes in vitro [4]. One assay was
performed in which the binding of anti-CCA Mabs to granulocytes was measured using
flow cytometry. In chapter 3, these anti-CCA Mabs were grouped according to their
interaction with mono-, di- and trimeric Lex and it was checked whether there was a
correlation between the interaction with granulocytes and the group the Mabs belong to.
Unfortunately no relation could be found, as the Mabs that interacted with the
granulocytes could belong to any group. Further studies will be necessary to determine if
any different effector functions can be ascribed to Mabs from different groups.
Immune responses to mono-, di- and trimeric Lex
Next we measured the antibody levels in vivo in the serum of mice infected with
schistosomes against Lex in different oligomeric states (i.e. mono-, di- and trimeric Lex) in
a time course study (chapter 6). A striking difference in the antibody response intensity
against monomeric Lex versus di- and trimeric Lex was observed. This indicates that in
response to a different presentation of Lex (monomeric vs multimeric) different groups of
anti-Lex antibodies are elicited. Although the anti- mono-, di- and trimeric Lex responses
all appeared at the same time, the anti-CCA response was delayed, indicating that the anti-
polymeric Lex antibodies represent yet another group of antibodies. As different oligomers
of Lex are capable of eliciting different humoral immune responses, it might well be that
also the cellular immune responses are triggered in different ways. So far only the effect
of monomeric Lex has been investigated. It should be considered however not only to
discriminate between the multivalency of monomeric Lex (i.e. free vs conjugated to a
carrier molecule) but also to include oligomeric Lex in future studies.
Structural studies of Lex-antibody interactions
Apart from studying the humoral immune response against Lex in a schistosomal
infection, we wanted to learn more about the structural requirements of the Mabs for
binding Lex at the molecular level. To this end, several Mabs from different groups were
selected for structural studies by X-ray crystallography (chapter 3). As it is very difficult
to crystallize intact antibodies, the antigen binding part (Fab fragment) is usually cleaved
off with papain, this Fab fragment will be used for crystallization. The papain digestion,
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subsequent purification of the obtained Fab fragments and the crystallization are described
in chapter 4. To obtain high quality crystals of Fab fragments it is of importance to use a
single isoform of the protein for crystallization. Fab fragments are usually obtained as a
mixture of isoforms having pIs in a close range, which makes the purification difficult.
The Fab fragment of Mab 291-2G3-A from group I (chapter 3) could be obtained as a
single isoform and well-diffracting crystals were grown. In order to obtain the crystal
structure of Fab 291-2G3-A with Lex, crystals of the Fab were soaked with Lex. Typically
Fab fragments are co-crystallized with their carbohydrate ligand, but in this case co-
crystallization resulted in phase separation of the crystallization droplets and no crystals
were obtained. X-ray datasets were measured for the Fab with and without Lex to 1.8 and
2.05 Å resolution respectively. The structure of the Fab fragment in complex with Lex to
1.8 Å resolution revealed that the antigen-binding site is a rather shallow binding pocket
with residues from all six complementary determining regions of the antibody contacting
all three sugar residues. An SPR study revealed that the binding was completely abolished
with a disaccharide lacking either the galactose or the fucose. Furthermore, no interaction
was measured with Lea, Ley or LDNF, an isomer of Lex having the Gal replaced by an
GalNAc (A. van Remoortere, personal communication). From these results it was
concluded that this Mab is specific for Lex, although this was not reflected by a strong
affinity. Most likely a multivalently presented ligand will provide higher binding affinity
as this is almost always the case in protein-carbohydrate complexes.
Mab 291-2G3-A binds terminal Lex and represents a cavity type antibody. It may
well be that the Mabs selectively interacting with oligomeric Lex from group III might
bind an internal repeat of Lex and display a groove-type binding site. Mab 54-5C10-A
interacts with trimeric Lex and might have a groove-type antigen-binding site. This Mab is
immunodiagnostically important as it is used in an antigen detection assay to diagnose
schistosomiasis. Therefore, to obtain the crystal structure of a Fab fragment of this Mab,
preferably in complex with trimeric Lex, would be very important. This will reveal the
basis of the specificity of this Mab for oligomeric Lex and might explain the difference in
selectivity for mono- or oligomeric Lex of 291-2G3-A and 54-5C10-A respectively.
Moreover, only one Fab-carbohydrate complex has so far been solved with a true groove-
type binding site [5], therefore it would be of general interest to solve more structures of
groove-type Mabs. Recently, an improved purification scheme for the Fab fragment of 54-
5C10-A did provide a protein sample with less
isoforms. Reasonably well diffracting crystals (Figure
1) could be grown from this sample using
crystallization conditions, which previously yielded
sea-urchin like crystals. An X-ray dataset has been
recorded of the native Fab fragment to 2.6 Å
resolution.
Figure 1 Crystals of Fab fragment of 54-5C10-A grown
from 11 % PEG 3350, 0.1 M Na-Citrate, pH 4.5
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Unfortunately, so far from this dataset no structure solution could be obtained by
molecular replacement. The use of different search models for molecular replacement
with the constant and variable domains separated might provide a better answer.
Furthermore, optimization of the crystallization conditions and the freezing conditions
might lead to better datasets, which will allow structure determination.
Interactions of anti-schistosomal Mabs with parasite-specific fuco-oligosaccharides
The interaction of other fucosylated glycoconjugates with anti-schistosomal Mabs has
been addressed in chapter 7. A series of fucosylated GlcNAcs ([Fucα1-2]n=0-2Fucα1-
3GlcNAc-spacer) was synthesized to study whether the humoral immune system can
discriminate between glycoconjugates with an increasing number (0, 1 or 2) of the
schistosome-characteristic α1-2 linked fucose. Similar to the findings for the Lex
neoglycoconjugates, from an SPR study Mabs could be grouped according to their
interaction with one or more of these neoglycoconjugates. Mabs from group I interacted
solely with GlcNAc (Gn), and Mabs from group II interacted with Fucα1-3GlcNAc
(FGn). Mabs from group III interacted with [Fucα1-2]n=1,2Fucα1-3GlcNAc (FFGn and
FFFGn respectively) and finally the Mab belonging to group IV interacted solely with
FFFGn. Next, the Mabs from different groups were used in an immunofluorescence assay
to localize these structures within the adult worms. Striking differences in staining
patterns were observed between Mabs from each group, except between Mabs from group
II and III. Taken together these results show that synthetic carbohydrate structures are
very useful in defining differences between the epitopes of Mabs, which can subsequently
be used to immunulocalize these carbohydrate structures within the different life stages of
the parasite. As the synthetic structures are possibly only partial representations of the real
antigenic structures, care should be taken in drawing definite conclusions about the
epitopes. Several Mabs from this study were previously found to interact with different
carbohydrate structures. For instance Mab 114-5B1-A has been reported to interact with
LDNDF [3], whereas from this study it has become clear that it interacts with FFFGn, this
makes it rather difficult to determine its real natural epitope. Better insight into its natural
binding partner might be obtained by determining the relative affinities of the Mabs for
these different structures in a quantative SPR study or by isolating the antigen from the
natural source by immunoaffinity column chromatography (M.L.M. Robijn, personal
communication).
Structure of an empty capsid of turnip yellow mosaic virus
In chapter 8 the structure of an artificially obtained empty capsid of turnip yellow mosaic
virus (TYMV), determined to 3.75 Å resolution, is discussed. The artificial top
components (ATCs) were co-crystallized with an RNA hairpin, which is thought to
function as an encapsidation initiation signal for the virus. Elucidation of the capsid-
hairpin complex will hopefully provide detailed understanding of protein-RNA
interactions in TYMV. Unfortunately, no clear electron density was observed for the RNA
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hairpin. This might stem from the fact that the hairpin is disordered with respect to the
icosahedral symmetry of the viral capsid, and as a result its electron density would be
averaged out. Another explanation might be that the high salt concentration used for the
crystallization interfered with RNA binding.
Some hints regarding RNA binding were obtained after comparing the structure
of the ATC with the intact virus. Major differences in a loop located at the opening of the
protruding pentamer and part of the N-terminus of the A-subunit were observed, which
might imply that the RNA binds to the N-terminus of the A-subunit in the pentamer.
However, it would still be of great interest to obtain a structure of the capsid in complex
with the encapsidation initiator hairpin. Not only might this lead to better insight in the
encapsidation process of TYMV but it could also shed some light on RNA-protein
interactions as to date these interactions in the intact virus have not yet been visualized by
X-ray crystallography or electron microscopy. A new type of interaction between protein
and RNA as proposed by Bink et al. [6] might be revealed between the unusual C•C+ and
A•C+ basepairs and acidic side chains of amino acids in the protein capsid. Further study
should be undertaken to find new crystallization conditions, which should contain
spermidine and lower salt concentrations, in order to improve the binding of the hairpin to
the capsid. Hopefully the hairpin will be well-ordered and obey the symmetry of the
capsid. The hairpin or part of it might then be visualized in the electron density map.
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structurele en biofysische aspecten van
Lewis X-antilichaam interacties
Schistosomiasis (ook bekend als Bilharzia) is een tropische parasitaire ziekte veroorzaakt
door schistosomen. Momenteel zijn er meer dan twee miljoen mensen geïnfecteerd met
deze parasieten, naast malaria is het een van de belangrijkste parasitaire infectieziekten in
de wereld. Als de infectie onbehandeld blijft kunnen de parasieten tot 5 jaar of zelfs langer
in het lichaam overleven. De parasiet heeft dus slimme ontsnappingsmechanismen
ontwikkeld om verborgen te blijven voor het immuunsysteem van de gastheer. Men denkt
dat de productie van zwaar geglycosyleerde eiwitten en lipiden door de parasiet hierbij
een belangrijke rol speelt. Een van de suikerstructuren die in alle levensstadia van de
parasiet tot expressie wordt gebracht is het trisacharide Lewis X (Lex, Galβ1-4[Fucα1-
3]GlcNAcβ). Deze suiker wordt zowel in monomere als in oligomere vorm
gesynthetiseerd door de parasiet.  In dit proefschrift staat voornamelijk de interactie van
antilichamen met verschillende oligomere vormen van Lex centraal, bekeken vanuit
biofysisch en structureel oogpunt.
174                                                                                                                Nederlandse samenvatting
In hoofdstuk 1 van dit proefschrift wordt een korte inleiding gegeven over
schistosomiasis: de ziekte en de levenscyclus van de parasiet en een overzicht van de
suikerstructuren die tot nog toe zijn gevonden in de verschillende levensstadia van de
parasiet. Het tweede gedeelte van de inleiding gaat over Lex, waar deze structuur tot
expressie wordt gebracht in zoogdieren en de vermoedelijke rol van Lex bij een
Helicobacter pylori-infectie en in bepaalde vormen van kanker. Tenslotte wordt in het
laatste gedeelte een literatuuroverzicht gegeven van suiker-eiwitinteracties op moleculair
niveau, van verschillende technieken om deze interacties te bestuderen en van de tot nog
toe gepubliceerde structuren van Fab- fragmenten in complex met een suikerantigeen.
In hoofdstuk 2 wordt de synthese beschreven van mono-, di- en trimeer Lex. Een
eerste belangrijk tussenproduct in de synthese is volledig beschermd monomeer Lex. Door
het gebruik van verschillende beschermgroepen op het reducerende en niet-reducerende
uiteinde kan deze bouwsteen selectief ontschermd worden en omgezet in respectievelijk
een glycosidische donor of acceptor. Vervolgens kunnen de monomeer Lex-bouwstenen
aan elkaar gezet worden om di- en trimeer Lex te verkrijgen. Door de glycosylering van de
Lex bouwstenen uit te voeren in acetonitril bij zeer lage temperatuur kunnen selectief de β-
gekoppelde producten worden verkregen.
Vervolgens wordt in hoofdstuk 3 bestudeerd of anti-schistosomale monoklonale
antilichamen (Mabs) onderscheid kunnen maken tussen de verschillende oligomere
vormen van Lex (mono-, di- en trimeer Lex). Allereerst wordt beschreven hoe de
gesynthetiseerde Lex-suikers worden gekoppeld aan een dragereiwit, om ze voor
bindingsstudies te kunnen immobiliseren op een BIAcore-CM5-sensorchip. Tegelijkertijd
kwamen commerciële Lex-neoglycoconjugaten beschikbaar met een veel hogere
suikerdichtheid op het eiwit. Dit maakte het mogelijk om het effect van de dichtheid van
de suiker op het dragereiwit op de interactie met anti-schistosomale Mabs te bestuderen.
De interactie van de Mabs met de neoglycoconjugaten is gemeten met behulp van "surface
plasmon resonance" (SPR) spectroscopie op een BIAcore. Uit de verkregen resultaten
blijkt dat de dichtheid van cruciaal belang is voor de interactie. Zo was bijvoorbeeld de
binding van Mabs aan de lage dichtheid-trimeer Lex-neoglycoconjugaten in vergelijking
met binding aan de hoge dichtheid-neoglycoconjugaten sterk gereduceerd of zelfs
afwezig. Vervolgens is de interactie van een grote groep Mabs met de hoge dichtheid
neoglycoconjugaten gemeten op de BIAcore. De Mabs die binden aan de Lex-
neoglycoconjugaten kunnen worden ingedeeld in 3 groepen; groep I bindt aan mono-, di-
en trimeer Lex, groep II bindt aan di- en trimeer Lex, terwijl de Mabs uit groep III alleen
interactie hebben met trimeer Lex. Uit iedere groep is één Mab geselecteerd voor
kristallisatie experimenten, met structuurbepaling als doel.
Aangezien het vrij lastig is intacte antilichamen te kristalliseren vanwege hun
flexibiliteit, wordt in het algemeen het antigen-bindende gedeelte (Fab fragment) van het
antilichaam geknipt met een enzym en dit wordt dan vervolgens gebruikt voor
kristallisatie. In hoofdstuk 4 wordt beschreven hoe de Fab-fragmenten van de 3 Mabs
gezuiverd werden voor de kristallisatie-experimenten. Een Fab-fragment van Mab 291-
2G3-A uit groep I kon zo zuiver verkregen worden dat goed diffracterende kristallen
konden worden gegroeid. Om gedetailleerd inzicht te krijgen in de antilichaam-Lex-
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interactie is het van belang ook de kristalstructuur op te lossen van het Fab-fragment in
complex met Lex. Na een aantal tevergeefse pogingen om de suiker en het Fab-fragment te
co-kristalliseren, bleek dat Lex direct in de kristallen kon diffunderen. Voor het Fab-
fragment met en zonder Lex zijn datasets opgenomen tot een resolutie van respectievelijk
1,8 Å en 2,05 Å.
De kristalstructuren van het Fab fragment met en zonder Lex zijn opgelost met
behulp van molecular replacement, de structuren worden besproken in hoofdstuk 5.
Vergelijking van beide structuren leert dat er haast geen verschillen zijn in de binding-
pocket van het Fab-fragment in aan- of afwezigheid van het suiker. Verder is de
conformatie van Lex vergeleken met de conformatie van Lex in de kristalstructuur van het
ongebonden suiker en deze structuren bleken bijna gelijk te zijn. Binding brengt dus geen
grote conformationele veranderingen teweeg, noch bij het eiwit, noch bij de suiker. Verder
wordt duidelijk dat de binding-pocket vrij klein is en dat Lex er precies in past, Mab 291-
2G3-A is dus zeer specifiek voor Lex. Waterstofbruggen spelen een belangrijke rol in de
stabiliteit van het complex: hydroxylgroepen van alle drie de suikerresiduen van Lex
maken waterstofbruggen met hoofd- en zijketen-atomen van het eitwit. Alle
hypervariabele domeinen van zowel de zware als de lichte keten van het antilichaam zijn
betrokken bij de interactie. Dit is opmerkelijk aangezien bij de meeste antilichamen
hypervariabel domein 2 van de lichte keten hierin vaak geen rol speelt. De hoge
specificiteit van Mab 291-2G3-A voor Lex blijkt ook uit een SPR studie met suikers die of
in structuur gerelateerd zijn aan Lex, zoals Lea of Ley of met suikers die een galactose of
een fucose missen; Mab 291-2G3-A bindt aan geen enkele van deze suikers.
Vervolgens is er gekeken of er ook in vivo een verschil is in de humorale
immuunrespons tegen mono-, di- en trimeer Lex. Hiertoe is de humorale immuunrespons
van met S. mansoni geïnfecteerde muizen tegen mono-, di- en trimeer Lex bestudeerd, dit
is beschreven in hoofdstuk 6. In een longitudinale studie is serum afgenomen van de
geïnfecteerde muizen en de antilichaam respons tegen de Lex-oligomeren in de tijd is
gemeten met SPR. Er blijkt een groot verschil in de intensiteit van de respons tegen
enerzijds monomeer Lex en anderzijds di- en trimeer Lex te bestaan. Dit geeft aan dat
tegen verschillende oligomeren van Lex een verschillende immuunrespons wordt
opgewekt. Verder is de immuunrespons tegen CCA (waarvan het immunogene gedeelte
polymeer Lex bevat) gemeten en het bleek dat de piek van de immuunrespons later optrad
ten opzichte van de piek in de immuunrespons tegen mono-, di- en trimeer Lex. Hieruit is
geconcludeerd dat de anti-polymeer Lex-antilichamen ook weer tot een andere groep
antilichamen behoren.
Niet alleen Lex is een belangrijk suiker dat tot expressie wordt gebracht door de
parasiet, ook series van Fucα1-2Fuc-bevattende suikers spelen een belangrijke rol in de
immunobiologie van de parasiet. In hoofdstuk 7 wordt de synthese van een serie
gefucosyleerde GlcNAcs, die 0, 1 of 2 van het schistosoom-specifieke α1-2 gebonden
fucose bevatten (GlcNAc, Fucα1-3GlcNAc, Fucα1-2Fucα1-3GlcNAc en Fucα1-2Fucα1-
2Fucα1-3GlcNAc), beschreven. Voor de synthese van het di- en trisacharide (dus met
respectievelijk 1 en 2 fucoses) is een stapsgewijze lineaire glycosyleringsstrategie
gebruikt, hetgeen echter leidde tot een zeer lage opbrengst voor het tetrasacharide dat 3
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fucoses bevat. Om de opbrengst te verhogen is voor de synthese van het tetrasacharide
daarom een 2+2 blokkoppelingsstrategie gebruikt. Dit gaf een aanzienlijk beter resultaat.
Vervolgens is er gekeken met behulp van SPR of anti-schistosomale Mabs onderscheid
kunnen maken tussen deze verbindingen. Dit was inderdaad het geval: alle Mabs die
binden aan één of meer suikers kunnen in 4 groepen worden ingedeeld. De eerste groep
bindt aan ongefucosyleerd GlcNAc, de tweede groep heeft specifiek interactie met Fucα1-
3GlcNAc, de derde groep bindt aan de suikers die tenminste een Fucα1-2Fuc-element
hadden, terwijl de Mab uit de laatste groep alleen significant bindt aan Fucα1-2Fucα1-
2Fucα1-3GlcNAc. Vervolgens zijn de Mabs uit de verschillende groepen gebruikt om de
aanwezigheid van deze verschillende suikerstructuren aan te tonen in de volwassen
wormen, gebruik makende van immunocytochemische analyse. Anti-GlcNAc Mabs
kleurden voornamelijk het tegument van de volwassen worm, terwijl de Mabs uit groep 2
en 3 cellulaire structuren binnenin de parasiet aankleurden. De Mab van groep 4 gaf een
heel ander patroon, waarbij kanaalachtige structuren werden aangekleurd.
Tot slot wordt in hoofdstuk 8 de kristallisatie en structuuropheldering van een
lege capside van het plantenvirus TYMV beschreven. Dit capside was gekristalliseerd in
aanwezigheid van een RNA haarspeld, welke vermoedelijk is betrokken bij het inpakken
van het virale RNA in het manteleiwit. Het ophelderen van de structuur zou een
belangrijke rol kunnen spelen in het verkrijgen van een beter inzicht in dit proces. Helaas
was er geen duidelijke elektronendichtheid  voor de RNA-hairpin te vinden. Echter de
structuur van de lege capside vertoonde wel degelijk verschillen met een eerder
gepubliceerde structuur van het intacte virus (met dus viraal RNA aanwezig in de
capside). De verschillen waren het grootst in de opening van de uitstekende pentameren
en een groter deel van de N-terminale gedeelte van een van de subunits was zichtbaar in
de elektronendichtheid mappen. Dit zou erop kunnen wijzen dat dit de plaatsen zijn
waarop het RNA de eiwitmantel bindt. Verdere studie is echter nodig om hierin beter
inzicht te verkrijgen.
Dit proefschrift wordt afgesloten met een korte algemene discussie en enkele
vooruitblikken op toekomstig onderzoek. De resultaten beschreven in dit proefschrift
leveren een belangrijke bijdrage aan het inzicht van de interactie van anti-schistosomale
antilichamen met verschillende oligomere vormen van Lex. Nu het duidelijk is geworden
dat de humorale immuunrespons tegen verschillende vormen van Lex verschilt kan
hiermee rekening worden gehouden in verdere studies waarin de humorale en cellulaire
immunogeniciteit van Lex wordt onderzocht. Verder heeft het ophelderen van de
kristalstructuur van het Fab fragment met Lex geleid tot beter inzicht in suiker-eiwit
interacties op moleculair niveau. Deze nieuwe informatie kan worden gebruikt voor een
verdere verbetering van diagnostische technieken en tevens voor een beter begrip van
schistosomiasis en andere ziekten waarbij Lex een rol speelt.
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Appendix I Sequences
Sequence alignment of variable domains of Mabs 291-2G3-A, 179-4B1-A and 54-5C10-A
Light chain             10                  20            CDR-L1
291 D I V M T Q A A F S N P V T L G T S A S I S C R S S K S L L
179 D I V M T Q S Q K S M S T S V G D R V S V T C K A S Q N - V
54 D V V M T Q T P L S L S V S L G D Q A S I S C R S S Q S L V
              30                  40                  50   CDR-L2
291 Y S N G I T Y L Y W Y L Q K P G Q S P Q L L I Y Q M S N L A
179 G I N V A - - - - W Y Q E K P G Q S P K A L I Y S A S Y R C
54 H S N G N T F L Q W Y L Q K P G Q S P K L L I Y K V S N R F
              60                  70                  80
291 S G V P D R F S S S G S G T D F T L R I S R V E A E D V G V
179 S G V P D R F T G S G S G T D F T L T I N N V Q S E D L A E
54 S G V P D R F S G S G S G T D F T L K I S R M E A E D L G I
              90  CDR-L3         100
291 Y Y C A Q N L E V P W T F G G G T K L E I K R A
179 Y F C Q H Y N N Y P L T F G T G T K L E L K R A
54 Y F C S Q T T H V P W T F G G G T K L E I K R A
Heavy chain             10                  20           CDR-H1 30
291 E V K L L E S G G G L V Q P G G S Q K L S C A A S G F D F S
179 E V K L V E S G G G L V K P G G S L K L S C A A S G F T F S
54 Q I T L E E S G P G I L Q P S Q T L S L T C S F S G F S L S
                            40                  50     CDR-H2
291 G Y W M S - - W V R Q A P G K G L E W I G E I N P D S S T I
179 S Y A M S - - W V R Q T P E K I L E W V A S I S S G D S T Y
54 S S G M S V G W I R Q P S G K G L E W L A H I W W N D D K Y
          60                  70                80
291 N Y T P S L K D K F I I S R D N A K N T L Y L Q M S K V R S
179 - Y S D S V K G R F T V S R D K A R N I L Y L Q M S S L R S
54 - Y N P A L K S R L T V S K D S S D N Q V F L K I A S V V T
                90                 CDR-H3        100
291 E D T A L Y Y C A R E T G T R - - - - - - - F D Y W G Q G T
179 E D T A M Y Y C S R V G N N D Y G S S H W Y F D V W G V G T
54 A D T A T Y Y C A R I P G - - - - - - - F G F D Y W G Q G T
         110
291 T L T V S S
179 T V T V S S
54 T L T V S S
Table Appendix I Primers used for sequencing.
heavy 5' heavy 3' light 5' light 3'
291-2G3-A MuIgVH5’-Fa MuIgGVH3’-2 MuIgκVL5’-F MuIgVL3’-1
179-4B1-A MuIgVH5’-A MuIgGVH3’-2 MuIgκVL5’-A MuIgVL3’-1
54-5C10-A MuIgVH5’-D MuIgGVH3’-2 MuIgκVL5’-G MuIgVL3’-1
aFor primer sequence see protocol of the mouse Ig-prime system (Novagen, San Diego, CA, USA).
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Appendix II Color pictures
Figure 3.2 Doublestained immunofluorescence
pattern of Mabs 99-1G3-A (red) group I and 99-3D3-
A (green) group II, on frozen sections of adult
Schistosoma mansoni eggs. Different Lex-containing
structures are stained within the miracidium (courtesy
of K.K. Van de Vijver).
Figure 5.1 Structure of the two Fab fragments in complex
with Lex present in the asymmetric unit. The light chains are
blue, the heavy chains are light blue, Lex is light green.
Complementary determining regions L1 and H1 are red, L2
and H2 are green, L3 and H3 are yellow.
Figure 5.5 Stereoview of the binding site for Lex. Protein residues and water molecules which are
directly interacting with the Lex trisaccharide are depicted as well as Lex.
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Figure 8.1 a) Pentamer of
subunits A (orange), B (yellow)
and C (blue) present in the
asymmetric unit. b) Secondary
structure of the subunits, the beta-
strands of the jellyroll beta-barrel
are labeled.
Figure 8.5 Surface representation of
subunits A (orange), B (yellow) and C
(blue) viewed along the quasi three-fold
axis from the interior of the capsid. The
histidines 68 and 180 (green) are located
close to the interface between subunits A, B
and C. The cavities containing the
Histidines 68 and 180 (green), accompanied
with Arg 67, Arg 140 (yellow) and Asp 143
(black) are surrounded by a Arg-Glu and a
Lys-Glu couple (R12/E135 and K32/E72)
(yellow/red and blue/red respectively). The
side chain of these residues point towards
the interior of the capsid.
Figure 8.7 a) Top view along
the five-fold axis of an overlay
of a loop containing residues
117 to 135 of subunit A from
ATC (yellow) and TYMV
(blue), with the loops
containing G120 to L128
highlighted. b) 90° rotated side
view of the overlay. The side
chain of I122 is shown in both
models, orange in ATC and green in TYMV. From this picture it becomes clear that this loop in
ATC has flipped in an upward direction, changing the opening of the pentamer.   
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